Effects of antimicrobial stewardship policy in improving antibiotic utilisation and reducing drug costs in a public hospital in Gauteng Province, South Africa by Bashar, Muhammad Augie
 
 
EFFECTS OF ANTIMICROBIAL STEWARDSHIP 
POLICY IN IMPROVING ANTIBIOTIC 
UTILISATION AND REDUCING DRUG COSTS IN 
A PUBLIC HOSPITAL IN GAUTENG PROVINCE, 
SOUTH AFRICA 
 
By 
 
Muhammad Augie Bashar 
 
 
 
A Dissertation submitted to the Faculty of Health Sciences, University of the 
Witwatersrand, Johannesburg, in fulfilment of the requirements for the degree of 
Master of Science in Medicine. 
 
 
 
Johannesburg, 2017 
ii 
DECLARATION
I, Muhammad Augie Bashar declare that this dissertation is my original work. 
Contributions made by other people to this body of work have been duly 
acknowledged. It is being submitted for the degree of Masters of Medicine 
(Pharmacology) at the University of the Witwatersrand, Johannesburg, South Africa. It 
has not been submitted before for any degree or examination at this or any other 
University. 
____________________________ 
Signature 
Muhammad Augie Bashar 
Signed on ….….15th November, 2017. 
iii  
 
DEDICATION 
 
I dedicate this work to my loving parents, wife, kids and siblings for your prayers, 
support, patience and commitment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
iv  
 
CONFERENCE PROCEEDINGS 
 
1. Bashar M.A, Miot J, Shoul E, and van Zyl R.L. Review of antibiotic utilisation 
and costs in a public hospital in Gauteng Province, South Africa. Poster 
presentation at the All Africa Congress on Pharmacology and Pharmacy, 5 to 8 
October 2016, Misty Hills and Conference Centre, Muldersdrift, Gauteng, South 
Africa. 
2. Bashar Augie, Jacqui Miot, Evan Shoul, and Robyn van Zyl. Improving antibiotic 
utilisation in surgery wards. Oral presentation at the 2017 Annual General 
Scientific Conference of the Nigerian Infectious Diseases Society, 9 to 10 
November 2017, Ayalla Hotels Ltd off Ahmadu Bello Way Garki, Area 11, Abuja, 
Nigeria. 
3. Bashar M. Augie, Jacqui Miot, Evan Shoul, and Robyn L. van Zyl. Impact of an 
antimicrobial stewardship ward round in a surgical ward setting. Poster 
presentation at the Antimicrobial resistance symposium, organised by the 
Nigerian Centre for Disease Control and Prevention 14 to 16 November 2017, 
Transcorp Hilton Abuja, Nigeria.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v  
 
ABSTRACT 
 
Antimicrobial stewardship (AMS) programmes along with infection and prevention 
control measures have been shown to reduce the burden of antimicrobial resistance 
(AMR) in hospitals. There is a global campaign by infectious diseases physicians and 
other stakeholders for hospitals to implement AMS programmes. In Africa, there have 
been a limited number of AMS studies conducted although South African private 
hospitals have published some outcomes on initiation of these programmes in the 
continent, with the aim of improving patients’ clinical outcomes and reducing the 
development of resistance to prescribed antibiotics. A formal AMS programme is yet 
to be implemented in the surgery departments of the Charlotte Maxeke Johannesburg 
Academic Hospital. 
 
This study was conducted in two surgical wards of the Charlotte Maxeke Johannesburg 
Academic Hospital (CMJAH). It was a quantitative study combining a prevalence 
cross-sectional observational stage, and an intervention study. It involved a 
retrospective review of patient records in the baseline stage followed by an intervention 
which took the form of a weekly antibiotic round led by an infectious diseases specialist. 
The appropriateness of antibiotic prescriptions was assessed using the criteria 
developed by Gyssens and colleagues, while the appropriateness of surgical 
prophylaxis was determined based on the recommendations of the South African 
Antibiotic Stewardship Programme (SAASP) and current Standard Treatment 
Guidelines and Essential Medicines Lists for South Africa. The prices of the antibiotics 
used were obtained from the central pharmacy of the CMJAH and Masters Price 
Catalogue list of the National Department of Health, while the prices of laboratory tests 
were obtained from the Tariff database. The volume of antibiotics consumed was 
determined by Defined Daily Doses (DDDs)/1000 patient days. 
 
In both stages of the study amoxicillin/clavulanic acid was the most frequently used 
agent. The intravenous route was the most commonly used route of drug 
administration in both stages of the study. There was a reduction in the proportion of 
patients who were treated with antibiotics for more than seven days in the intervention 
stage, from 6.19% in the baseline stage to 2.07% in the intervention stage. A significant 
reduction in the duration of antibiotic therapy for two days and more was observed from 
vi  
 
4.74 ± 4.58 days in the baseline stage compared to 3.96 ± 2.04 days in the intervention 
stage (p = 0.01). A shift from empiric to culture directed therapy was also observed in 
the intervention stage compared to the baseline stage. There was a significant 
reduction in the volume of antibiotic consumption from a total of 739.30 DDDs/1000 
patient days in the baseline stage to 564.93 DDDs/1000 patient days in the intervention 
stage (p = 0.038). Overall, there was a significant reduction of inappropriate antibiotic 
utilisation from 35% in the baseline stage to 26% in the intervention stage (p = 0.006). 
A high percentage of inappropriate surgical prophylaxis was found which was mostly 
due to the incorrect choice of agent with 64.75% and 61.54% in the baseline and 
intervention stages, respectively. The average antibiotic cost per patient was reduced 
from R 268.23 ± 389.32 to R 228.03 ± 326.88 in the Vascular Surgery Ward compared 
to the General Surgery Ward where there was an increase in average cost per patient 
from R 219.80 ± 400.75 in the baseline stage to R 284.06 ± 461.28 in the intervention 
stage. Gram-negative bacteria were the most prevalent pathogens in both stages of 
the study at 53% in the baseline and 54% during the intervention stage. 
 
The findings of this study show an improvement in the appropriateness of antibiotic 
utilisation, reduction in antibiotic consumption and cost reduction in one of the study 
wards, following implementation of an AMS programme. Also, there was an 
improvement in culture directed therapy, requests for an appropriate biological 
specimen for culture, with a consequent increase in the cost of laboratory 
investigations per patient during the intervention stage, which was due to increases in 
culture request. Rational antimicrobial prescribing habits, strong AMS interventions 
along with infection and prevention control measures, sound government policies and 
surveillance of resistant organisms in Africa will go a long way in preserving our 
antibiotics and preventing the spread of multidrug-resistant pathogens. 
 
 
 
 
 
vii  
 
ACKNOWLEDGEMENTS 
 
 I am extremely grateful to my supervisors; Dr. Jacqui Miot, Dr. Evan Shoul and Prof. 
Robyn L. van Zyl who have demonstrated a great deal of support, commitment and 
mentorship throughout the programme. You taught me to be hardworking and 
committed to my work.  
 
 I would like to acknowledge the contributions of Dr. Martin Brand and Dr. Abdus-
sami Adewunmi who advised with the classification of surgical diagnoses and 
procedures.  
 
 I also appreciate funding from the Tertiary Education Trust Fund (TETFUND), 
Nigeria and Faculty of Health Sciences Research Office, University of the 
Witwatersrand, for financial assistance.  
 
 I am grateful to the Division of Pharmacology, Department of Pharmacy and 
Pharmacology, for the opportunity given to attend courses and conferences. I also 
acknowledged the support from my employers at the Federal University Birnin-
Kebbi, Kebbi State Nigeria. 
 
 My sincere gratitude also goes to Mrs Irene Henriëtte Janse van Noordwyk for 
formatting my work and Alfred Kwesi Manyeh who assisted with data analysis.  
 
 I thank all the patients who have given permission to use their records, a sincere 
gratitude also goes to all the staff of wards 395 and 396 of the surgery department, 
main hospital pharmacy and the information health management department at 
Charlotte Maxeke Johannesburg Academic Hospital for their support throughout 
the study period.  
 
 Last but not the least, I thank the Almighty Allah for making me resilient throughout 
the programme.  
 
 
 
viii  
 
TABLE OF CONTENTS 
  Page 
 Declaration…………………………………………………………….. ii 
 Dedication……………………………………………………………... iii 
 Conference Proceedings…………………………………………….. iv 
 Abstract………………………………………………………………... v 
 Acknowledgements…………………………………………………... vii 
 Table of Contents……………………………………………………... viii 
 List of Figures…………………………………………………………. xiii 
 List of Tables…………………………………………………………... xv 
 List of Abbreviations…………………………………………………... xvii 
 Preface…………………………………………………………………. xix 
   
1. Chapter One: Overview of the Study…………………………….. 1 
1.1 Introduction……………………………………………………………. 1 
1.1.1 Antimicrobial resistance…………………………………………….... 1 
1.1.2 Antimicrobial stewardship …………………………………………… 2 
1.1.3 Problem statement……………………………………………………. 3 
1.1.4 Rationale for the study……………………………………………….. 4 
1.2 Aim of the study………………………………………………………. 4 
1.3 Research objectives…………………………………………………. 4 
1.4 Study design……………………………………………………….…. 5 
1.5 Hypothesis……………………………………………………….……. 5 
   
2. Chapter Two: Literature Review…………………………………. 6 
2.1 Overview of antibiotic resistance…………………………………… 6 
2.2 Mechanisms of antibiotic resistance……………………………….. 8 
2.3 Drivers of antibiotic resistance………………………………….….. 9 
2.3.1 Inappropriate antibiotic use…………………………………………. 9 
2.3.2 Use of broad-spectrum antibiotics…………………………………. 10 
2.3.3 Self-medication………………………………………………………. 11 
2.3.4 Antibiotics use in agriculture and environment…………………… 11 
2.3.5 Counterfeit drugs…………………………………………………….. 14 
2.4 Bacteria of global concern…………………………………………… 14 
2.4.1 Acinetobacter baumannii……………………………………………. 15 
2.4.2 Pseudomonas aeruginosa…………………………………………... 16 
2.4.3 Enterococcus faecium……………………………………………….. 16 
2.4.4 Escherichia coli……………………………………………………….. 17 
2.4.5 Klebsiella pneumoniae………………………………………………. 17 
2.4.6 Enterobacter cloacae……………………………………………….... 18 
2.4.7 Methicillin-resistant Staphylococcus aureus………………………. 18 
ix  
 
2.4.8 Extended spectrum beta-lactamase producers…………………… 19 
2.4.9 Carbapenem-resistance Enterobacteriaceae……………………... 20 
2.4.10 Clostridium difficile……………………………………………...……. 20 
2.4.11 Vancomycin-resistant Enterococci…………………………………. 21 
2.5 Global antibiotic consumption………………………………………. 21 
2.6 Emergence of resistance to last resort antibiotics………………… 22 
2.7 Antibiotic pipeline……………………………………………………... 24 
2.8 Surveillance of resistant bacteria in Africa………………………..... 24 
2.9 Infection control……………………………………………………….. 25 
2.10 Surgical site infections……………………………………………….. 25 
2.10.1 Classification of surgical wounds…………………………………... 27 
2.10.2 Surgical prophylaxis………………………………………………….. 28 
2.11 Economic burden of antibiotic resistance………………………...... 29 
2.12 Overview of antimicrobial stewardship…………………………….. 31 
2.12.1 Goals of antimicrobial stewardship…………………………………. 34 
2.12.2 Antimicrobial stewardship in South Africa…………………………. 34 
2.12.3 Antimicrobial stewardship strategies………………………………... 36 
2.12.3.1 Education………………………………………………………………. 36 
2.12.3.2 Formulary restriction and pre-authorisation………………………... 36 
2.12.3.3 Streamlining/de-escalation………………………………………….. 37 
2.12.3.4 Conversion from intravenous to oral………………………………... 37 
2.12.3.5 Antibiotic cycling……………………………………………………..... 37 
2.12.3.6 Institutional guidelines………………………………………………... 38 
2.12.3.7 Prospective audit and feedback…………………………………….. 38 
2.12.3.8 Dose optimisation…………………………………………………….. 38 
2.12.3.9 Antibiotic order form………………………………………………….. 38 
2.12.4 Antimicrobial stewardship studies in South Africa………………... 39 
2.12.5 Antimicrobial stewardship team…………………………………….. 39 
2.12.6 Antimicrobial stewardship in surgical settings…………………….. 40 
2.12.7 Impact of AMS on cost and resistance…………………………….. 42 
2.12.8 Antimicrobial stewardship care-bundles………………………….... 44 
2.12.9 Role of biomarkers in antimicrobial stewardship……………......... 44 
2.12.10 Barriers and limitations of successful AMS………………………... 47 
2.13 Drug utilisation review……………………………………………….. 47 
2.13.1 Anatomic Therapeutic Chemical (ATC) classification…………….. 48 
2.13.2 Defined Daily Doses …………………….………………………….... 48 
2.13.3 Limitations of using DDD techniques…………………………….... 50 
2.13.4 Prescribed Daily Dose ……………………………………………….. 50 
2.13.5 Days of Therapy ………………………….…………………………... 51 
2.13.6 Minimum Marketed Dose ……………………………………………. 51 
2.13.7 Equipotential Dose……………………………………………………. 51 
2.13.8 Cost…………………………………………………………………...... 52 
x  
 
2.13.9 Other methods of quantifying drug utilisation……………………… 52 
   
3. Chapter Three: Research Design and Methods………………. 53 
3.1 Introduction…………………………………………………….……… 53 
3.2 Research design……………………………………………………... 53 
3.2.1 Setting…………………………………………………………………. 53 
3.2.2 Study design…………………………………………………………... 54 
3.2.2.1 Stage 1: Cross-sectional observational and descriptive study...... 54 
3.2.2.2 Stage 2: Intervention study…………………………………………... 55 
3.3 Research methods……………………………………………………. 56 
3.3.1 Population……………………………………………………………... 56 
3.3.2 Sample and sampling………………………………………………... 56 
3.3.3 Data collection………………………………………………………... 57 
3.3.4 Data categorisation…………………………………………………… 59 
3.3.5 Data analysis………………………………………………………….. 60 
3.4 Ethical consideration…………………………………………………. 60 
3.4.1 Permission to conduct the study………………………………….…. 60 
3.4.2 Informed consent…………………………………………….……….. 61 
3.4.3 Anonymity and confidentiality……………………………………….. 61 
   
4. Chapter Four: Results……………………………………………… 62 
4.1 Demographic characteristics of patients…………………………... 62 
4.1.1 Gender…………………………………………………………………. 62 
4.1.2 Age distribution……………………………………………………….. 63 
4.1.3 Hospital length of stay ……………………………………………..... 64 
4.1.4 Type of diagnoses…………………………………………………….. 64 
4.1.5 Classification of surgical procedures………………………………... 66 
4.1.6 Number of surgical procedures per stay…………………………… 67 
4.2 Antibiotic utilisation………………………………………………….... 68 
4.2.1 Number of antibiotics per patient per stay………………………….. 68 
4.2.2 Duration of antibiotic therapy……………………………….............. 69 
4.2.3 Clinical indications for the use of antibiotics……………………….. 70 
4.2.4 Allergy to prescribed antibiotics……………………………………... 71 
4.2.5 Route of drug administration………………………………………... 72 
4.2.6 Antibiotic prescriptions……………………………………………….. 72 
4.2.7 Volume of antibiotics consumption…………………………………. 74 
4.2.8 Most frequently utilised antibiotics………………………………….. 76 
4.2.9 Comparison of average daily DDD to WHO DDD………………... 78 
4.3 Utilisation of laboratory investigations……………………………... 80 
4.3.1 Prevalence of pathogens…………………………………………….. 80 
4.3.2 Multi-drug resistant pathogens……………………………………… 83 
4.3.3 Classification of cultured pathogens………………………………... 84 
xi  
 
4.3.4 Timing of culture request……………………………………………. 86 
4.3.5 Nature of specimens collected for culture……………………….…. 86 
4.4 Appropriateness of antibiotic utilisation and surgical prophylaxis... 87 
4.4.1 Appropriateness of all antibiotic prescriptions……………………... 88 
4.4.2 Categories of inappropriate prescriptions………………………….. 89 
4.4.3 Appropriateness of all prophylactic therapy………………………... 91 
4.4.4 Appropriateness of surgical prophylaxis…………………………… 92 
4.4.5 Appropriateness of empiric/targeted therapy……………………… 93 
4.4.6 Predictors of appropriateness of antibiotic prescription………….. 94 
4.5 Compliance rate to AMS recommendations……………….……… 97 
4.6 Cost…………………………………………………………………….. 98 
4.6.1 Average cost of antibiotics and laboratory investigations……….. 98 
4.6.2 Overall antibiotic cost………………………………………………... 99 
   
5. Chapter Five: Discussions and Conclusion…………………….. 102 
5.1 Introduction………………………………………………………….… 102 
5.2 Patient demographic characteristics……………………………….. 103 
5.3 Antibiotic utilisation…………………………………………………… 105 
5.3.1 Antibiotic consumption……………………………………………….. 108 
5.3.2 Route of administration………………………………………………. 109 
5.3.3 Duration of therapy …………………………………………………... 111 
5.3.4 Appropriateness of antimicrobial prescription……………………... 112 
5.4 Predictors of appropriateness of antibiotic therapy……………….. 116 
5.5 Prevalence of pathogens…………………………………………….. 117 
5.6 Compliance to ASM recommendations…………………………….. 120 
5.7 Cost…………………………………………………………………….. 121 
5.7.1 Cost of antibiotic utilisation……………………………………….…. 121 
5.7.2 Cost of laboratory investigation……………………………………... 123 
5.8 Study limitations………………………………………………………. 123 
5.9 Recommendations………………………………………………….... 126 
5.10 Conclusion…………………………………………………………….. 127 
5.11 Future research……………………………………………………….. 127 
   
 Reference List………………………………………………………... 129 
   
Appendix 1 : ATC codes………………………………………………………… 157 
 
Appendix 2 
: Data table on demographic characteristics and nature of  
  surgery……………………………………………………………... 
 
158 
Appendix 3 : Data table on drug utilisation…………………………………….. 159 
 
Appendix 4 
: Gyssen’s criteria for assessing appropriateness of 
  antimicrobial drug therapy (ADT)…………………………….….. 
 
160 
Appendix 5 : Antibiotic price list……………………………………………........ 161 
xii  
 
Appendix 6 : Data collection sheet on culture and sensitivity and biomarkers                                  162
Appendix 7 : Laboratory investigations price list………………………………. 163 
Appendix 8 : Ethical clearance certificate to conduct a prospective study…. 164 
Appendix 9 
: Ethical clearance certificate to conduct a retrospective study… 
165 
Appendix 10 : Letter of hospital permission to conduct study…………………. 166 
Appendix 11 
: Letter of permission to conduct study in surgery department…       
167 
Appendix 12 : Letter of protocol title approval…………………………………… 168 
Appendix 13 : Letter of consent…………………………………………………... 169 
Appendix 14 : Information sheet……………………………………………….…. 171 
 
Appendix 15  
: Specimens which grew multidrug resistant bacteria in the   
  baseline stage…………………………………………………….. 
 
173 
 
Appendix 16 
 
: Specimens which grew multidrug resistant bacteria in the  
  intervention stage……………………………………………........ 
 
174 
 
  
xiii  
 
LIST OF FIGURES 
   Page 
Figure 2.1 : Illustration of antibiotic resistance  (Schmieder and 
Edwards, 2012) ………………………………………………… 
9 
Figure 2.2 : Interaction between antimicrobial use in man, animals and 
environment [Based on Linton (1977), as adapted by 
Rebecca Irwin, Health Canada (Prescott 2000) and IFT]..... 
13 
Figure 2.3 : Global transmission of antimicrobial resistant bacteria 
(World Economic Forum, 2013)………………………………. 
23 
Figure 2.4 : Global deaths due to AMR every year (O'Neill, 2016)……... 30 
Figure 2.5 : Predicted regional burden of AMR by 2050 (O'Neill, 2014)... 31 
Figure 2.6 : Strategies to contain antimicrobial resistance (Fishman, 
2006)……………………………………………………………. 
32 
Figure 2.7 : Pillars of South African AMR strategy framework (NDoH, 
2014b)…………………………………………………………... 
35 
Figure 4.1 : Patient age distribution in the baseline stage....................... 63 
Figure 4.2 : Patient age distribution in the intervention stage…………... 64 
Figure 4.3 : Categories of diagnoses in the baseline stage……………… 65 
Figure 4.4 : Categories of diagnoses in the intervention stage…………. 65 
Figure 4.5 : Surgery type based on type of surgical wound in the 
baseline stage………………………………………………….. 
66 
Figure 4.6 : Surgery type based on type of surgical wound in the 
intervention stage……………………………………………… 
 
67 
Figure 4.7 : Number of antibiotics per patient per stay in the baseline 
stage……………………………………………………………. 
68 
Figure 4.8 : Number of antibiotics per patient per stay in the intervention 
stage…………………………………………………………….. 
69 
Figure 4.9 : Antibiotic treatment based on clinical indications in the 
baseline stage………………………………………………… 
 
70 
Figure 4.10 : Antibiotic treatment based on clinical indications in the 
intervention stage……………………………………………… 
 
71 
Figure 4.11 : Nature of cultured pathogens in the baseline stage……….. 85 
Figure 4.12 : Nature of cultured pathogens in the intervention stage…… 85 
Figure 4.13 : Appropriateness of antibiotic utilisation in the baseline 
stage…………………………………………………………….. 
88 
Figure 4.14 : Appropriateness of antibiotic utilisation in the intervention 
stage…………………………………………………………….. 
89 
Figure 4.15 : Categories of inappropriate antibiotic utilisation in the 
baseline stage…………………………………………………. 
 
90 
Figure 4.16 : Categories of inappropriate antibiotic utilisation in the 
intervention stage…………………………………………….... 
 
90 
Figure 4.17 : Appropriateness of prescriptions used for prophylactic 
therapy in the baseline stage…………………………………. 
 
91 
xiv  
 
Figure 4.18 : Appropriateness of prescriptions used for prophylactic 
therapy in the intervention stage…………………………….. 
 
91 
Figure 4.19 : Appropriateness of prescriptions for empiric and targeted 
therapy in the baseline stage…………………………………. 
 
93 
Figure 4.20 : Appropriateness of prescriptions for empiric and targeted 
therapy in the intervention stage……………………………... 
 
93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xv  
 
LIST OF TABLES 
   Page 
Table 2.1 : National Health Laboratory Services Guideline for the use of 
biomarkers…………………………………………………......... 
 
45 
Table 4.1 : Gender distribution of patients in the baseline stage………… 62 
Table 4.2 : Gender distribution of patients in the intervention stage…..... 62 
Table 4.3 : Number of surgical procedures per patient per stay in the 
baseline stage……………………………………………............ 
 
67 
Table 4.4 : Number of surgical procedures per patient per stay in the 
intervention stage………………………………………………. 
 
68 
Table 4.5 : Patients duration of antibiotic therapy in days in the baseline 
stage…………………………………………………................... 
 
70 
Table 4.6 : Patients duration of antibiotic therapy in days in the 
intervention stage………………………………………………… 
 
70 
Table 4.7 : Allergy to prescribed drugs in the baseline stage…………….. 71 
Table 4.8 : Allergy to prescribed drugs in the intervention stage…………. 71 
Table 4.9 : Route of drug delivery in the baseline stage…………………… 72 
Table 4.10 : Route of drug delivery in the intervention stage……………….. 72 
Table 4.11 : Number of antibiotic prescriptions in the baseline stage…....... 73 
Table 4.12 : Number of antibiotic prescriptions in the intervention stage..... 74 
Table 4.13 : Antibiotic consumption in the baseline stage………………….. 75 
Table 4.14 : Antibiotic consumption in the intervention stage………………. 76 
Table 4.15 : DDDs and DDD/1000 patient days of the most frequently used 
antibiotics in the baseline stage…………………………………. 
 
77 
Table 4.16 : DDDs and DDD/1000 patient days of the most frequently used 
antibiotics in the intervention stage……………………………... 
 
78 
Table 4.17 : Average DDD/WHO DDD ratio in the baseline stage………... 79 
Table 4.18 : Average DDD/WHO DDD ratio in the intervention stage…..... 80 
Table 4.19 : Prevalence of pathogens in the baseline stage……………….. 81 
Table 4.20 : Prevalence of pathogens in the intervention stage…………… 82 
Table 4.21 : Pattern of multi-drug resistant bacteria in the baseline 
stage……………………………………………………………...... 
83 
Table 4.22 : Pattern of multi-drug resistant bacteria in the intervention 
stage……………………………………………………………...... 
84 
Table 4.23 : Time of request culture in the baseline stage…………………. 86 
Table 4.24 : Time of request culture in the intervention stage……………... 86 
Table 4.25 : Specimens collected in the baseline stage…………………….. 87 
Table 4.26 : Specimens collected in the intervention stage………………... 87 
Table 4.27 : Surgical prophylaxis in the baseline stage…………………….. 92 
Table 4.28 : Surgical prophylaxis in the intervention stage………………… 92 
Table 4.29 : Crude and adjusted odds of the appropriateness of antibiotics 
prescription………………………………................................... 
 
95 
xvi  
 
Table 4.30 : Rate of recommendations compliance………………………... 97 
Table 4.31 : Patient’s average cost of antibiotics and laboratory 
investigations in the baseline stage…………………………… 
 
98 
Table 4.32 : Patient’s average cost of antibiotics and laboratory 
investigations in the intervention stage………………………... 
 
99 
Table 4.33 : Cost of antibiotics utilisation in the baseline stage…………… 100 
Table 4.34 : Cost of antibiotics utilisation in the intervention stage……….. 101 
Table 5.1 : AMS studies that showed improvement of antibiotic 
consumption……………………………………….…………….... 
111 
 
 
 
 
  
xvii  
 
LIST OF ABBREVIATIONS 
 
ADT              : Antimicrobial Drug Therapy 
AMR   : Antimicrobial Resistance 
AMS   : Antimicrobial Stewardship 
ATC  : Anatomical Therapeutic Chemical  
BCA  : Best Care Always 
BRICS : Brazil, Russia, India, China, and South Africa 
CDC   : Centre for Disease Control and Prevention  
CEO    : Chief Executive Officer 
CRP   : C - reactive protein 
CMJAH  : Charlotte Maxeke Johannesburg Academic Hospital 
CRE   : Carbapenem-Resistant Enterobacteriaceae  
DDDs  : Defined Daily Doses 
DOT   : Days of Therapy 
DoTh   : Duration of Therapy  
DNA   : Deoxyribonucleic acid   
DUR              : Drug Utilisation Review 
EMA              : European Medicines Agency 
FBC   : Full Blood Count 
FDA   : Food and Drug Administration 
FTEs             : Full-time equivalents 
GARP  : Group for Antibiotic Resistance Partnership 
GBLCs  : Gallbladder Biliary-Tract and Liver Cases 
HIV   : Human Immunodeficiency Virus 
hVISA           : Heterogeneous Vancomycin Intermediate Staphylococcus aureus 
ICU   : Intensive Care Unit 
IDSA   : Infectious Diseases Society of America 
IV   : Intravenous  
LGCs   : Lower Gastrointestinal Cases 
MCS   : Microscopy Culture and Sensitivity 
mrc-1    : Mannose receptor, C type 1 
MRSA  : Methicillin-Resistant Staphylococcus aureus  
MSSA  : Methicillin-Sensitive Staphylococcus aureus  
xviii  
 
NDM-1  : New Delhi Metallo-Beta-lactamase-1 
NDoH  : National Department of Health 
NHLS    : National Health Laboratory Service 
OR   : Odds ratio 
PCT   : Procalcitonin 
PBPs             : Penicillin-Binding Proteins 
RCTs             : Randomised Control Trials  
SAASP  : South African Antibiotic Stewardship Programme 
SSIs   : Surgical Site Infections 
SUs   : Standard Units 
UGCs    : Upper Gastrointestinal Cases 
USA   : United State of America 
UTI   : Urinary Tract Infection 
VRE   : Vancomycin-Resistant Enterococci 
VRSA            : Vancomycin-Resistant Staphylococcus aureus 
WCC    : White Cell Count 
 
 
 
 
 
 
 
 
 
 
 
 
xix  
 
PREFACE 
“Today, antibiotics are rarely prescribed based on a definitive diagnosis. Diagnostic 
tests can show whether or not an antibiotic is actually needed, and which one. Having 
rapid, low-cost, and readily available diagnostics is an essential part of the solution to 
this urgent problem.’’ 
Dr Margaret Chan, Director-General of the World Health Organization (O'Neill, 
2016). 
 
“A crucial part of tackling this challenge is to create the circumstances for behavioural 
change. From reducing smoking rates, to convincing people to wear seatbelts, 
effective public campaigns have repeatedly changed social attitudes and improved 
human health. In this case, a public health campaign has the potential to build 
understanding and change behaviour, helping to avoid a future catastrophe that could 
see 10 million people dying every year.’’  
 Donald A. Baer, Worldwide Chair and CEO, Burson-Marsteller (O'Neill, 2016). 
 
“Tackling antimicrobial resistance requires a wide range of approaches and developing 
alternatives to antibiotics, in humans and animals, is critical to the fight. Vaccines have 
a vital role to play in combatting drug resistance, by preventing infections in the first 
place.’’  
Dame Sally Davies, Chief Medical Officer for England (O'Neill, 2016).  
 
“The basics of public health – clean water, good sanitation and hygiene, infection 
prevention and control and surveillance – are as critical for reducing the impact of 
antimicrobial resistance as they are for infectious disease control. While we also need 
new technologies and medicines, and better use of existing medicines, we cannot let 
attention to fundamental public health practices suffer, or else antimicrobial 
resistance will continue to thrive.” 
Dr Keiji Fukuda, the Director General’s Special Representative for Antimicrobial 
Resistance at the World Health Organization (WHO) (O'Neill, 2016). 
 
“Without good surveillance, we cannot effectively counter the threat that antimicrobial 
resistance poses to health systems and people all over the world. It is also vital that 
countries work together to make sure old and new technologies are rolled out in a way 
xx  
 
that supports better global One Health AMR surveillance including animals and the 
environment.’’  
Yasuhisa Shiozaki, Minister of Health, Labour and Welfare for Japan (O'Neill, 
2016). 
 
“Infectious Diseases and Microbiology are among the least subscribed specialities in 
medicine and research, this leading to a shortage of key personnel on the frontlines of 
the challenge of drug-resistant infections. This needs to change immediately if we are 
to turn the tide against rising resistance.” 
Dr Jeremy Farrar, Director, Wellcome Trust (O'Neill, 2016). 
 
“We have to dramatically shift incentives for pharmaceutical companies and others to 
create a long-term solution to this problem, with new rewards, funded globally, that 
support the development of new antibiotics and ensure access to antibiotics in the 
developing world.’’  
George Osborne, Chancellor of the Exchequer, United Kingdom (O'Neill, 2016). 
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CHAPTER ONE: OVERVIEW OF THE STUDY 
   
1.1 INTRODUCTION  
 
Before the discovery of antibiotics, patients were dying from simple bacterial 
infections (Donaldson, 2009), however, since their discovery more than seven 
decades ago, antibiotics have saved millions of lives globally (CDC, 2013). 
Almost half of hospitalised patients have been reported to receive antibiotics 
during their inpatient stay in the United States (Owens, 2009). Even higher rates 
have been reported in China, ranging from 85% to 100% (Sweidan et al., 2005). 
In its 2013 annual report on global risks, the World Economic Forum reported 
that the biggest public health risk facing humankind was hard-to-treat bacterial 
infections (World Economic Forum, 2013). Ways to address this challenging 
issue include paying attention to infection and prevention control measures, 
antimicrobial stewardship programmes and encouraging new economic models 
to promote research and development of new antibacterial agents (Howell, 
2013).  
 
1.1.1 Antimicrobial resistance 
Antimicrobial resistance (AMR) is an ancient survival strategy adopted by 
microorganisms such as bacteria to withstand treatment with antimicrobial 
agents (D'costa et al., 2011; NDoH, 2014b). Microorganisms are an important 
component of this planet; playing an important function in striking a balance of 
the ecosystem. Microorganisms have lived for more than 3.8 billion years, 
making up nearly 50% of all living organisms and have over the years 
manifested various genetic and metabolic strategies to survive harsh 
environmental conditions (Byarugaba, 2010; Ramsamy et al., 2016). Boseley 
(2010) reported that AMR follows the concept of the Darwinian theory of natural 
selection - identification of mutant bacterial genes from a 30,000-year-old 
pergélisol residue in Yukon indicates that AMR precedes modern day antibiotics 
(D'costa et al., 2011).   
 
Antibiotic resistance is an unavoidable occurrence but can be delayed by 
adopting programmes that encourage appropriate antibiotic utilisation (Gould, 
2  
 
2009). To curtail the menace of AMR, the Infectious Diseases Society of 
America (IDSA) in 2010 proposed that the global community needs to adopt 
Antimicrobial Stewardship (AMS) programmes to optimise the use of antibiotics. 
IDSA also encouraged the pharmaceutical industries to develop ten new 
antibacterial agents by 2020 (IDSA, 2010). Prof J O’Neill and colleagues in their 
report proposed a quick release of a US$ 2 billion innovation fund to revitalise 
research and development of new antibiotics (O'Neill, 2016). 
 
One of the causes of AMR is inappropriate surgical prophylaxis, however, when 
appropriately implemented surgical prophylaxis has been shown to reduce the 
chances of developing surgical site infections (SSIs) (Bowater et al., 2009; 
Enzler et al., 2011). Of note, surgical prophylaxis is not a substitute for standard 
infection control measures (Bratzler et al., 2013). A multicentre AMS initiative, 
led by non-specialised pharmacists significantly improved adherence to a peri-
operative antibiotic prophylaxis bundles which in turn led to a significant 
reduction in SSI rates across a large network of diverse urban and rural 
hospitals in South Africa (Brink et al., 2017). The updated American surgical 
prophylaxis guideline of 2013, recommends the use of an agent with bactericidal 
and in vivo activities on common pathogens causing SSIs after an operation 
(Bratzler et al., 2013). The United States guideline also recommends the use of 
a surgical prophylactic agent for less than 24 hours, thereby reducing cost, 
adverse events and AMR (Bratzler et al., 2013).  
 
1.1.2  Antimicrobial stewardship 
Very little data are available on the implementation of AMS activities on the 
African continent (Brink et al., 2016a). In a joint statement, the Society for 
Healthcare Epidemiology of America, the IDSA and the Paediatric Infectious 
Diseases Society defined AMS as “Coordinated interventions designed to 
improve and measure the appropriate use of an antimicrobial agents by 
promoting the selection of the optimal antimicrobial drug regimen including 
dosing, duration of therapy and route of administration” (Fishman, 2012). An 
AMS programme involves many strategies with different approaches and when 
properly conducted will impact positively on patient clinical outcomes (Davey et 
al., 2017). It is an essential tool for preserving the value of current and 
subsequent generations of antibiotics (Tillotson, 2015). The main aim of AMS 
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programmes is to ensure patients receive appropriate antibiotic therapy, 
improved clinical response and tolerable adverse reactions, along with reducing 
costs associated with inappropriate antibiotic use (Fishman, 2012). A 
pharmacist-driven prospective audit and feedback model across a diverse 
group of 47 urban and rural South African hospitals, has recorded a sustainable 
reduction in overall antibiotic consumption (Brink et al., 2016a). 
 
A significant percentage of surgical presentations such as appendicitis, 
cholangitis, peritonitis and osteomyelitis are associated with infections which 
require treatment or prevention through antibiotic prophylaxis (Leeds et al., 
2016). Inappropriate surgical prophylaxis can contribute significantly to the 
development of resistance. The Surgical Infection Society and the World 
Society of Emergency Surgery have encouraged surgeons to actively 
participate in AMS programmes (Sartelli et al., 2016b). Surgeons are required 
to update their knowledge with the current local surgical prophylactic guidelines 
for surgical operations they routinely conduct and apply appropriate antibiotic 
treatment options in case complications ensue. They are also encouraged to 
work with AMS teams (Leeds et al., 2016). 
 
1.1.3  Problem statement 
AMR is a major global problem affecting public health, especially in developing 
African countries where data on the degree and surveillance of resistant 
organisms are lacking (WHO, 2014). Globally, around 700,000 people die every 
year because of difficult to treat bacterial infections (O'Neill, 2016). Thus, there 
is an urgent need to develop programmes to address emerging drug resistant 
pathogens. Despite the intensified global campaign by infectious diseases 
physicians and other stakeholders, on the need of the hospitals to implement 
AMS programmes and to limit the burden of AMR, the uptake by hospitals has 
been erratic (Rawson et al., 2015). In South Africa, there have been a limited 
number of AMS studies conducted in public hospitals especially in the surgical 
setting. An AMS programme has not been officially implemented in the Surgery 
Department at the Charlotte Maxeke Johannesburg Academic Hospital 
(CMJAH), hence the need to conduct such a study. A systematic Cochrane 
review showed that an AMS programme can reduce AMR and improve rational 
antibiotic utilisation among hospitalised patients (Davey et al., 2017). The 
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findings of this study will provide the hospital with research data that will support 
recommendations for rational antimicrobial utilisation and cost-effective of 
antibiotic therapy. 
 
1.1.4   Rationale for the study 
The need for AMS in the Surgery Department was identified because of the 
large volume of antibiotics use in the department. A series of meetings were 
held at CMJAH with representatives from the surgery department, a 
microbiologist from the National Health Laboratory Health Services (NHLS), 
pharmacists, myself and my supervisors prior to commencement of the study. 
During these meetings, it was established that there was no formal AMS policy 
and no antibiotic policy was implemented in the department. A provisional AMS 
team was identified, and two wards with high antibiotic utilisation in the surgery 
department were selected for the study. An AMS policy as determined by the 
South African Antibiotic Stewardship Programme (SAASP) was adopted in this 
study to guide the intervention process and was recommended to the 
department. 
 
1.2  AIM OF THE STUDY 
The aim of this study was to describe the current practice in antibiotic utilisation 
and measure the impact of an AMS intervention on cost and usage in selected 
surgical wards of the Charlotte Maxeke Johannesburg Academic Hospital. 
 
1.3  RESEARCH OBJECTIVES 
The objectives of this study are as follows: 
1. To determine the impact of the introduction of an AMS policy on antibiotic 
utilisation by carrying out AMS rounds in two surgery wards. 
2. To determine the appropriateness of antibiotic prescribing in the selected 
surgery wards using the guideline developed by Gyssens and colleagues 
(Plenat et al., 1992). 
3. To determine the cost impact of the introduction of this AMS intervention on 
antibiotic utilisation. 
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1.4  STUDY DESIGN  
This is a quantitative study of patient records combining a prevalence cross-
sectional observational and descriptive study with an interventional study. The 
study is divided into two stages; in the first stage the data was collected 
retrospectively from patient records, and in the second stage it was collected 
prospectively following an AMS intervention. 
 
1.5  HYPOTHESIS 
The hypothesis in this research study was that the introduction of an AMS 
programme will result in an improvement in appropriateness of antibiotic 
utilisation and reduction of consumption and cost of antibiotics. 
 
Null Hypothesis (H0) – that there is no difference in antibiotic utilisation, 
consumption or cost between the baseline cohort and intervention cohort. This 
study aims to reject the Null hypothesis 
 
The Alternate hypothesis (HA) – is that there is a difference in antibiotic 
utilisation, consumption or cost between the baseline cohort and intervention 
cohort. 
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CHAPTER TWO: LITERATURE REVIEW 
  
2.1  OVERVIEW OF ANTIBIOTIC RESISTANCE 
The discovery of antibiotics about seven decades ago has considerably 
transformed modern medicine by playing a pivotal role in the fight against 
infectious diseases and decreasing mortality caused by bacterial infections 
(Anand et al., 2016; Barlam et al., 2016). The rapid development of resistance 
by bacteria to available antibacterial agents and slow pace of research and 
development of new agents over the years is negatively affecting this initial 
success (Barlam et al., 2016). Over the years, the research community has 
discovered over 5000 novel agents with antimicrobial activity. However, only 
about 100 are used clinically for managing infectious diseases (Khardori, 2006).  
 
The first antibiotic to be discovered was penicillin in 1928 by Alexander Fleming 
(Kimang'a, 2012) following an accidental contamination of an agar plate by a 
mould (Paskovaty et al., 2005) in his laboratory at St Mary's Hospital London 
(O'Neill, 2014). Penicillin was first administered to humans in 1941 (Grossman, 
2008). A considerable quantity of antibiotics was shipped to North Africa for use 
by the United States army in 1943 (Kimang'a, 2012) and these played a critical 
role in managing infections during the Second World War (Sykes, 2001). Since 
their introduction into modern medicine in the 1940's, antibiotic use has widened 
from managing severe infections in surgical patients to the prevention of 
infections in patients on cancer therapy, in immunocompromised individuals and 
those undergoing organ transplantation as well as many other clinical 
indications (Gelband et al., 2015). Antibiotics are also used widely as treatment, 
growth promoters and prophylaxis in livestock and farm animals (Laxminarayan 
et al., 2016; Gelband et al., 2015). The recent increase in the rate of AMR is 
alarming considering the slow pace of the discovery of new antibacterial agents 
in contrast with increased use in both humans and animals worldwide (O'Neill, 
2014).  
 
Antibiotic resistance is a direct function of antibiotic usage, the higher the 
volume of antibiotics consumed the greater the chances of developing 
resistance by bacteria as a mechanism of survival, in line with the Darwinian 
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theory of natural selection (Gelband et al., 2015). Pressure from patients, 
especially those on medical insurance, to be treated with newer high cost 
agents and the high commercial demand for animal proteins are driving 
pressures that have resulted in increased antibiotic consumption (Gelband et 
al., 2015). Chemotherapy, especially with cytotoxic agents, is associated with 
suppression of the immune system, thereby making patients vulnerable to 
infections, which in the absence of effective antimicrobial agents to treat or 
prevents such infections, increases the risk of chemotherapy (O'Neill, 2014). 
Similarly, without effective antibiotics, it would be risky to undertake many 
surgical procedures (O'Neill, 2014). Shortly after his Nobel Prize award for 
discovering penicillin in 1945, Prof Fleming warned that bacteria would develop 
resistance to these novel agents if they were not judiciously used (Paphitou, 
2013; WHO, 2014).  
 
Prof Fleming on June 26, 1945 said “…the microbes are educated to resist 
penicillin, and a host of penicillin-fast organisms is bred out… In such cases the 
thoughtless person playing with penicillin is morally responsible for the death of 
the man who finally succumbs to infection with the penicillin-resistant organism. 
I hope this evil can be averted” (Fishman, 2012). 
 
Nearly three years after the warning by Prof Fleming about 38% of 
Staphylococcus aureus strains were found to be resistant to penicillin in a 
London hospital (Huttner et al., 2013; Paskovaty et al., 2005). In 2008, the 
former United Kingdom Chief Medical Officer Sir Donaldson made the following 
remarks on antibiotic resistance “Every antibiotic expected by a patient, every 
unnecessary prescription written by a doctor, every uncompleted course of 
antibiotics, and every inappropriate or unnecessary use in animals or agriculture 
is potentially signing a death warrant for a future patient” (Donaldson, 2009). 
Similarly, the present United Kingdom Chief Medical Officer Davies in her 
annual report described AMR as a “ticking time-bomb” about to explode, 
requiring international attention like that given to global warming (Davies, 2013). 
 
The percentage of prescriptions containing antibiotics per visit in developing 
countries is high, with about 58% in an Ethiopian teaching hospital (Desalegn, 
2013), 48.43% in rural health centres of western China (Dong et al., 2008) and 
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54.8% in Lagos, Nigeria (Odusanya, 2005), compared to 15.3% in the USA 
(Roumie et al., 2005). A study conducted in two South African provinces, the 
Western Cape and Limpopo, found a high level of antibiotic use of about 68.1% 
in government hospitals and 31.9% of surgical cases in private hospitals. This 
is likely due to the high prevalence of tuberculosis and HIV-associated 
opportunistic infections in these regions, and lack of prescriber’s knowledge on 
the rational use of antibiotics (Mohlala et al., 2010). In 2010, a multicentre study 
in the USA, showed that 56% of patients had antibiotics during their inpatient 
stay and 30% of these patients had more than one dose of broad-spectrum 
antimicrobial agents (Fridkin et al., 2014). 
 
In some countries, governmental policies are contributing towards inappropriate 
antibiotic prescriptions. A study conducted in China between 2002 and 2005 
found that some hospitals largely depend on pharmaceutical sales as their 
primary source of revenue, which makes up to 45% to 50% of their budget, and 
nearly 50% of these were from antibiotic sales (Sweidan et al., 2005). Doctors 
have no option other than to continue prescribing antibiotics even when patients 
do not require them because their remuneration depends on the number of 
prescriptions they order (Reynolds and Mckee, 2009). In India and China some 
pharmacies offer incentives to prescribers who direct patients to them (Sweidan 
et al., 2005; Laxminarayan et al., 2013).  
 
2.2  MECHANISMS OF ANTIBIOTIC RESISTANCE  
Bacteria have been found to develop resistance to antibiotics using one of the 
following genetic strategies (Figure 2.1). Schmieder and Edwards (2012) shows 
that the following are the general mechanisms used by bacteria to cause 
resistance.  
 The inactivation or modification of the antibiotic; 
 An alteration in the site of the antibiotic that reduces its binding capacity; 
 The modification of metabolic pathways to circumvent the antibiotic effect; 
 The reduced intracellular antibiotic accumulation by decreasing permeability 
and/or increasing active efflux of the antibiotic; 
β- lactamases cause resistance to β- lactam antibiotics via alteration in the 
target site of the antibiotics. The three mechanisms of β- lactam resistance are 
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reduced access to the penicillin-binding proteins (PBPs), reduced PBP binding 
affinity, and destruction through expression of β- lactamases (Rice, 2012). 
Figure 2.1 shows how bacteria develop resistance to different classes of 
antibiotics. This has all accumulated in the high percentage of resistance to 
antibiotics via several mechanisms in various bacterial strains (Schmieder and 
Edwards, 2012). 
 
Figure 2.1: Illustration of antibiotic resistance (Schmieder and Edwards, 
2012). 
 
2.3  DRIVERS OF ANTIBIOTIC RESISTANCE 
 There are several factors that drive resistance to antibiotics and these include: 
2.3.1  Inappropriate antibiotic use 
This refers to the use of antibiotics either in the absence of bacterial infections 
or without indication for prophylaxis. For instance, the use of antibiotics for 
treating viral upper respiratory tract infections or suboptimal treatment of 
infections with inadequate drug dosage, incorrect route of delivery or poor 
adherence to the prescribed medications (Starrels et al., 2009). A 2015 survey 
conducted by the World Health Organisation (WHO) in twelve countries 
revealed that 64% of the participants thought that antibiotics could be used in 
the management of disease conditions caused by viruses (World Economic 
Forum, 2015). The global community needs to do something to bridge this 
elementary gap of knowledge (World Economic Forum, 2015). It has been 
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shown that over 50% of antibiotic use in humans is inappropriate (Paskovaty et 
al., 2005). Both appropriate and inappropriate antibiotic use drives pressure for 
resistance, further worsened by widespread abuse facilitated by easy 
accessibility over the counter without a prescription in many countries (O'Neill, 
2014; Okeke et al., 2005). Of note, while antibiotic therapy impacts positively 
only on patients who received them appropriately, the resistance developed 
because of their irrational usage will affect the entire community (Coulter et al., 
2015; World Economic Forum, 2013). Based on the findings of a study 
conducted between 2009 and 2010 in six USA hospitals, it was found that only 
59% of the patients had a culture before the commencement of antibiotics. It 
further showed that up to 66% of antibiotic prescriptions were not de-escalated 
by the fifth day of treatment despite negative cultures in 58% of the cases 
(Braykov et al., 2014). Also, a study conducted to assess the antibiotic utilisation 
in South African Intensive Care Units (ICUs), found the percentage of 
inappropriate antibiotic usage to be 43.5% and 60.8% in public and private 
ICUs, respectively, with all patients receiving an average of three antibiotics 
(Paruk et al., 2012). The percentage of inappropriate duration of antibiotic use 
was also found to be 53.2% and 81.7% in public and private hospitals, 
respectively (Paruk et al., 2012). 
 
2.3.2  Use of broad-spectrum antibiotics 
Broad-spectrum antibiotics are often used empirically to treat infections before 
culture results and this is associated with the development of resistance and 
toxicity especially when used for a long period (Pogue et al., 2015). Treatment 
of infections with broad-spectrum classes of antibiotics are strongly linked to the 
emergence of resistant pathogens like methicillin-resistant Staphylococcus 
aureus (MRSA), Vancomycin-resistant Enterococci (VRE), C. difficile and 
multidrug resistant Gram-negative bacteria (SARI, 2009). In Canada, a 
relationship between a decrease in the susceptibility to fluoroquinolones among 
pneumococci and an increase in the number of prescriptions was observed. 
Almost all the strains of Streptococcus pneumoniae were susceptible to 
ciprofloxacin in 1988 when the prescription rate was 0.8 per 100 persons, but 
by 1998 about 1.7% of S. pneumoniae strains showed a decreased 
susceptibility to ciprofloxacin when its prescription rate had increased to 5.5 per 
100 persons (Fishman, 2006). 
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2.3.3 Self-medication 
Kotwani and Holloway (2011) reported that about 80% of all antibiotics are used 
outside the hospital setting, and most of the medicines purchased by patients 
in the community are without prescription especially in Low and Middle-Income 
Countries (Gelband et al., 2015). In countries, such as Nigeria, the high use of 
self-medication is due to the availability of these drugs without a prescription in 
pharmacies (Olayemi et al., 2010). The use of antibiotics without prescription 
outside of Europe and United States varies from 19% to 100% depending on 
their accessibility in the community (Morgan et al., 2011). The purchase of 
antibiotics without prescription in Saudi Arabia is estimated to be 77.6% and 
less than 23% of pharmacists care to ask questions about the status of 
pregnancy before dispensing antibiotics in suspected cases of a urinary tract 
infections (UTI) (Abdulhak et al., 2011). In Syria, the percentage of sales of 
antibiotics without a prescription is up to 87% to 97%, and this is mostly seen in 
Damascus the Syrian capital (Al-Faham et al., 2011). Similarly, in a survey 
conducted in Vietnam in 2010, about 88% and 91% of urban and rural 
pharmacies, respectively, dispensed antibiotics without prescription (Do Thi et 
al., 2014).  
 
2.3.4  Antibiotics use in agriculture and environment  
Antibiotics are mainly employed in agriculture to treat and prevent infections or 
as growth promoters in farm animals and livestock (Gelband et al., 2015). The 
volume of antibiotic use in the agricultural sector is greater than the amount 
used by the human population (Gelband et al., 2015).  A survey conducted in 
the USA showed that over 80% of the total antibiotic consumption is in farm 
animals (Gelband et al., 2015). Indiscriminate and misguided use of 
antimicrobial agents as growth promoters, in the treatment of infections, 
metaphylaxis and prophylaxis among farm animals, in livestock as well as in 
aquaculture has also significantly contributed to the spread of resistant strains 
to humans through direct contact and via environmental contamination (Roca et 
al., 2015). Colistin (Polymyxin E) is one of the few cationic antimicrobial peptides 
used in both human and as a growth promoter in veterinary medicine (Rhouma 
et al., 2016). For several years now, colistin has been considered the last line 
of defence against infections caused by multidrug resistant Gram-negative 
bacteria such as Acinetobacter baumannii, Pseudomonas aeruginosa and 
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Klebsiella pneumonia (Rhouma et al., 2016). To prevent cross-resistance, the 
WHO in 2005 identified antimicrobial agents that are crucial for human health 
and made a recommendation to restrict their uses for nonhuman purposes 
some of which include; tigecycline, carbapenems and daptomycin (WHO, 
2011b). 
 
Antibiotic consumption in farm animals is predicted to increase in coming years 
in response to the need for meat and dairy products which is expected to double 
by 2050 due to the projected increase in human population from 7 billion at 
present to 9 to 10 billion in the next 35 years (Gelband et al., 2015). An 
estimated 63,151 tons of antibiotics were used on livestock in 2010 worldwide 
(Van Boeckel et al., 2015) amounting to two-thirds of the global 100,000 tons of 
antibiotics produced (Bbosa and Mwebaza, 2013). Antibiotic consumption in 
farm animals is predicted to increase by 67% i.e. 105,600 tons by 2030 (Van 
Boeckel et al., 2015). Similarly, use in the Brazil, Russia, India, China and South 
Africa (BRICS) countries is expected to double by 2030 (Van Boeckel et al., 
2015). Even in countries like the United Kingdom where there are established 
laws regulating the use of antibiotics for agricultural purposes, nearly 387 tons 
of antibiotics were utilised for farming activities in 2007 (Donaldson, 2009). 
Similarly, in 2010 in the USA about 13,000 tons of antibiotics were used on 
animals mostly as growth enhancers (Spellberg et al., 2013). A study to 
determine the volume of antibiotics consumed by farm animals in South Africa 
between 2002 and 2004, has found a high level of consumption where more 
than 1,538 tons were consumed mostly in feeds (Eagar et al., 2012). Macrolides 
and pleuromutilins were the most commonly used classes, followed by 
tetracyclines, sulphonamide and penicillin (Eagar et al., 2012). 
  
Price et al. (2007) found that the incidence of drug-resistant bacteria in the 
gastro-intestinal tract is higher in individuals who work on farms that use 
antibiotics as growth promoters than those who work on farms that do not use 
them. Also, there is a 32-fold higher chance of contracting a gentamycin-
resistant E. coli infection in workers that work on such farms than the general 
public (Price et al., 2007). To further contribute to the development of 
resistance, excreted antibiotic residues by both humans and animals through 
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urine and faeces will find their ways into the environment (Daghrir and Drogui, 
2013). Some of these residues disintegrate in the environment, while others 
may withstand treatment chemicals in water processing plants, therefore 
selecting pressure for resistance (Gelband et al., 2015). A study conducted in 
the United Kingdom has found the presence of genes encoding resistance to 
certain antimicrobial agents such as sulphonamide, tetracyclines and 
trimethoprim in rivers that receive waste materials from farms and water 
treatment plants (Rowe et al., 2016).  
 
Similarly, researchers in India and Bangladesh have identified a significant 
number of enzymes, such as New Delhi Metallo-beta-lactamase-1 (NDM-1) and 
Cefotaximase-Munich-15 that confer resistance to some broad-spectrum 
antibacterial agents in municipal water supplies and the environment (Rashid et 
al., 2015; Toleman et al., 2015; Walsh et al., 2011). The use of bioengineering 
technologies in the treatment of sewage helps to disintegrate these antibiotics 
and their residues, thereby reducing the chances of selecting resistant bacteria 
in the environment (Spellberg et al., 2013). If preventive measures such as 
vaccination, farm hygiene and cross breeding are used, they will go a long way  
in reducing the demand for antibiotics in treating infections and growth 
promotion in farm animals (Gelband et al., 2015). Figure 2.2 shows how man, 
animals and environment relate in the development of AMR. 
 
 
Figure 2.2: Interaction between antimicrobial use in man, animals and 
environment [Based on Linton (1977), as adapted by Rebecca 
Irwin, Health Canada (Prescott 2000) and IFT]. 
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2.3.5 Counterfeit drugs  
The use of counterfeit antibiotics is associated with the development of AMR, 
increased morbidity and mortality (Kelesidis et al., 2007). WHO held a joint 
workshop in 1992 with the International Federation of Pharmaceutical 
Manufacturers Association on the negative public health impact of substandard 
drugs. This forum adopted the definition of counterfeit drugs as “One which is 
deliberately and fraudulently mislabelled on identity and/or source. 
Counterfeiting can apply to both branded and generic products, and counterfeit 
products may include products with the correct ingredients or wrong ingredients, 
without active ingredients with an insufficient active ingredient or fake 
packaging.”  (WHO, 1999).  
As stated in a report by the WHO and Food and Drug Administration (FDA) 
nearly 10% of drugs in the global market are counterfeit and even more alarming 
is that this figure may be more than 30% in developing countries (Pincock, 2003; 
Rudolf, 2004). In Africa and Asia up to 60% of antimicrobial agents have been 
reported to be substandard (Kelesidis and Falagas, 2015; Nayyar et al., 2015). 
Nigeria is one of the African countries reported to have over 70% counterfeit 
drugs in circulation with most of these substandard drugs imported from India, 
China, Pakistan, Egypt and Indonesia (Raufu, 2002; Raufu, 2003).   
 
2.4 BACTERIA OF GLOBAL CONCERN 
The bacteria of global concern are the ESCAPE pathogens and these are 
Enterococcus (VRE), Staphylococcus (MRSA, VRSA, hVISA), and C. 
difficile/Candida spp, Acinetobacter, Pseudomonas and Enterobacteriaceae 
(including Klebsiella, E. coli, Serratia and Proteus) (Richard G, presented during 
AMS workshop at CMJAH, 2016). These are similar to ESKAPE pathogens 
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter 
species) as referred by IDSA (IDSA, 2010). The resistance of E. coli to 
fluoroquinolones and third generation cephalosporins has been estimated to be 
over 50% in five of the six WHO regions (WHO, 2014). The rate of K. 
pneumoniae resistance to third generation cephalosporins is over 30% in many 
of the WHO member countries and above 60% in some parts (WHO, 2014). 
Between 2011 and 2014 England reported an increase in the prevalence of E. 
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coli and K. pneumoniae bloodstream infections by 15.6% and 20.8%, 
respectively, compared with a 23% reduction in bloodstream infections caused 
by S. pneumoniae probably due to pneumococcal vaccination (Ashiru-Oredope 
and Hopkins, 2015). As reported by Johnson et al. (2012) the resistance of S. 
aureus to penicillin in the United Kingdom and in parts of the USA is presently 
estimated at 90%. Resistance may develop to penicillin, and in some regions in 
the USA, 50% of its strains are resistant to methicillin (Klevens et al., 2007). In 
Africa, resistance patterns in methicillin-sensitive Staphylococcus aureus 
(MSSA) is high in urban areas which is around 73.7% to 100% for penicillin, 
15% to 89.1% for co-trimoxazole and 21.8% to 92% tetracycline compared to 
remote regions where the resistance rate is around 35.3% penicillin, 11.8% co-
trimoxazole and 5.8% for tetracycline (Schaumburg et al., 2014). A study 
conducted in surgical wards and the ICU of a Greek hospital found S. aureus to 
be the most frequent bacteria causing SSIs (Călina et al., 2017). It was highly 
resistant to first-and second-line antibiotics, such as, ceftriaxone (100%), 
penicillin (91.4%), amoxicillin/clavulanic acid (87.5%) and amikacin (80.0%) 
(Călina et al., 2017). The resistance of MRSA was found to be above 20% in all 
the WHO regions and in some areas, it exceeded 80% (WHO, 2014). The South 
African National Department of Health (NDoH) reported an outbreak of 
Klebsiella pneumoniae bacteria in 2011 which was resistant to all available 
antibacterial agents except colistin which was not licensed for use in South 
Africa at the time (NDoH, 2014a).  An increase in intercontinental travel, 
especially for medical tourism, facilitates the smooth spread of drug-resistant 
pathogens globally (O'Neill, 2014). This mixing of different pathogens facilitates 
the rapid development of new resistant strains (O'Neill, 2014). Most of the cases 
of hospital acquired infections are caused by these bacteria (Rice, 2008). Some 
bacteria causing bacterial infections in hospitals include the following listed 
below:   
 
2.4.1 Acinetobacter baumannii 
This is a Gram-negative bacterium causing a broad range of infections such as 
nosocomial bloodstream infections and pneumonia and has been found to be 
highly resistant to beta-lactams and fluoroquinolones (Kim et al., 2014). It 
causes resistance by pumping drugs out of the cell via the porin-efflux pump 
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(Cag et al., 2016). Other ways it causes resistance are via antimicrobial 
inactivating enzymes, reduced access to bacterial targets, or mutations that 
changes targets or cellular functions. It also produces carbapenemases and 
uses combinations of AMPc and porin mediated resistance (Eliopoulos et al., 
2008). In China, more than 60% of A. baumannii are resistant to carbapenems 
(Fupin et al., 2014). Sentinel surveys in South African public hospitals show it is 
resistant to most antibiotics. Rates of resistance to some of those drugs tested 
include imipenem 77%, colistin 5%, cefepime 79% and ceftazidime 75% 
(Perovic et al., 2014). Colistin is regarded as the drug of choice in treating 
carbapenem-resistant A. baumannii, although its resistance is reported globally 
especially in Europe and Asia (Cai et al., 2012).    
2.4.2  Pseudomonas aeruginosa 
This Gram-negative pathogen causes resistance similar to Acinetobacter 
baumannii by pumping drugs out of the cell via the porin-efflux pump (Cag et 
al., 2016). Other ways include; antimicrobial inactivating enzymes, reduced 
access to bacterial targets, or mutations that change targets or cellular 
functions. It also produces carbapenemases and uses combinations of AMPc 
and porin mediated resistance (Eliopoulos et al., 2008). A recent study in the 
USA identified a certain strain of P. aeruginosa that was resistant to 
ceftazidime/avibactam, and ceftolozane/tazobactam - newly approved by the 
FDA for treating P. aeruginosa (Gangcuangco et al., 2016). In South African 
public hospitals, it is less resistant than A. baumannii, with 33% resistance to 
piperacillin/tazobactam and rare resistance to colistin (Perovic et al., 2014). 
Piperacillin/tazobactam, ciprofloxacin, aminoglycoside or cefepime are 
empirically recommended by the SAASP in treating suspected infections 
caused by P. aeruginosa before culture results are available (Wasserman et al., 
2014).  
 
2.4.3  Enterococcus faecium 
Enterococcus faecium causes resistance via enzymatic degradation 
(Giedraitienė et al., 2011). It is intrinsically resistant to penicillin and 
cephalosporin and low concentrations of aminoglycosides (Perovic et al., 2014). 
Resistance to vancomycin decreased from 13% to 5% between 2013 and 2014 
in South Africa probably because of an improvement in infection control in some 
17  
 
hospitals (Perovic et al., 2014). Vancomycin is empirically recommended by the 
SAASP as a drug of choice for treating suspected infections caused by E. 
faecium while waiting for culture results (Wasserman et al., 2014).  
 
2.4.4  Escherichia coli 
A plasmid-mediated resistant gene transfer is the primary mode of resistance 
operated by E. coli with a minor contribution from the porin-efflux system (Cag 
et al., 2016). In Europe, 17 of 22 countries reported 80% to 100% of isolated E. 
coli were ESBL-producers (EARS-Net, 2014). Sentinel surveys in South African 
public hospitals found a small rise in resistance to the beta-lactam class of 
antibiotics without a considerable increase in ciprofloxacin resistance (Perovic 
et al., 2014). The SAASP recommends the use amoxicillin/clavulanic acid, 
ceftriaxone, aminoglycosides and ciprofloxacin to treat community acquired 
UTIs caused by E. coli (Wasserman et al., 2014). Carbapenems such as 
ertapenem are the drug of choice in cases of ESBL- producing E. coli and 
Klebsiella spp (Van Aken et al., 2014; Wasserman et al., 2014). The most 
appropriate antibiotic to treat carbapenem-resistant Enterobacteriaceae (CRE), 
related sepsis is still debatable, however, combination therapy is preferred to 
monotherapy (Alhashem et al., 2017). In severely ill patients with co-morbidities 
a combination of two or more antibiotics is preferred. One of the most commonly 
used combinations until recently was meropenem, tigecycline and colistin. 
However, a second option to be considered is tigecycline, gentamycin and 
meropenem (Alhashem et al., 2017).     
 
2.4.5 Klebsiella pneumoniae 
Klebsiella pneumoniae is the primary Gram-negative bacterium causing 
infections in Africa and Asia and it is responsible for almost half of all Gram-
negative infections in neonates (Le Doare et al., 2015). The rate of resistance 
of K. pneumoniae to ampicillin and cephalosporins in Africa is up to 100% and 
50%, respectively, and in Asia it is around 94% and 84%, respectively (Le Doare 
et al., 2015). There was a steep increase in the rate of resistance of K. 
pneumoniae to carbapenems reported in Indian tertiary health care centres from 
2% in 2002 to 52% in 2009 in New Delhi (Datta et al., 2012). Blood analysis of 
inpatients from 2010 to 2012 in South Africa showed that 75% of K. pneumoniae 
infections were ESBL-producers (Mendelson, 2015b). In 2008, doctors in 
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Sweden diagnosed a man from India who developed a UTI, which was resistant 
to all antibacterial agents except colistin (Moellering, 2010). The infection was 
caused by K. pneumoniae carrying a gene encoding NDM-1 which rapidly 
spread across the globe within a few years (Moellering, 2010). The first case of 
K. pneumoniae carrying the gene encoding NDM-1 in Africa was reported in 
Kenya in 2009 (Poirel et al., 2011). NDM-1 K. pneumoniae was isolated in both 
South African public and private hospitals in 2011 (Brink et al., 2012; Lowman 
et al., 2011). NDM-1’s are carbapenemases which are β- lactamases enzymes 
with an ability to hydrolyse not only the carbapenems but also all other β- lactam 
agents (Perovic et al., 2016). Other carbapenemases include veronica integron 
metallo-beta-lactamases type (VIM), imipenemases (IMP), Klebsiella 
pneumoniae carbapenemase (KPC), and oxacillinase-48 (OXA-48) (Okoche et 
al., 2015). A 4 year study in South Africa showed that the most common 
carbapenemase-producing genes were blaNDM (59%),
 bla
OXA-48 (29%), 
bla
VIM (7%), 
bla
IMP (2%), 
bla
GES (1%) and 
bla
KPC (1%) (Perovic et al., 2016).  
Amoxicillin/clavulanic acid, ceftriaxone, ciprofloxacin or aminoglycoside are 
empirically recommended by the SAASP in treating suspected infections 
caused by K. pneumoniae before culture results (Wasserman et al., 2014). 
 
2.4.6 Enterobacter cloacae 
It is an enterobacteriaceae which produces enzymes that are EBLS in nature 
and there is a global increase in IMP-Producing Enterobacter cloacae among  
carbapenemase-producing Enterobacteriaceae (Sidjabat et al., 2015). It causes 
resistance to antibiotics via enzymatic degradation (Giedraitienė et al., 2011). 
It’s resistant rates to imipenem and meropenem in South African public 
hospitals have been reported at 2% with cefepime resistance noted at 35% 
(Perovic et al., 2014). The SAASP has recommended the use of ciprofloxacin, 
aminoglycoside or cefepime empirically in suspected infections caused by E. 
cloacae before culture results (Wasserman et al., 2014). 
 
2.4.7  Methicillin-resistant Staphylococcus aureus  
MRSA was previously limited to the hospital environment, but recently it has 
been associated with community-acquired infections associated with skin and 
soft tissue infections, pneumonia and severe blood stream infections (Gelband 
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et al., 2015). Sub-Saharan African countries have witnessed a sharp increase 
in MRSA prevalence since the beginning of the 2000s (Gelband et al., 2015). 
However, in South African referral hospitals it has been demonstrated that it’s 
prevalence has decreased from 36% in 2006 to 24% during 2007 to 2011, 
because of the implementation of effective infection control policies (Kariuki and 
Dougan, 2014). Bamford et al. (2011) reported that MRSA was 30% to 60% 
resistant to cloxacillin in South Africa. Similarly, reports from Europe and the 
USA showed a reduction in MRSA over the past eight years from 22% to 18% 
and from 53% to 44%, respectively (Gelband et al., 2015). Conversely, in some 
developing countries like India, there has been a sudden increase in MRSA 
prevalence from 29% of S. aureus isolates in 2009 to 47% in 2014 (Gelband et 
al., 2015). MRSA is responsible for over 10% of blood stream infections in 15 
European countries (Gelband et al., 2015). In South Africa about 75% of 
nosocomial S. aureus infections in tertiary paediatric hospitals are caused by 
MRSA (Gelband et al., 2015). Similarly, positive blood cultures from nosocomial 
S. aureus infections were caused by MRSA in more than half of patients in other 
public sector hospitals (Mendelson, 2015b). Sentinel surveys in South African 
public hospitals show that MRSA is 41% resistant to cefoxitin and 20% to 35% 
resistant to lincosamides and macrolides (Perovic et al., 2014). The SAASP has 
recommended the use of cloxacillin and vancomycin as drugs of choice for 
treating MSSA and MRSA, respectively (Wasserman et al., 2014). 
 
2.4.8  Extended spectrum beta-lactamase producers  
ESBLs are Gram-negative bacteria that produce enzymes which resist the most 
commonly used antibiotics (Reuland et al., 2014; WHO, 2014). ESBLs 
inactivate all penicillins and cephalosporins (Gelband et al., 2015). As stated by 
Leopold et al. (2014) resistance patterns of ESBLs to third generation 
cephalosporins in sub-Saharan Africa vary from one country to another, with a 
wide range of resistance from 0% to 47%. In South African hospitals rates range 
from 0.3% – 13.1% in some communities (Storberg, 2014). ESBL Gram-
negative bacteria commonly cause hospital-acquired UTIs with resistance to 
first-line antibiotics, necessitating the use of more expensive second-line 
antibiotics (Mendelson, 2015a). In West African United Nation, = sub-regions, 
the prevalence of ESBLs ranges from 10% to 96% of community samples 
(Storberg, 2014). In Maiduguri, north-eastern Nigeria 33.5% of K. pneumoniae 
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and E. coli isolates were found to be ESBL producers, but only 23.6% were 
positive on the double disk synergy technique (Mohammed et al., 2016). In 
North African countries, ESBL prevalence ranges from 11% to 78% in hospitals 
and 1% to 8% in the communities (Storberg, 2014). In East Africa, ESBLs were 
found in 38% to 63% of hospitals samples and 6% of population samples 
(Storberg, 2014). In Central Africa, 55% to 83% of hospital samples were ESBL-
positive and rates of 11% to 17% were noted in the community (Storberg, 2014).   
 
2.4.9 Carbapenem-resistant Enterobacteriaceae 
While a report from hospitals in developed countries has shown an increased 
infection rate caused by CRE (Lerner et al., 2014), a similar pattern has also 
been reported in developing countries (Gelband et al., 2015). In 2012, about 
11% of Klebsiella spp and 2% of E. coli were resistant to carbapenems in the 
USA (Gelband et al., 2015). In 2015, there was an outbreak of carbapenem-
resistant Providencia rettgeri among patients in an ICU of a tertiary South 
African hospital, with one of them developing the infection after abdominal and 
pelvic procedures required to treat gunshot injuries (Tshisevhe et al., 2016).  
 
2.4.10 Clostridium difficile 
Treatment of infections with antimicrobial agents either appropriately or 
inappropriately changes the equilibrium of intestinal microflora by destroying 
bacterial volume, thereby creating an enabling environment for C. difficile to 
proliferate (CDC, 2013; Mcdonald et al., 2012). These infections can be fatal 
especially in individuals with compromised immunity and in the elderly (Fridkin 
et al., 2014). Treatment of infections with broad-spectrum antibiotics such as 
third generation cephalosporins, clindamycin and fluoroquinolone are 
associated with the development of C. difficile infection, with about US$ 8 billion 
spent annually in the treatment of diseases associated with C. difficile in the 
USA (Owens et al., 2008), especially with chronic antibiotic therapy. The annual 
incidence of C. difficile infection was about 8.7 cases per 100,000 admissions 
in a South African tertiary hospital, and one-third of these infections were 
community acquired, this is below the annual incidence of western countries of 
about 74 cases per 100,000 admissions (Rajabally et al., 2013). According to 
Onwueme et al. (2011) in Nigeria, the prevalence of C. difficile in HIV-positive 
individuals was 43% among hospitalised cases and 14% among outpatients 
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with diarrhoea. It was responsible for 250,000 cases and up to 14,000 
mortalities in the USA (CDC, 2013). It has been reported that there is a 7 to 10-
fold increase in the chance of acquiring a C. difficile infection after a month of 
discontinuing antibiotics treatment (Brown et al., 2015; Hensgens et al., 2012). 
AMS programmes have been shown to reduce the likelihood of developing C. 
difficile infections by 52% (Feazel et al., 2014). The SAASP has recommended 
metronidazole and oral vancomycin as the drugs of choice in the treatment of 
infection caused by C. difficile (Wasserman et al., 2014).  
 
2.4.11 Vancomycin-resistant Enterococci 
Vancomycin-resistant Enterococci (VRE) were first discovered in 1987 in 
Europe and within a few years they had spread globally (Willems et al., 2005). 
In 2012, South Africa recorded an outbreak of VRE in both public and private 
health facilities (NDoH, 2014a). In North America, a reduction in its spread was 
noticed following implementation of infection control measures (Huttner et al., 
2013). Linezolid is empirically recommended by the SAASP as a drug of choice 
for treating suspected infections caused by VRE while waiting for culture results 
(Wasserman et al., 2014). 
 
2.5 GLOBAL ANTIBIOTIC CONSUMPTION 
The world has witnessed a tremendous increase in the volume of antibacterial 
use in the last decade by over 30%, from approximately 50 billion standard units 
(SUs) in 2000 to 70 billion SUs in 2010. Globally, penicillin and cephalosporins 
are the most commonly consumed antibiotics accounting for up to 41% in 2000; 
with this figure steeply increasing to 60% in 2010 (Van Boeckel et al., 2014). 
There is also an increase in the global use of last resort antibiotics such as 
carbapenems (45%) and polymyxins (13%) (Van Boeckel et al., 2014). Some of 
the old antimicrobials that had lost their popularity in the past due to toxicity like 
colistin, are now gradually being re-introduced to treat multidrug-resistant 
bacterial infections (Wertheim et al., 2013a). An increase of 6.7% in antibiotic 
consumption was noted in England from 21.6 Defined Daily Doses (DDDs) per 
1000 inhabitants per day in 2011 to 23 DDDs per 1000 inhabitants per day in 
2014 (Ashiru-Oredope and Hopkins, 2015). In 2010, countries like India, China 
and the United State were the leading consumers of antibiotics with these 
countries alone consuming 13 billion SUs, 10 billion SUs, and 7 billion SUs, 
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respectively. But in per capita terms, the United States has exceeded the other 
two countries, with 22 SUs per individual compared with 11 SUs and 8 SUs per 
individual in India and China, respectively (Van Boeckel et al., 2014). A 
substantial increase in antibiotic utilisation has been noted in the five fastest 
growing economies in the world, the so-called BRICS countries, from 2000 to 
2010, these countries alone accounted for three-quarters of the global 
consumption in 10 years (Van Boeckel et al., 2014). Laxminarayan et al. (2016) 
predicted that effective pneumococcal vaccination would reduce antibiotic use 
by up to 11.4 million antibiotic days for treating pneumonia cases in children 
under five years, which is almost equivalent to a 47% decrease in the volume 
of antibiotics for treating pneumonia in 75 countries. Figure 2.3 shows the world 
economic burden and impact of AMR. 
 
2.6  EMERGENCE OF RESISTANCE TO LAST RESORT ANTIBIOTICS 
A review of carbapenem-resistant bacteria across South African provinces from 
January 2000 to May 2016 showed that about 2,315 cases were isolated with 
the Gauteng province having the highest number of cases at 1,220 followed by 
KwaZulu-Natal with 515 (Sekyere, 2016). Most of these cases could not be 
linked with travel history from other countries indicating that the strains were 
selected due to high carbapenem consumption nationwide (Sekyere, 2016). 
There has been a gradual increase in isolation of these pathogens that confer 
resistance to last resort antibacterial agents such as carbapenems, colistin and 
tigecycline in South Africa (Sekyere, 2016). Of note, the recent identification of 
Mannose Receptor, C Type 1 (mcr-1) gene among E. coli in two provinces is a 
great public health concern not only in South Africa, but also in other African 
and European countries (Sekyere, 2016). Patients from all over Africa seek 
medical care in South Africa because of the quality of health facilities, while 
patients from Europe come to this country because of more affordable services 
(Crush et al., 2012). Medical tourism is considered a quick way of transmitting 
resistant pathogens across the globe (Crush et al., 2012).   
 
Colistin is regarded as one of the last resort antibiotics for treating resistant 
bacterial infections (Sprenger, 2016). Even though it was discovered in 1949; 
its intravenous usage on humans was gradually abandoned due to its toxicity, 
however, it continued to be used widely in animals as a growth promoter 
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selecting resistant bacteria (Falagas et al., 2005). But recently its usage has 
increased due to an increase in bacterial resistance to first- and second-line 
antibiotics (Sprenger, 2016). Bacteria develop resistance to colistin and 
tigecycline by promoting a mutation in lipid A and by pumping these drugs out 
of the cells via porin-efflux pumps (Osei Sekyere et al., 2016). 
 
Figure 2.3:  Global transmission of antimicrobial resistant bacteria (World 
Economic Forum, 2013).   
 
Until recently, colistin resistance was limited to chromosomal mutation, 
however, in 2015 the first case of plasmid-mediated mcr-1 resistant 
Enterobacteriaceae was identified in pigs in China which is of global concern 
(Liu et al., 2016). Since its discovery in China, it has spread across the globe 
and has recently been identified in the United States in a urine specimen of a 
patient suffering from a UTI (Mcgann et al., 2016).  In South Africa, the mrc-1 
gene has been isolated from colistin- resistant strains of E. coli in two different 
Provinces namely Gauteng and Western Cape (Coetzee et al., 2016).  
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2.7 ANTIBIOTIC PIPELINE  
The pipeline to produce new classes of antibacterial agents has not been active 
recently leading to significant scientific bottlenecks in the development of new 
agents. As a result, the last time a new class of antibacterial agent was 
discovered was in the 1980s (WHO, 2014; Roca et al., 2015). Four sets of new 
antibiotics from existing classes were approved by the FDA in the USA in 2014, 
namely dalbavancin, tedizolid, oritavancin and ceftolozane/tazobactam; and in 
2015 it also licenced ceftazidime/avibactam (Doshi, 2015). Drug development 
is a capital-intensive business with only a small proportion of drugs that begin 
preclinical trials progressing through to obtain approval from stringent drug 
regulatory bodies such as the European Medicines Agency (EMA) and FDA 
(Gelband et al., 2015). Antimicrobial agents provide little profit to 
pharmaceutical companies because they are usually prescribed for a short 
duration compared to other classes of medicines used for treating chronic 
conditions (Marston et al., 2016). In addition, inexpensive generics of original 
products that are relatively active in certain infections are preferred as first-line 
drugs to preserve newer agents for life-threatening bacterial infections (Morel 
and Mossialos, 2010). Only a few pharmaceutical companies invest in the 
research and development of antimicrobial agents. These companies 
aggressively market their products to doctors to recover their capital investment 
and this may compromise the effort at preventing resistance (Donaldson, 2009).  
 
2.8 SURVEILLANCE OF RESISTANT BACTERIA IN AFRICA 
In 2014 the WHO report on AMR and surveillance indicated that there is a lack 
of accurate and reliable data concerning the extent of AMR in Africa, as 
surveillance of drug-resistant organisms is conducted in only a few countries of 
the region (WHO, 2014). It further noted a lack of regional collaboration in the 
monitoring of resistant organisms and sharing of information among the 
networks of laboratories in the area (Gelband et al., 2015). However, high rates 
of resistance have been reported in many bacteria, increasing the risk of spread 
of resistance in both hospitals and communities in this region (Gelband et al., 
2015; WHO, 2014). South Africa is one of the few African countries with a good 
surveillance system with reliable data captured in both public and private health 
institutions. It has established surveillance for ESKAPE organisms (Gelband et 
al., 2015). The data collected in public laboratories are reported to the National 
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Institute of Communicable Diseases and consists of data gathered from public 
sentinel hospitals by the group for Enteric, Respiratory and Meningeal Disease 
Surveillance in South Africa, a national clinical microbiology network (Gelband 
et al., 2015). About 31 hospitals and over 200 laboratories conduct surveillance 
on 12 organisms (Gelband et al., 2015). The South African Society of Clinical 
Microbiology is responsible for collating data on 13 microorganisms in five 
laboratory groups of private organisations. These sets of data are centrally 
analysed and consolidated by the South African Antibiotic Resistance 
Partnership and Group for Antibiotic Resistance Partnership (GARP) (Gelband 
et al., 2015).   
 
2.9  INFECTION CONTROL 
Healthcare-associated infections refer to infections acquired by patients while 
being treated in hospital; they are mostly transmitted through the hands of 
hospital personnel, hospital equipment or contamination of surgical wounds 
(Cristina et al., 2013; Gelband et al., 2015; Pittet et al., 2006). Infection control 
measures such as hand hygiene are shown to reduce transmission of 
pathogenic microorganisms from hospital personnel to patients (Boyce and 
Pittet, 2002). Infection-control measures also reduce sepsis (Sinha et al., 2015) 
and decrease infections caused by MRSA (Aldeyab et al., 2008). They also 
reduce antibiotic prophylaxis in patients with UTI by up to 2 DDDs per day 
(Stéphan et al., 2006). Evidence from randomised controlled trials (RCTs) show 
that hand washing with soap and water or alcohol solution reduces hospital 
acquired infections (Allegranzi and Pittet, 2009; Barnett et al., 2014; Pittet et al., 
2006). Despite these benefits, a significant percentage of health-care providers 
do not follow hand washing guidelines in developed countries (Erasmus et al., 
2010). While in developing countries lack of water, soap and understaffing are 
the primary barriers to hand washing (Boyce and Pittet, 2002).  
 
2.10  SURGICAL SITE INFECTIONS 
SSIs are the 3rd most common type of nosocomial infections and represent 
about 15% of all nosocomial infections (ECDC, 2013). Patients with SSIs have 
a 60% chance of ICU admission, high rate of readmission, increased hospital 
cost and are more likely to die compared to those who do not develop SSIs 
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(Brink et. al., 2016c). A retrospective review that measured the impact of SSIs 
in the 1990s on patient outcomes found that the median duration of inpatient 
stay was 11 days for patients who developed SSIs and 6 days for patients who 
did not develop SSIs (Kirkland et al., 1999). The total hospital cost incurred by 
patients who developed SSIs was US$ 7,531 compared to US$ 3,844 incurred 
by those who did not have SSIs (Kirkland et al., 1999). Developing countries 
have a higher burden of nosocomial infections compared to developed countries 
(Nejad et al., 2011). A systematic review by the WHO in 2011 showed that there 
are limited studies conducted on nosocomial infections in Low and Middle 
Income Countries (Allegranzi et al., 2011). Another review indicates that there 
are a limited number of interventional studies designed to address the burden 
of SSIs in Africa and only found 24 of such studies over 15-year period in sub-
Saharan Africa (Aiken et al., 2012).  
 
SSIs are responsible for a significant proportion of hospital-acquired infections, 
yet many hospitals do not have information on probable risk factors for SSIs in 
patients undergoing an operation (Wilson, 2014). Conducting surgical 
operations in developing African countries is associated with serious problems 
ranging from shortage of skilled personnel and standard operating theatres to 
the high incidence of SSIs (Aiken et al., 2012). Factors that causes SSIs include 
pathogens introduced into the operation site, the number of bacteria that remain 
when the wound is dressed, the ability of the pathogen to grow and invade 
tissues and the inability of the host's immune system to fight back (Wilson, 
2014). Other factors include malnutrition, diabetes and smoking (Reichman and 
Greenberg, 2009).  
 
A study conducted in southern Nigeria showed that S. aureus was the most 
common cause of SSIs, at 25%, then P. aeruginosa at 20%, followed by E. coli 
at 15% and K. oxytoca and Proteus mirabilis accounted for 10% each; while the 
coagulase-negative Staphylococcus, Streptococcus pyrogenes, K. aerogenes 
and Proteus vulgaris each accounted for 5% (Anthony et al., 2010). Gram-
positive bacteria were strongly resistant to penicillin, cloxacillin, and ampicillin 
except for S. aureus which was found to be 70% to 90% sensitive to 
streptomycin and erythromycin (Anthony et al., 2010). Antibiotic susceptibility 
shows that Gram-negative bacteria were strongly resistant at 70% to 100% to 
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co-trimoxazole, ampicillin, streptomycin and tetracycline, but sensitive in about 
70% to 90% of samples to colistin and gentamycin excluding P. aeruginosa and 
K. oxytoca (Anthony et al., 2010). The incidence of SSIs in India varies from 4% 
to 30% for clean operations to 10% to 45% for clean-contaminated operations, 
with S. aureus and P. aeruginosa being the commonest cultured bacteria (Lilani 
et al., 2005). Prolonged surgical procedures, drained wounds and extended 
hospitalisation before and after surgery were associated with high chances of 
contracting SSIs in India (Lilani et al., 2005). SSIs increase health care cost 
because of additional days of admission, laboratory investigations, other 
antibiotic courses and increased possibility of repeat surgeries (Reichman and 
Greenberg, 2009). In 2009, a study showed that SSIs prolong duration of 
hospital admission by an average of 9.5 days with an associated cost 
implication of US$ 20,842/admission (De Lissovoy et al., 2009). The WHO has 
recently adopted 29 recommendations to lessen the chances of SSIs before, 
during and after surgical procedures. These include: preoperative bathing, 
appropriate timing of surgical prophylaxis, bowel preparation, and non-shaving 
of hair before surgery, others are proper hand washing before scrubbing and 
intranasal application of mupirocin among S. aureus carriers undergoing 
orthopaedic and cardiothoracic procedures (WHO, 2016b).  
 
Fungal infections are often neglected when evaluating patients with surgical 
infections, the rate of these infections after intra-abdominal procedures is rising 
(Soop and Carlson, 2017). A study across 97 hospitals in the United States 
showed that Candida albicans 39.6% and Candida glabrata 35.7% were the 
most common pathogens causing fungal septicaemia after intra-abdominal 
procedures. It further showed an increased chance of acquiring an infection with 
fluconazole-resistant pathogens among patients who had fluconazole 
prophylaxis (Zilberberg et al., 2014). 
 
2.10.1 Classification of surgical wounds 
Surgical wounds are classified into four different types (Mangram et al., 1999). 
 Clean wounds: these refer to injuries that are uninfected, without inflammation. 
They are primarily closed under aseptic condition.  
 Clean-contaminated wounds: here the surgical procedures are performed under 
controlled techniques without contamination but mostly in aseptic condition. 
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 Contaminated wounds: these are recent traumatic injuries with spillage from the 
infected site, non-purulent inflammation, with a high risk of septic condition. 
 Dirty wounds: here the wounds contain purulent inflammatory tissues, foreign 
bodies, faecal matter or perforated viscera.  
 
2.10.2 Surgical prophylaxis 
Surgical prophylaxis is a process of administering an antibiotic to a patient 
before a surgical procedure, with the aim of avoiding a bacterial infection 
following an anticipated bacterial exposure (Wasserman et al., 2014). 
Appropriate surgical prophylaxis is an effective way of addressing SSIs 
(Wanyoro et al., 2013). Usually, a single dose is sufficient unless a repeat dose 
is required in cases where there are long surgical procedures or a large volume 
of blood is lost (Wasserman et al., 2014). The SAASP, and Standard Treatment 
Guidelines and Essential Medicines lists for South Africa have recommended 
the use of cefazolin in most surgical procedures, however metronidazole is also 
given where anaerobic infection is anticipated. Other antibiotics such as 
ciprofloxacin, cefuroxime, vancomycin and chloramphenicol eye drops are 
recommended in certain specific surgical procedures (NDoH, 2015; Wasserman 
et al., 2014). A review of RCTs, conducted by Cochrane in 2008 showed that 
short-term use of intranasal mupirocin ointment decreases the tendency of 
developing SSIs due to S. aureus with no chance of developing resistance (Van 
Rijen, 2009). Similarly, Wilcox et al. (2003) found that the use of prophylactic 
nasal mupirocin and 2% triclosan before orthopaedic operations resulted in a 
remarkable reduction of incidence of SSIs secondary to MRSA from 23/1000 
surgeries to about 3.3 to 4.0/1000 surgeries, with a subsequent decrease in the 
demand for vancomycin by 23%. 
 
Surgical prophylaxis is considered appropriate when the antibiotic is 
administered 0 to 60 minutes before first surgical incision or 120 minutes in 
cases where fluoroquinolones or vancomycin is used (Saied et al., 2015). 
Antibiotic therapy should also not exceed a duration of 24 hours after surgical 
operation (Saied et al., 2015). A study conducted in surgical settings of five 
Egyptian hospitals found that only a few hospitals had policies guiding general 
antibiotic usage or surgical prophylaxis. Additionally, no national guideline for 
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the optimisation of antibiotic therapy through AMS was available (Saied et al., 
2015). With the introduction of an educational intervention in these hospitals, a 
significant improvement was observed in the timing of the first dose of surgical 
prophylactic antibiotics in three hospitals with low support before the project 
from 0% - 6.7% to 11% - 38.7% in both pre-and post-implementation stages of 
the study, respectively (Saied et al., 2015). There was also a reduction in the 
volume of antibiotic consumption in four hospitals from 843 Day of Therapy 
(DOT)/1000 patient days in the pre-intervention stage to 334 DOT/1000 patient 
days in the post-intervention stage. All the participating hospitals reported an 
improvement in the duration of surgical prophylaxis (Saied et al., 2015). 
 
Upon introduction of an educational intervention in thirteen Dutch hospitals, the 
volume of antibiotic consumption reduced from 121 DDDs/100 procedures in 
the pre-intervention stage to 79 DDDs/100 procedures in the post-intervention 
stage with a consequent reduction in antibiotic cost per procedure by 25% from 
€ 10.96 to € 8.24 (Van Kasteren et al., 2005). The number of cases with 
prolonged duration of inappropriate prophylaxis dropped to about 778 cases 
instead of 1,024 cases, the number of cases that received prophylaxis at an 
optimal duration increased from 805 (50%) cases pre-intervention to 1,197 
(61%) post-intervention (Van Kasteren et al., 2005). Cefazolin and 
metronidazole were the prophylactic drugs of choice if anaerobic bacteria were 
suspected during the study. Other agents used were first- and second-
generation cephalosporins and co-amoxiclav in some surgical cases (Van 
Kasteren et al., 2005). 
 
2.11  ECONOMIC BURDEN OF ANTIBIOTIC RESISTANCE  
Only a small number of studies on the economic implications of AMR in 
developing countries have been published. The WHO (2011a) reports that 
hospital acquired infections caused over 37,000 deaths with an additional 16 
million days of admission in Europe at a cost of € 7 billion per annum. These 
figures are even higher in developing countries (Laxminarayan et al., 2013). A 
report from the North-West province of South Africa showed that a full course 
of treatment of multidrug-resistant tuberculosis cost around R 26,354 (US$ 
4,300) compared to R 215 (US$ 35) for drug-susceptible tuberculosis (Okeke et 
al., 2005). Similarly, data from Peru has proven that the cost of treating 
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multidrug-resistant tuberculosis is far higher than drug-susceptible tuberculosis 
which was estimated at US$ 8,000 and US$ 267, respectively (Okeke et al., 
2005). Just over 50,000 lives are lost to antimicrobial resistance in Europe and 
the USA alone, leading to costs associated with loss of productivity (O'Neill, 
2014). 
 
As stated by the United States Centre for Disease Control and Prevention 
(CDC), about two million infections and over 23,000 mortalities occur annually 
because of antibiotic resistance in the United States (CDC, 2013). This amounts 
to a cost of US$ 20 billion with productivity losses of up to US$ 35 billion (CDC, 
2013). Similarly, in Europe up to 25,000 deaths are linked to antibiotic 
resistance, with a financial loss of over € 1.5 billion (ECDC/EMEA, 2009). To 
assess the burden of AMR the United Kingdom government in 2014, under 
Prime Minister D. Cameron appointed Prof J O' Neil, an economist to chair a 
review of AMR (O'Neill, 2016). The work was carried out by two separate 
auditing firms to determine the future economic consequences of neglecting 
AMR; it was found that over 700,000 patients die every year because of AMR 
(Figure 2.4). It was forecast that if measures to contain antibiotic resistance are 
not taken, over 300 million people will die of infections from resistant organisms 
in the next 35 years (O'Neill, 2016). With the consequent reduction of up to 2% 
to 3.5% of the world's Gross Domestic Product, this means that US$ 60 to 100 
trillion will be lost to AMR (Figure 2.5) (O'Neill, 2016). Based on this prediction 
4,150,000 people from Africa will die every year (O'Neill, 2014).  
 
 
Figure 2.4:  Global deaths due to AMR every year (O'Neill, 2016). 
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Even though reliable data on the economic implications of antibiotic resistance 
are lacking in developing countries, estimated attributable mortality rates have 
been calculated (Laxminarayan et al., 2013). About 58,000 deaths from 
neonatal sepsis were found to be secondary to resistant bacterial infections in 
India alone (Laxminarayan et al., 2013). Similarly, research from Tanzania and 
Mozambique shows an increased mortality in children under five years, because 
of difficult to treat bacterial infections (Kayange et al., 2010; Roca et al., 2008). 
Further research is required to determine the economic burden of these 
mortality rates. 
 
 
 
Figure 2.5:  Predicted regional burden of AMR every year by 2050 
(O'Neill, 2014).  
 
2.12  OVERVIEW OF ANTIMICROBIAL STEWARDSHIP 
The term “Antimicrobial Stewardship” was coined by two infectious diseases 
specialists McGowan JE and Gerding DN in 1996 (Mcgowan Jr and Gerding, 
1996). However, programmes to optimise antimicrobial have been in existence 
since the 1970s, known as “Antimicrobial management” or “Antimicrobial 
control” projects (Bennett et al., 2014). It is a multidisciplinary, systematic 
approach which reduces the duration of treatment, improves patient outcomes, 
minimises drug side effects, reduces drug costs, limits the emergence of 
resistance and ensures the safety of the patient (Fishman, 2012; Dellit et al., 
2007). According to Cruickshank (2011) AMS programmes, alongside infection 
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control, hand hygiene and surveillance are regarded as critical tools for 
preventing the emergence of AMR in our health facilities. The FDA is promoting 
AMS programmes in the United States by supporting the research and 
development of new antibiotics (Cunha et al., 2013). In 2015, the WHO 
encouraged all member states to design a national plan on how to address the 
burden of AMR in two years (Figure 2.6) and it should include the following 
(WHO, 2015): 
 Decrease demand for antimicrobial agents through the provision of potable 
water, sanitation and immunisation. 
 Implement measures such as infection control and AMS policy at hospital level. 
 Change attitudes that encourage antibiotic overuse and misuse to positions that 
support AMS. 
 Encourage appropriate antibiotic use in agriculture. 
 Enlighten the public, health care providers and policy makers on appropriate 
use of antibiotics and implications of antibiotics misuse. 
 Political will to address the burden of antibiotic resistance.  
 
 
Figure 2.6:  Strategies to contain antimicrobial resistance (Fishman, 2006). 
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The National Action Plan for Combating Antibiotic-Resistant Bacteria was 
launched by the United States government at the White House in March 2015, 
with it’s goal to identify the need for all critical care centres in the United States 
to adopt AMS by 2020 in line with the CDC's recommendations (White House, 
2015). Nursing homes, general outpatient departments, hospital wards and 
emergency units were also encouraged to adopt AMS programmes (Barlam et 
al., 2016). Similarly, in South Africa, the GARP is collaborating with both public 
and private sectors to address this problem (Gelband et al., 2015). In view of 
the constant danger caused by resistant pathogens and the uncertainty 
surrounding the development of new classes of antimicrobials, a need exists for 
the Health Service Executives in our hospitals to adopt AMS programmes (Roca 
et al., 2015). In 2011, the AMS and resistance working groups of the 
International Society of Chemotherapy came up with recommendations to guide 
the appropriate use of antibiotics in hospital inpatients (Hara et al., 2016). The 
IDSA in collaboration with the Society for Health Care Epidemiology of America 
has recently developed 27 recommendations to guide hospital AMS 
programmes (Barlam et al., 2016). Global implementation of AMS is facing 
serious challenges especially in Low and Middle Income Countries, where it is 
mostly absent (Wertheim et al., 2013b). Most hospitals in developing countries 
do not have AMS (Gelband et al., 2015) with only 14% of hospitals in Africa 
having AMS compared with 46% and 53% in Latin American and Asian 
hospitals (Howard et al., 2015).  
 
Training and education in AMS is key. Incorporation of AMS and infection 
control courses into both undergraduate and postgraduate curricula of all health 
professionals will prepare them early enough to embrace the culture of 
appropriate prescription (Abbo et al., 2013; Ashiru-Oredope and Hopkins, 2015; 
Thriemer et al., 2013). Based on the findings of a survey conducted in thirteen 
European countries involving 35 medical schools, it was found that all the 
schools except one offered courses on AMS to undergraduate students but only 
one-third of these countries had implemented national programmes. (Pulcini et 
al., 2015). Comprehensive AMS programmes have yielded a significant 
reduction in the use of antimicrobial agents, an increase in institutional cost 
saving, improvement in the appropriate use of antimicrobial agents, and a 
decrease in resistance rates, morbidity, mortality and hospital readmission 
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(Cruickshank, 2011; SARI, 2009). AMS provides a shorter duration of treatment 
and reduces hospital costs (Ohl and Ashley, 2011). In 2015, data on antibiotic 
consumption across European Primary Health Centres showed France as one 
of the countries with the highest rate of antibiotic consumption (ECDC, 2016). 
However, this is relatively stable in hospital environments, which is probably 
because the government has made it mandatory for hospitals in France to adopt 
AMS programmes before they can be given an operational licence (Le Coz et 
al., 2016). Upon implementation of an AMS programme in acute care centres in 
9 countries over a period of 14 years, there was a reduction in antibiotic 
consumption of 11% to 38%, as well as reduction in cost by US$ 5 to 
10/patient/day (Kaki et al., 2011). There was also an improvement in 
inappropriate antibiotic therapy and a reduction in average length of treatment 
(Kaki et al., 2011). AMS also reduces hospital acquired infections (Davey et al., 
2017).   
 
2.12.1 Goals of antimicrobial stewardship 
 To partner with the physicians to ensure each patient receives optimal antibiotic 
therapy, by paying attention to the following “Ds” of appropriate antibiotic 
treatment: the “Ds” are right Drug, the right Dose, the best route of Delivery, 
attention to De-escalation and proper Duration of administration (Doron and 
Davidson, 2011; Joseph and Rodvold, 2008). 
 To discourage unnecessary antibiotic usage especially in infections caused by 
viral agents (Doron and Davidson, 2011). 
 To decrease chances of acquiring infections with difficult to treat bacteria such 
as C. difficile (Doron and Davidson, 2011). 
2.12.2 Antimicrobial stewardship in South Africa 
The Annual Conference of the Federation of Infectious Diseases of Southern 
Africa held on February 2012, gave birth to the South African Antibiotic 
Stewardship Programme with the following goals:  
 To organise training on the appropriate use of antibiotics and share experiences 
with AMS to all South African health institutions and civil society groups. 
 To establish strong leadership for strengthening AMS in both South African 
public and private health-care institutions. 
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 To develop a harmonised national guideline on antibiotic prescription out of the 
existing national guidelines, and include other infections, not in the guideline 
and incorporate improved diagnostic techniques. 
 To recommend to the stakeholders the areas that need to be researched to 
bridge the gap of knowledge. 
 To partner with the NDoH and other stakeholders in the private sectors (NDoH, 
2014b).     
In response to the WHO resolution “Combating antimicrobial resistance 
including antibiotic resistance’’ adopted by the World Health Assembly, the 
South African NDoH launched the Antimicrobial Resistance National Strategy 
Framework 2014 to 2024 (Figure 2.7) (NDoH, 2014b).  These enablers were 
debated at a summit on AMR 2014 in Johannesburg and have since been 
accepted by the government of South Africa (Mendelson, 2015b).  
 
 
 
Figure 2.7:  Pillars of South African AMR strategy framework (NDoH, 2014b). 
 
The objectives are: 
 Strengthen, coordinate and institutionalise interdisciplinary efforts. 
 Enhance surveillance and early detection of antibiotic resistance. 
 Optimise infection control and prevention.    
 Promote AMS programmes.  
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            While the four enablers being:        
 Legislative measures to guide antimicrobial utilisation.  
 Educational empowerment.  
 Communication.  
 Research (NDoH, 2014b).  
 
2.12.3 Antimicrobial stewardship strategies 
These strategies include; 
2.12.3.1 Education 
Education is an important strategy in AMS projects as it provides 
prescribers with new evidence and recommendations on how to 
prescribe antibiotics in line with best practices (Barlam et al., 2016). 
Educational programmes like lectures and tutorials are more useful in 
academic and training hospitals than in non-academic hospitals (Barlam 
et al., 2016). However, educational interventions alone without 
incorporation of other active strategies have been shown to play little role 
in changing prescribers attitudes and behaviour (Dellit et al., 2007). Knox 
and Edye (2016) reported that implementation of education interventions 
alone in an Australian hospital did not show any significant difference in 
the compliance rate of surgical prophylaxis. The compliance rate before 
and after programme implementation was 18% and 15%, respectively.  
 
2.12.3.2 Formulary restriction and pre-authorisation 
This approach restricts access to certain antimicrobial agents, either 
because of their cost, adverse effects, or to delay the chance of bacteria 
developing resistance to these agents (Barlam et al., 2016). Prior 
approval from the AMS team is required before the pharmacist releases 
specified restricted agents (Barlam et al., 2016). This has been shown to 
reduce antimicrobial consumption, resistance and cost (Barlam et al., 
2016). Some of the limitations of this strategy are that it can often be 
bypassed and some physicians feel their autonomy to prescribe 
antibiotics is restricted (Gross et al., 2001). 
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2.12.3.3 Streamlining/de-escalation 
Streamlining is the process whereby a specialist reviews antibiotic 
treatment regimens and decides whether to discontinue, remove 
redundant combinations or narrow the therapy base on the results of the 
culture (Barlam et al., 2016). A recent systematic review showed that 
guideline adherence and de-escalation are associated with 35% and 
66% relative risk decreases in mortality (Schuts et al., 2016). This 
reduces the number of antibiotics patients are receiving with a 
consequent reduction in cost. However, this strategy usually comes late 
after a patient has received certain inappropriate doses of antibiotics 
(Dellit et al., 2007; Gross et al., 2001). 
  
2.12.3.4 Conversion from intravenous to oral 
Converting a patients’ antibiotic medications from intravenous to oral 
formulation is a major component of AMS programmes (Barlam et al., 
2016). It encourages an early switch as soon as the patient can tolerate 
oral formulations and there are no indications to continue with IV 
medications (Barlam et al., 2016). This strategy also encourages the 
initial commencement of oral treatment in patients that can tolerate oral 
formulations especially regarding drugs with high bioavailability (Barlam 
et al., 2016). This strategy lowers the cost, duration of hospital stay, the 
risk of developing sepsis and thrombophlebitis associated with a cannula 
(Barlam et al., 2016). 
 
2.12.3.5 Antibiotic cycling  
Antibiotic cycling refers to periodic planned substitution of antibacterial 
agents that have been used for a while in a hospital or a unit with other 
drugs to lower the chances of pathogens selecting resistance to them 
(Dellit et al., 2007). There is no substantive clinical evidence that 
antibiotic cycling has a beneficial effect in reducing resistance over a long 
period (Barlam et al., 2016). However, use of an alternative agent may 
reduce the selective pressure and possible chances of resistance 
developing to the substituted agent (Dellit et al., 2007). 
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2.12.3.6 Institutional guidelines  
A well-designed guideline based on local resistance patterns reduces 
inappropriate empirical therapy. These guidelines need to be updated on 
a regular basis (Dellit et al., 2007). Treatment guidelines for common 
clinical conditions are useful, especially for new professionals (Barlam et 
al., 2016).  
 
2.12.3.7 Prospective audit and feedback 
This involves auditing of antibiotic therapy in line with laboratory results 
by the AMS team and sending feedback to doctors; this has been shown 
to increase appropriateness of antibiotic treatment (Brink et al., 2016a). 
 
2.12.3.8 Dose optimisation 
This considers the individual patient characteristics, microorganisms 
causing the infection, pharmacokinetic and pharmacodynamic properties 
of the prescribed drug (Drew, 2009). It also involves adjusting the 
duration of therapy and dosing interval to ensure the required 
pharmacokinetic and pharmacodynamic properties are achieved (Drew, 
2009). 
 
2.12.3.9 Antibiotic order form 
This plays an integral part in AMS and reduces the volume of antibiotic 
consumption by prescribing antibiotics with an automatic stop date. It 
may also encourage adherence to institutional guidelines (Drew, 2009; 
Dellit et al., 2007). 
 
Best Care Always (BCA), a South African private healthcare initiative, has 
adopted the following AMS interventions to reduce the effects of AMR: early 
conversion from IV to oral formulations; avoid use of antibiotics with overlapping 
activity unless there is clear indication; antibiotics should only be requested 
when they are absolutely needed and avoid unnecessary use of antibiotic 
therapy (Best Care Always, 2011). The guidelines also recommend sending 
appropriate specimens for culture and sensitivity routinely; laboratory results 
should guide antibiotic therapy; antibiotics should be prescribed at an 
appropriate dosage with correct frequency of administration and where empiric 
39  
 
antibiotic treatment is necessary, evidence-based guidelines should be adhered 
to (Best Care Always, 2011).   
 
2.12.4 Antimicrobial stewardship studies in South Africa 
There is limited study data on AMS in Africa (Brink et al., 2016a). The first AMS 
study in Africa in a hospital setting was conducted in South Africa in 2013 
(Boyles et al., 2013). A study carried out at Groote Schuur Hospital, University 
of Cape Town, South Africa, showed that following the introduction of an AMS 
ward round and dedicated antibiotic charts in two wards; there was 19.6% and 
35% reduction in total volume of antibiotics and pharmacy budget, respectively. 
No adverse effect was observed on inpatients or on 30 day-readmission 
following this intervention (Boyles et al., 2013). In a private health care setting 
involving 47 Netcare hospitals in South Africa, a general pharmacist-led AMS 
programme which involved a prospective audit and feedback strategy resulted 
in a decrease in antibiotic consumption from 101.38 to 83.04 DDDs/100 patient 
days (Brink et al., 2016a). A study at a trauma ICU of a tertiary health centre in 
Durban revealed that improved surveillance of bacterial pathogen along with an 
AMS programme encouraged appropriate empiric antibiotic usage with reduced 
demand for broad-spectrum antibiotics (Ramsamy et al., 2013). 
 
2.12.5 Antimicrobial stewardship team  
The core members of this team are the infectious diseases specialists, clinical 
pharmacists, clinical microbiologists and hospital epidemiologists, even though 
they are not involved in the day-to-day activities of the team (Paskovaty et al., 
2005). Infection prevention and control nurses, where present, should be an 
integral part of the team (SARI, 2009). For the programme to succeed, hospital 
administrators must also be actively involved (Cruickshank, 2011; Goff et al., 
2017). The infectious diseases specialist usually serves as the team leader and 
is charged with the responsibility of determining appropriate use of 
antimicrobials, designing and modifying antimicrobial formularies, and 
educating colleagues on rational antibiotic use, and the review and 
implementation of guidelines (Paskovaty et al., 2005). Clinical pharmacists, 
especially those with infectious diseases training assist with decisions regarding 
switching from intravenous to oral routes, prior approval and post-prescription 
assessment, drug purchases and dispensing (Paskovaty et al., 2005). They also 
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offer expert advice on pharmacokinetics, practical and cost efficient use of 
antimicrobials, dose adjustments, approval of restricted antibiotics after 
consulting other team members, and advise on drug interactions and toxicity 
monitoring (Paskovaty et al., 2005; SARI, 2009). A clinical microbiologist 
provides the team with data and information on resistance patterns (Dellit et al., 
2007). A hospital epidemiologist creates avenues to limit transmission of 
resistant pathogens, through examining the relationship between the nature of 
antibiotics use and trend of AMR (Paskovaty et al., 2005).  
 
An important factor obstructing the implementation of AMS in South Africa and 
other developing countries is the shortage of infectious diseases specialists to 
drive the process (Brink et al., 2016b). The Netcare model in which a general 
pharmacist drove the project without specific infectious disease training is an 
assurance that AMS can successfully be implemented in a resource-limited 
setting of Africa (Brink et al., 2016b). Charani and Holmes (2013) proposed that 
in a resource constrained setting, rural and district hospitals can collaborate with 
academic hospitals with established AMS programmes; they can also design 
simple interventions to address factors associated with inappropriate antibiotic 
consumption. Recently South Africa designated two centres to train pharmacists 
from regional hospitals across the regions on AMS to be able to implement 
these programmes in their various hospitals (Brink et al., 2016b).  
 
The role of nurses has not been clearly defined in most AMS guidelines, unlike 
pharmacists whose involvement ranges from dose optimisation to leading AMS 
programmes (Olans et al., 2016; Schellack et al., 2016). However, nurses may 
play a critical role in AMS especially in a resource constrained setting like Africa. 
As health professionals in close contact with patients, nurses can help in 
ensuring patients receive their antibiotics as prescribed, report adverse events, 
allergies and side effects (Edwards et al., 2011). A study conducted across 33 
private sector hospitals in South Africa showed how nurses and pharmacists 
played a significant role in reducing antibiotic ‘hang time’ (Messina et al., 2015).  
 
2.12.6 Antimicrobial stewardship in surgical settings 
Surgical wards are often a setting for high levels of antibiotic consumption and 
therefore the opportunity for inappropriate antibiotic utilisation and the 
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development of antibiotic resistance is substantial. There are limited studies on 
AMS in surgical settings. In 2002, one of the first AMS programmes in a surgical 
setting was launched at the surgical ICU of the University of Szeged Hungary, 
where critically ill orthopaedics, neurosurgical and trauma cases were managed 
(Peto et al., 2008). A policy to restrict the use of certain antibiotics was 
implemented with an infectious diseases specialist and a microbiologist 
conducting an AMS ward round 5 times a week (Peto et al., 2008). A substantial 
reduction in consumption of antibiotics was recorded from 162.9 DDDs/100 
patient days’ pre-intervention to 101.2 DDDs/100 patient days’ post-intervention 
(Peto et al., 2008). The reduction was linked to the decline in the use of 
quinolones, aminoglycosides, metronidazole and carbapenems (Peto et al., 
2008). The consumption of 3rd generation cephalosporins was reduced by 
nearly 50%, from 11 to 6.1 DDDs/ 100 patient days. However, the utilisation of 
2nd generation cephalosporin rose to 39.1 from 29.5 DDDs/ 100 patient days 
(Peto et al., 2008). In Canada, an AMS intervention programme involving the 
use of a local guideline, education programmes, pocket cards, posters, and 
regular academic meetings was implemented at the Surgery Department of 
tertiary public teaching hospital (Popovski et al., 2014). This led to decreased 
consumption of ciprofloxacin from 221 to 74 DOT/1000 patient days, and 
piperacillin/tazobactam from 116 to 67 DOT/1000 patient days, with an increase 
in the utilisation of ceftriaxone from 6 to 92 DOT/1000 patient days (Popovski et 
al., 2014). 
 
At the neurological ICU of the Freiburg University Hospital Germany, a guideline 
for the treatment of hospital- and community-acquired pneumonia in patients 
with neurosurgical problems was amended in 2004 (Meyer et al., 2007). The 
duration of therapy for hospital-acquired pneumonia was shortened from 14 to 
7 days; while that of community-acquired pneumonia decreased from 10 to 5 
days with patients being regularly reviewed by an infectious diseases physician, 
a microbiologist and a pharmacist (Meyer et al., 2007). The volume of antibiotic 
consumption was reduced to 626.7 from 949.8 DDDs/1000 patient days 
because of the intervention. The reduction in antibiotic density was attributed to 
decreased use of 2nd generation cephalosporins, imidazole, β-lactams and 
glycopeptides. The antibiotic cost per patient day reduced from € 13.16 down to 
€ 7.31 following the intervention (Meyer et al., 2007). An AMS at an orthopaedic 
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surgery unit in Germany which involved a weekly antibiotic round, telemedicine 
consultation, bedside teaching and review of local guideline, resulted in 
significant reduction in antibiotic usage between the two study stages from 
334.9 to 221.4 Recommended Daily Doses, with an overall monthly cost saving 
of € 2,575 (Borde et al., 2016). 
 
2.12.7 Impact of AMS on cost and resistance 
In a study conducted in Michigan USA to assess the cost-effectiveness of an 
AMS programme, usage of eight antibiotics was assessed: daptomycin, 
ertapenem, aztreonam, voriconazole, meropenem, caspofungin, tigecycline, 
and linezolid (Malani et al., 2013). A 15% reduction in the budget was observed 
from US$ 1,503,748 to US$ 1,274,837, resulting in savings of US$ 228,911 a 
year after instituting the policy (Malani et al., 2013). Also, a significant decrease 
in the budget of the target antibiotics was observed from US$ 462,404 down to 
US$ 297,851, equivalent to 35.6% with a saving of US$ 164,553. A 25.4% 
reduction in consumption of the target antibiotics was seen from 215.7 
DDDs/1000 to 160.8 DDDs/1000 patient days (Malani et al., 2013). Dellit et al. 
(2007) reported a 19% reduction in antibiotic expenditure with a consequent 
increase in hospital saving of US$ 177,000 after the introduction of an 
educational intervention in the form of written or verbal instructions to 
prescribers. 
 
Bantar et al. (2003) in Argentina employed four steps, namely baseline data 
collection, the introduction of a prescription form, education and prescription 
control, to implement AMS. The AMS team could modify dosing, narrow the 
antibiotic regimen and shorten the duration of treatment. A persistent reduction 
in antimicrobial consumption was observed with a total cost saving of US$ 
913,236. There was also a reduction in resistance of Proteus mirabilis and 
Enterobacter cloacae to ceftriaxone (Bantar et al., 2003). Similarly, Saizy-
Callaert and colleagues conducted a study in which four multidisciplinary 
measures were employed (1) develop a prescription form through consensus 
with all prescribers (2) restricting prescriptions of most expensive antibiotics (3) 
regular assessment and audits of prescribed antibiotics (4) training of 
prescribers (Saizy-Callaert et al., 2003). Drugs were only released if validated 
by a pharmacist. It was reported that a significant reduction in the rate of 
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unjustified prescriptions and the antimicrobial cost per inpatient day also fell 
drastically from US$ 13.8 million in 1997 to US$ 11 million in 2000. Although 
the prevalence of MRSA and CRE remained stable, a significant reduction in 
Enterobacteriaceae producing extended-spectrum β-lactamase was observed 
(Saizy-Callaert et al., 2003).  
 
According to Feucht and Rice (2003) concerns were raised about an increase 
in the unnecessary use of parenteral vancomycin and fluoroquinolones in the 
treatment of Gram-negative bacteria at a Veterans Affairs Medical Centre in the 
USA. A computerised review of patients on intravenous vancomycin and 
fluoroquinolone for more than 48 hours was initiated. If the team decided the 
choice of antimicrobial was inappropriate, the prescribing doctor was contacted. 
Following this, a change was made to the prescription. Using this intervention 
an overall reduction of cost of nearly US$ 48,000 from 1998 to 2011 was 
observed. During this stage, a 43% decrease in the use of intravenous 
fluoroquinolone was noted along with a 16% reduction in inappropriately 
prescribed vancomycin (Feucht and Rice, 2003). The impact of using a 
computer-assisted screening programme in the United States to eliminate 
redundant antibiotic combinations in a pharmacist-based intervention in a public 
teaching hospital was assessed (Glowacki et al., 2003). Almost 192 patients 
16.1% out of 1,189 patients were found to be receiving redundant antibiotic 
combinations, and this was commonly seen in ICU and surgical units compared 
to medical units. Interventions recorded a 98% success rate with a saving of 
US$ 10,800 and a reduction of 584 days from a redundant antibiotic 
combination (Glowacki et al., 2003). The focus of AMS programmes is to 
improve appropriate antibiotic utilisation, but hospital management is also 
motivated by the cost implications of implementing such projects (Beardsley et 
al., 2012). An academic hospital in Taiwan spent a sum of US$ 3,935 every 
month as a cost of implementing AMS programmes by an infectious diseases 
physician, two clinical pharmacists and two infection control nurses (Lin et al., 
2013). In three years, the programme saved the hospital a sum of US$ 
2,495,954 and they paid a total of US$ 141,660 to the AMS team for 
implementing the programme (Lin et al., 2013).  
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2.12.8 Antimicrobial stewardship care-bundles 
Bundles are collections of 3 to 5 simple evidence-based practices that when 
employed simultaneously will enhance the patient’s clinical condition (Resar et 
al., 2012). These tend to have a better impact than applying individual practices 
independently (Resar et al., 2012). Antibiotic care bundles are the easiest way 
of implementing AMS policies to patients (Cooke and Holmes, 2007). The idea 
of using bundles in the treatment of patients was first brought about in 2001 by 
the Institute for Health Care Improvement, with bundles providing an opportunity 
for all patients to receive regular and optimal care always (Resar et al., 2012). 
Antibiotic care bundles decrease the chances of resistance and transmission of 
C. difficile (Cooke and Holmes, 2007). It also reduces the likelihood of 
contracting hospital-acquired infections by reducing the duration of hospital 
stay. It should be noted that the absence of one of the components of bundle 
should not delay commencement of antibiotics in emergency situations (Cooke 
and Holmes, 2007). In South Africa, the BCA has developed an AMS bundle to 
guide the use of antibiotics for both treatment and prophylactic purposes (Best 
Care Always, 2011). Upon admission, a member of the AMS team should 
determine the probable cause of infection; whether an appropriate clinical 
specimen has been sent for analysis; whether an infection is community or 
hospital acquired and on day seven decide on whether to continue or stop 
therapy. For prophylactic usage, the AMS team should also determine; whether 
a prophylaxis is required in a procedure and agent was appropriately chosen; 
whether given 0 – 60 minutes before surgical incision and stopped within 24 
hours (Best Care Always, 2011).  
 
2.12.9 Role of biomarkers in antimicrobial stewardship 
Moribund patients with sepsis are usually on prolonged courses of antibiotics 
that encourage resistance. Procalcitonin (PCT) is a precursor in the synthesis 
of calcitonin and is used to guide and monitor antibacterial therapy more reliably 
than white cell count and C - reactive protein (CRP) (Nobre et al., 2008). The 
CRP biomarker, though not as accurate as PCT (Zhang and Singh, 2015) in 
guiding antibiotic therapy, can be used to reduce inappropriate antimicrobial 
therapy. CRP takes 36 to 50 hours to reach it’s peak level after bacterial 
infections (Sullivan and Von Rueden, 2016), while PCT values rise within two 
hours in response to bacterial stimuli and reaches it’s peak level at 24 hours 
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(Foushee et al., 2012). A RCT conducted across Vietnamese Primary Health 
Centres, among patients managed for simple acute respiratory tract infections, 
show a reduced antibacterial consumption among group of patients in which 
CRP was requested (n = 581/902; 64.4%), compared to the control group (n = 
738/947; 78%) in which CRP was not requested (Do et al., 2016). A similar trial 
in developed countries showed a reduced demand for antibiotics among the 
CRP - requested groups (n = 631/1685; 37.5%) compared to the control group 
(n = 785/1599; 49.1%) (Aabenhus et al., 2014). Table 2.2 shows the NHLS 
guideline for use of biomarkers in South Africa (NHLS, 2012). Surgeons should 
bear in mind that surgical operations, trauma, renal replacement therapy, 
multiple organ failure and burns are factors that elevate PCT values without 
infections (Hohn et al., 2017). PCT has been shown to encourage rational 
antibiotic utilisation, reduces chances of developing AMR and decreases the 
cost of antibiotic therapy (Sullivan and Von Rueden, 2016). 
 
Table 2.1: National Health Laboratory Services Guideline for the use of  
                biomarkers (NHLS, 2012).  
 
Biomarkers Clinical condition Reference range 
Procalcitonin 
(μg/L) 
Lower Respiratory Tract 
Infection 
<0.1 – No signs of any bacterial 
infection 
0.1 - 0.25 – Localised bacterial 
infection unlikely 
0.25 - 0.5 – Localised bacterial 
infection possible  
>0.5 – Suggestive of bacterial 
infection 
Systemic bacterial 
infection/sepsis 
<0.5 – Systemic infection unlikely but 
localised infection not excluded 
0.5 - 2 – Systemic infection possible 
2 - 10 – Suggestive of systemic 
infection 
>10 – Severe systemic 
infection/septic shock 
C - Reactive 
Protein (mg/L) 
 <10 
White Cell Count  3.90 - 12.60 
 
A RCT showed that PCT could be used to guide antibacterial therapy with serial 
PCT assays being utilised as a guide to reducing days of antibiotic treatment 
(Bouadma et al., 2010; Hochreiter et al., 2009; Nobre et al., 2008; Schroeder et 
al., 2009). The use of this marker to monitor therapy among severely ill patients 
46  
 
in ICU battling with sepsis has led to the reduction of 2 to 4 antibacterial-free 
days without any significant difference in 28 days’ mortality (Prkno et al., 2013). 
Clinical evidence advises against a delay in commencement of antibiotics in 
severely ill patients with negative PCT (Jensen et al., 2011; Layios et al., 2012).  
A 2015, study conducted in a Chinese hospital to assess the impact of 
implementing PCT-guided antimicrobial therapy in patients with acute 
respiratory infections, noted a considerable reduction in the cost of treatment 
(Stojanovic et al., 2016). The intervention resulted in a 38.9% reduction of 
antimicrobial cost from ¥ 1.8 million (US$ 288,000) among the cohort of patients 
in which PCT was not used to ¥ 1.1 million (US$ 176,000) in a group in which 
PCT was used to guide the therapy. The hospital saved a sum of ¥ 250,699 
(US$ 40,112) and ¥ 2.4 million (US$ 384,000) in the ICU and outpatient 
department, respectively (Stojanovic et al., 2016). In contrast, the introduction 
of an AMS programme along with PCT-guided antimicrobial therapy at a 
surgical ICU of a German hospital resulted in a 21% reduction of antimicrobial 
usage from 1,005 DDDs/1000 patient days in 2010 to 791.9 DDDs/1000 patient 
days in 2012 (Hohn et al., 2015). This has led to a decreased utilisation of 
aminoglycosides, quinolones and cephalosporin with a relative increase in the 
consumption of carbapenems. The interventions also decreased the cost of 
antibiotics from € 54,498 to € 33,297 over 3 years (Hohn et al., 2015).  
 
The following guidelines were adopted by a surgical ICU to guide the use of 
PCT among patients on antimicrobial therapy in Germany (Hohn et al., 2015; 
Hohn et al., 2017). Commencement of antibiotics is based on clinical evaluation; 
daily monitoring of PCT in patients on antibacterial agents for the first 3 days of 
admission or from when the diagnoses of suspected systemic bacteria is made; 
from the fourth day of antibiotic therapy, PCT is assessed every other day and 
consider stopping antimicrobial therapy when the PCT level is ≤ 0.25 ng/ml, with 
signs of clinical improvement; it is also recommended to discontinue antibiotic 
therapy when the PCT level is between >0.25 and <0.50 ng/ml or reduces to 
10% from its highest level (Schuetz et al., 2015). The use of PCT to guide 
antibiotic therapy in patients with acute respiratory tract infection attending 
hospitals in the United States has shown a significant reduction of antibiotic 
cost. A sum of US$ 6,409,179 was saved from a US$ 12,296,714 spent on 
antibiotic therapy in a group of patients in which PCT was not used to guide 
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therapy, compared to US$ 5,887,535 in a group in which PCT was used to guide 
treatment (Schuetz et al., 2015). 
 
2.12.10 Barriers and limitations to successful AMS 
Although AMS has the potential benefit of improving appropriate antibiotic 
utilisation, improving clinical outcomes, reducing antibiotic resistance and cost, 
there are barriers to the successful implementation of AMS which include lack 
of staff commitment, lack of funding and collaboration between healthcare 
professionals. Limitations in education and funding have also contributed to 
poor implementation of AMS programmes. 
 
2.13 DRUG UTILISATION REVIEW 
According to the WHO drug utilisation review (DUR), also known as drug use 
evaluation “refers to a system of continuous, systematic, criteria-based drug 
evaluation that ensures the appropriate use of the drug” (WHO, 2003). It also 
involves ways of capturing data on problems relating to drug consumption, 
developing strategies for solving these problems, thereby improving appropriate 
drug treatment (WHO, 2003). In drug utilisation review studies, electronic 
medical records and records from pharmacy databases provide superior and 
more reliable information than records from patient files, wholesale data or 
information from patients during interviews (Schneeweiss and Avorn, 2005). 
Regular assessment of the pattern of antibiotic consumption in hospitals with 
feedback to the prescribers and decision makers can go a long way in 
encouraging prescribers to embrace the culture of rational antibiotic prescription 
(Hutchinson et al., 2004).  
 
To date, there is no single standard unit of measurement of drug consumption 
across all clinical settings globally. However, the DDD has been recognised by 
the WHO (Ashiru-Oredope and Hopkins, 2015). Norwegian researchers working 
in collaboration with the Nordic Council on Medicine came up with the concept 
of DDDs as a way of quantifying drug use in 1976 (Monnet, 2007). Similarly, 
Norwegian researchers also developed the Anatomical Therapeutic Chemical 
(ATC) drug classification in the 1970s (Hutchinson et al., 2004) by reviewing the 
classification of the European Pharmaceutical Market Research Association 
(WHO, 2003). It classifies medicines into different categories based on targeted 
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organ-systems and their chemical or curative properties. Every drug has a 
minimum of one ATC code which is further subdivided into five various levels 
(Hutchinson et al., 2004). For instance, all amoxicillin/clavulanic acid 
preparations are given J01CR02 as their ATC code (Appendix 1), an agent may 
have several ATC codes due to its different therapeutic uses such as 
prednisolone, however, this is not common with antibiotics (WHO, 2016a). 
 
The WHO European office approved the use of ATC/DDD methodology for drug 
utilisation review in 1981 (Monnet, 2007). Following this in 1982 the WHO 
Collaboration Centre for Drug Statistics Methodology was launched which 
receives applications for assignment of ATC codes and DDDs for new drugs 
(Monnet, 2007). In 1996, the WHO International Working Group for Drug 
Statistic Methodology was launched and it receives applications and assumes 
the responsibility of assigning ATC codes and DDDs after a comprehensive 
literature consultation (Monnet, 2007; Sketris et al., 2004). 
 
2.13.1 Anatomic Therapeutic Chemical (ATC) classification  
The ATC classification system places active ingredients of drugs into different 
groups based on the body organ system upon which they exert their therapeutic, 
pharmacological and chemical actions (WHO, 2016a). Drugs are categorised 
into groups and further subdivided into five different levels (WHO, 2016a). There 
are 14 main categories (first level), then pharmacological/therapeutic subgroups 
(second level), the third and fourth levels are 
chemical/pharmacological/therapeutic subgroups, while the fifth level is the 
chemical substance (WHO, 2016a).  
    
2.13.2 Defined Daily Doses 
The WHO has defined DDD in human medicine as “the average maintenance 
dose of the drug when used for its primary indication in adults” (WHO, 2003). 
For instance, paracetamol has a DDD of 3 grams as assigned by WHO, so an 
average patient (70kg) who received paracetamol for its primary indication of 
pain relief, would have consumed 3g per day. This is equivalent to 6 tablets of 
500mg of paracetamol daily. If a patient consumes 24 of these tablets (12g of 
paracetamol) over a specified period, this equal to the consumption of 4 DDDs 
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                                             𝐷𝑟𝑢𝑔 𝑢𝑠𝑎𝑔𝑒 =
24 𝑋 500𝑚𝑔
3𝑔
= 4  
The DDD metric has existed for many years and has been widely reported in 
many studies (Chauvin et al., 2001). It allows tracking of the volume of 
antibiotics consumed by an organisation over a period both regionally or 
nationally by considering the regional or national population as a denominator. 
It also allows for international comparisons between different studies (Ashiru-
Oredope and Hopkins, 2015). The process of comparing antibiotic utilisation 
between hospitals, regions or countries is called benchmarking (Polk et al., 
2007; Shetka et al., 2005).  
 
Only drugs with assigned ATC codes can be given a DDD (WHO, 2016a). Every 
medicine is given a DDD at its 5th level of ATC classification. A medication may 
have more than one WHO assigned DDD depending on the formulation 
(Hutchinson et al., 2004). For example, the intravenous formulation of 
amoxicillin/clavulanic acid = 3 DDDs, while the oral formulation = 1 DDD (WHO, 
2016a). The DDD for a drug is usually given after it has been released on the 
market and reviewed for three years after monitoring its use and 
recommendations from different countries (Chauvin et al., 2001). Drug 
utilisation is often expressed as DDDs/1000 patients’ days or alternatively 
DDDs/100 bed-days when reporting consumption of inpatients, but for 
medicines used for short durations it’s preferable to report the values in 
DDDs/inhabitant/year (Kuster et al., 2008; WHO, 2003). The IDSA has adopted 
the use of DDDs/1000 patient days for measuring antibiotic utilisation in AMS 
studies (Dellit et al., 2007). However, recently DOT is gaining popularity in the 
United States (Barlam et al., 2016). The DDDs enable easy comparison 
between hospitals, and can also be used to quantify the volume of antibiotic 
consumption in a setting that has no established computerised pharmacy 
records, such as in developing countries (Polk et al., 2007). It is worth noting 
that the DDD does not necessarily correspond to Prescribed Daily Dose (PDD) 
because drugs are prescribed to patients based on their age, weight and 
pharmacokinetic factors (WHO, 2003). Also, some prescribed medications are 
not dispensed, and patients do not always take all their medications that are 
dispensed (WHO, 2003).  
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2.13.3 Limitations of using DDD techniques  
Limitations in using DDDs are generally related to altered dosing such as use 
in renal or hepatic impairment or paediatrics. The DDD usually gives a lower 
value in patients who had their antibiotics adjusted because of compromised 
renal function (Shetka et al., 2005) compared to individuals with normal renal 
function (Zagorski et al., 2002). The DDD methods will underestimate antibiotic 
exposure when the administered daily dose is reduced for a patient with renal 
failure (Polk et al., 2007). This is relevant in benchmarking between hospitals, 
where the proportion of patients with renal failure in one hospital is different from 
that of another hospital (Polk et al., 2007).   In a study to evaluate the effect of 
renal insufficiency on DDD in a group of patients receiving ceftriaxone, 
levofloxacin or vancomycin, two methods of quantifying antimicrobial duration 
of therapy (Stop-Start Days and Transaction Days) were used (Zagorski et al., 
2002). The vancomycin use rate for patients with renal insufficiency was 36% 
lower than that of patient with normal function for DDDs; and this was 23% lower 
for Transaction days; for levofloxacin, there was a 27% rate reduction for DDDs. 
No significant reduction was observed when the Stop-Start Day method was 
used. Compared with the DDD method, measures of therapy duration are less 
affected by renal function and may improve comparison between populations 
(Zagorski et al., 2002). The DDD method is also not applicable in a paediatric 
population (Shetka et al., 2005). Drugs such as topical preparations especially 
dermatological agents, along with cytotoxic medications, anaesthetic agents 
and vaccines have no assigned DDD (WHO, 2016a). Topical preparations are 
not usually given a DDD because the dose administered per day depends 
mainly on the extent and severity of the clinical condition (Sketris et al., 2004).  
 
2.13.4 Prescribed Daily Dose  
PDD is an average daily prescribed dose of a certain number of prescriptions 
and it is usually obtained by review of patient's prescriptions or pharmacy 
records (WHO, 2003). For drugs with different dosage regimens depending on 
the clinical condition it is being used for, it is important to take diagnoses into 
consideration when calculating PDD; because a drug with various indications 
tends to have a different PDD depending on the condition (WHO, 2003). This 
unit of measurement is commonly employed in studies aimed at determining the 
pattern of prescription (Chauvin et al., 2001). It is also useful in determining 
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doctor's prescription habits and prevalence of morbidity (Merlo et al., 1996). The 
PDDs tend to differ from one country to another, and it is also affected by the 
severity of the clinical condition being managed. All these should be taken into 
consideration when using PDD to make a comparison between countries 
(WHO, 2003). The PDD does not always give an accurate picture of drug 
utilisation because not all patients complete their dosages especially in 
outpatient settings. Therefore, to measure actual drug use by the patients, the 
patients need to be interviewed to know the level of drug intake the so-called 
consumed daily doses (WHO, 2003). 
 
2.13.5 Days of Therapy 
A single day of therapy (DOT) of a drug refers to a single drug agent delivered 
to a patient per day irrespective of its strength or frequency of delivery (Polk et 
al., 2007). The use of the DOT metric to determine the volume of antibiotic 
utilisation in the USA is gradually replacing DDD (Ibrahim and Polk, 2014). A 
digital pharmacy record is required to accurately measure it, which is absent in 
most developing countries and it is therefore difficult to use this metric to make 
an international comparison and therefore the DDD is still most widely used in 
developing countries (Monnet, 2007).  
 
2.13.6 Minimum Marketed Dose 
The Minimum Marketed Dose is the minimum dose needed to produce a 
required therapeutic effect and its equivalent to the minimum dose marketed by 
the producer (Chauvin et al., 2001). A similarity exists between Minimum 
Marketed Dose and DDDs as both define the amount of drug, but DDDs give 
additional information on daily quantity, which is independent of the number of 
doses per day (Merlo et al., 1996). 
 
2.13.7 Equipotential Dose 
Two Danish doctors developed the Equipotential Dose with a focus in the 
treatment of hypertension; it refers to the active substance in each drug having 
the same effect on blood pressure (Merlo et al., 1996). 
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2.13.8 Cost 
Though price can be used to determine total drugs expenditure, it plays little 
role in evaluating drug utilisation. It is difficult to make a comparison between 
countries using this metric measure, because it is easily affected by inflation, 
national regulatory policies, price fluctuations and exchange rate variations 
(WHO, 2016a).  
 
2.13.9 Other methods of quantifying drug utilisation 
Some of the less commonly used methods of estimating drug consumption 
include the number of packages, the number of prescriptions, number of tablets 
and gram of active ingredients. These are useful when evaluating a single 
agent, but none of these can be used to compare the volume of consumption 
between countries (WHO, 2003; Shetka et al., 2005).  
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CHAPTER THREE: RESEARCH DESIGN AND METHODS 
 
3.1  INTRODUCTION 
This is a quantitative study combining a prevalence cross-sectional and 
observational, descriptive study with an intervention study. The study was 
divided into two stages; in the first stage the data was collected retrospectively, 
and in the second stage it was prospectively collected. 
 
3.2  RESEARCH DESIGN 
3.2.1  Setting  
The study was conducted at Charlotte Maxeke Johannesburg Academic 
Hospital (CMJAH), Gauteng Province, South Africa. The CMJAH is a 1,088-bed 
tertiary academic hospital located in Johannesburg, Gauteng Province. It 
provides a full range of care including general, vascular, orthopaedics, 
neurosurgery, organ transplant and gastrointestinal surgeries, it also has many 
diagnostic facilities. It serves as a training and research facility for students of 
the University of the Witwatersrand and it is also a referral centre for many other 
hospitals in Gauteng province. The two surgical wards selected for this study 
were the Vascular and General Surgery Wards. The Vascular Ward has 24 beds 
with four extra beds in side rooms for isolation and critical cases. It is headed 
by a Professor of Vascular Surgery with consultants, fellows, registrars and 
interns under his supervision. A wide range of cases are admitted and managed 
in this ward which include; chronic and acute vascular ischemic diseases, 
diabetic foot diseases, stab injuries and many other vascular conditions. 
Sometimes other surgical conditions are transferred from other surgical units 
when there are bed space shortages. Surgical procedures performed on 
patients in this unit include vascular bypass surgeries, amputations, vascular 
injury repairs, angiograms, angioplasties, as well as a variety of other 
procedures. Many of the patients in this ward are mostly middle aged or elderly 
with one or more chronic conditions and multiple co-morbidities. 
 
The General Ward is also under the supervision of a Professor of Surgery with 
consultants, fellows, registrars and interns working under him. They treat cases 
such as hepatobiliary and abdominal malignancies, appendicitis, pancreatitis, 
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various forms of upper and lower gastrointestinal conditions and a full range of 
general surgical conditions. The ward has 24 beds with five extra in side rooms 
for isolation and critical patients and patients of all ages from 18 years are 
treated here. A full range of surgical procedures for acute and chronic surgical 
conditions are performed, and these include cholecystectomies, 
appendicectomies, abscess drainage, herniorrhaphies, colostomies, 
pancreatectomies, splenectomies amongst others. The two wards were 
selected for the study because of high antibiotic consumption and high turnover 
of patients.  
 
3.2.2  Study design  
The study was conducted in two stages.  
 3.2.2.1 Stage 1: Cross-sectional observational and descriptive study 
In this stage, patient record data was collected retrospectively in two of the study 
wards and served as the control stage as well as a situational review (Appendix 
2). Records of 264 patients who were given antibiotics during their inpatient stay 
and met study inclusion criteria were reviewed from February to May 2016 
(Appendix 3). The parameters evaluated in this study include antibiotic use, 
indication for antibiotic therapy, dosage and route of administration, appropriate 
duration of treatment and de-escalation to a narrow-spectrum in line with 
microbiological investigation results. The costs of antibiotic treatment and 
pathology tests were determined. The volume of antibiotics consumed was 
measured using DDDs/1000 patient days. The appropriateness or otherwise of 
antibiotic prescriptions was determined using a guideline developed by Gyssens 
and colleagues in 1992 (Appendix 4) (Plenat et al., 1992). The appropriateness 
of surgical prophylaxis was determined based on the recommendations of 
SAASP (Wasserman et al., 2014) and Standard Treatment Guidelines and 
Essential Medicines Lists for South Africa (NDoH, 2015). The appropriateness 
of other forms of prophylaxis in which fluconazole was used in patients with 
suspected intra-abdominal sepsis was determined. Regarding the choice of 
prophylactic agent, dose, and duration, the incision time was not assessed 
because such record was not found in most of the patient’s files (NDoH, 2015). 
Patient diagnoses were categorised and type of surgical procedure was 
determined based on the type of wound.   
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3.2.2.2 Stage 2: Intervention study 
The intervention involved a dedicated AMS weekly round in each of the two 
surgical wards; which was separate to the general daily ward rounds. Ward 
rounds were started on the 20th May 2016.  Two weeks were allowed for the 
doctors, nurses, and other professionals in the wards to become familiar with 
the study. Intervention data were not collected during this stage. Data collection 
began on 3rd June 2016. Ward rounds consisted of making recommendations 
on the patient files based on AMS guidelines. Fellows, resident doctors, and the 
interns participated in the rounds and assisted by explaining the rationale 
behind the choice of antibiotics. The infectious diseases consultant discussed 
each condition at the bedside, especially regarding antibiotics selection, 
laboratory investigations and emphasis on collecting appropriate specimen and 
culture directed therapy. The intervention also involved dose optimisation and 
adjustments of dose in patient with renal and hepatic impairment. This stage 
lasted for four months from June to September 2016, and a total of 212 patients 
who met the inclusion criteria and agreed to participate in the study were 
included.  
 
The AMS ward round was led by an infectious diseases specialist. 
Microbiologists were not able to participate in the weekly round due to a conflict 
with other functions on the same day. A pre-round was conducted on Thursday 
by the investigator to identify patients on antibiotics that met the inclusion 
criteria, obtain their consent to review their records and their permission to 
participate in the study. Patient demographics, antibiotic utilisation information 
and available results of the investigation in the patient files were reviewed during 
the pre-round. Laboratory results not available in the patient files were retrieved 
from the microbiology computers in the record room to assist in deciding 
whether the treatment was appropriate or otherwise, to de-escalate or stop the 
treatment. Appropriateness of antibiotic utilisation, antibiotic cost and volume of 
drug consumption were determined as in the first stage. Each ward round began 
at 8:30 am every Friday, usually starting in the Vascular Ward before proceeding 
to General Surgery Ward. Each round took an average of two hours. During the 
AMS round, all patients on antibiotic treatment were evaluated, but the data was 
collected only on those with signed consent. Each case was discussed to 
determine the appropriateness and rational of antibiotic choice or otherwise of 
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therapy. During rounds the following recommendations could be made based 
on the patient clinical condition; early conversion from intravenous to oral 
formulations, change in duration or frequency of treatment, conversion from 
broad-spectrum to a narrow-spectrum antibiotic base on the culture result, 
discontinuation of antibiotic therapy when there is no indication or when 
antibiotics with overlapping activities are used, encourage early removal of 
drains, cannulae and catheters when their functions are not required. Others 
included dosage adjustment of dose in patients with renal or liver dysfunction. 
Recommendations were also made on the collection of appropriate specimens 
for culture. Where required, discussions were held with the Head of Infectious 
Diseases unit as well as senior doctors in surgery on the rational antibiotic 
usage and implication of unnecessary antibiotic prescription in specific patients.  
All patients that were seen during the antibiotic round were followed up until 
discharge to assess the implementation of the recommendations and capture 
their data.  
 
3.3  RESEARCH METHODS 
3.3.1  Population 
Inclusion criteria were:  
 
 Any patient 18 years or older,  
 Currently taking an antibiotic for infection or having taken an antibiotic 
prescribed within the previous 48 hours of the time of capturing information.  
 
The exclusion criteria were: 
 Pregnant women on antibiotic treatment 
 Patients who did not give consent 
 
3.3.2 Sample and sampling 
Patient records were selected using convenience sampling, which is a type of 
nonprobability sampling typically consisting of persons either known by the 
researchers and/or readily available to the investigators (Özdemir et al., 2011). 
The sample size was determined to be a total of 350 for both stages of the study, 
as calculated by biostatisticians of the Faculty of Health Sciences Research 
Office, University of the Witwatersrand and based on the outcomes of a similar 
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study conducted in Egypt using an average number of patients admitted in each 
of the study wards per month, an α = 0.05 and power of 80% (Saied et al., 2015). 
 
3.3.3  Data collection 
In both stages of the study the same variables were collected. In the first stage 
of the study, patient hospital numbers were extracted from the surgery 
department electronic discharge records and were used to retrieve files that 
were electronically scanned as portable document format (pdf) files on the 
hospital computers at the Hospital Information Management unit. Data on 
patient demographics, antibiotic utilisation, microbiology laboratory results and 
biomarkers were obtained. Laboratory results that could not be found in the 
patient's files were retrieved from NHLS database at the Microbiology 
Department. The data were captured on the data collection sheets (Appendices 
2, 3 and 6) and later transferred to spreadsheets, and coded. However, in the 
second stage, the data were collected from the patient files in the ward after 
informed consent was obtained and the patients were then followed up until 
discharge to capture the remaining set of data. As in the first stage, for the 
laboratory investigations that were not present in the patient files, the NHLS 
database was also used to support and verify the microbiology records including 
inflammatory markers such as FBC, CRP and PCT that can be used to 
distinguished bacterial from acute viral respiratory infections (Mendelson, 
2015a). 
 
In both stages, patient's demographic characteristics and information on the 
diagnoses, type of surgery, and number of surgical procedures were captured. 
The data on antibiotic utilisation collected included the name of medicines, 
clinical indication for the use of antibiotics (prophylactic/empiric/targeted), 
doses, duration of therapy, route of administration, allergy and adverse reaction. 
For each patient receiving antibiotics, data on microscopy culture and sensitivity 
(MCS), type of specimen requested, type of bacteria cultured, susceptible, 
resistant and recommended antibiotic by microbiologist and whether the culture 
was sought before the commencement of antibiotics. The list of WHO assigned 
DDDs for drugs were obtained from the website of WHO Collaborating Centre 
for Drug Statistics and Methodology (WHO, 2016a).  
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 DDD 
The number of doses administered for each drug, the net quantity of drug 
administered to patients and WHO DDD was used to calculate the DDD for each 
drug. DDD is an internationally recognised unit of measurement of drug 
consumption (personal communication with the Director of the WHO 
Collaborating Centre for Drug Statistics Methodology Oslo – “Hanne Strøm” and 
other researchers who use this metric to determine the volume of antibiotic 
consumption in their studies were contacted for advice). The drug consumption 
in DDD/1000 patient days was also calculated by dividing DDD by the number 
of patient days in each stage of the study and then multiply by 1000. 
 
𝐷𝑟𝑢𝑔 𝑢𝑠𝑎𝑔𝑒 =
𝐼𝑡𝑒𝑚𝑠 𝑖𝑠𝑠𝑢𝑒𝑑 ×  𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑝𝑒𝑟 𝑖𝑡𝑒𝑚
𝑊𝐻𝑂 𝐷𝐷𝐷
 
 
                       𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑠𝑢𝑚𝑝𝑡𝑖𝑜𝑛 =
𝐷𝐷𝐷𝑠
𝑃𝑎𝑡𝑖𝑒𝑛𝑡 𝑑𝑎𝑦𝑠
×  1000 
 
                      Patient days = ∑Date of discharge minus ∑date of admission 
 
 Cost 
The price of medicines used by the patients in both stages was determined 
using the rate obtained from the central hospital pharmacy of the CMJAH and 
Master Price Catalogue (2015) list of the National Department of Health, in 
South African Rand (R) (Appendix 5). The prices were also converted to United 
State dollar (US$) to enable comparison of costs with other international 
studies. The utilisation of microbiological tests before the commencement of 
antibiotics or in the monitoring of treatment progress and use of other biological 
markers that change in response to bacterial infections were assessed. The 
microbiology and biomarker's results were also reviewed retrospectively from 
patient records and NHLS database (Appendix 6). The prices of laboratory 
investigations were obtained from the investigation price list of the NHLS tariffs 
((Appendix 7). 
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3.3.4  Data categorisation 
 Appropriateness of antibiotic utilisation 
Antibiotics therapy can be inappropriate for several reasons at the same time, 
and the Gyssen’s guideline provides a flat form to categorise inappropriate 
prescriptions into more than one sub-category from category ii to iv. The 
antibiotic prescription is regarded as inappropriate if prescribed for an improper 
dosage (sub-category iia), improper dosage interval (sub-category iib), and 
improper route (sub-category iic). Excessive duration of therapy (sub-category 
iiia), short duration of therapy (sub-category iiib), more effective alternative 
agent (iva), less toxic alternative drug (ivb), less expensive alternative 
antibiotic (ivc), less broad-spectrum alternative agent (ivd). Unjustified 
prescription (v) and insufficient information for categorisation (vi), category (i) 
represent appropriate prescription. Unlike other guidelines it also provides an 
avenue to classify further inappropriate prescription based on the development 
of toxicity to the prescribed medicines to using of broad-spectrum antibiotic 
when a narrow-spectrum is available. This is a validated guideline used in 
many previous studies as reported in (Akhloufi et al., 2015); (Hadi et al., 2008); 
(Willemsen et al., 2007) and (Willemsen et al., 2010).  
 
 Type of diagnoses  
In consultation with experts in the field from the University of the Witwatersrand 
the following categories for patient diagnoses were grouped accordingly: 
- Upper gastrointestinal cases; these included perforated peptic ulcer diseases, 
oesophageal carcinomas etc. 
- Lower gastrointestinal cases; these included lower gastrointestinal bleeding, 
rectal carcinomas etc. 
- Gallbladder, biliary tract and liver cases; these included acute cholangitis, 
cholecystitis, pyogenic liver abscesses, primary liver cell carcinomas etc. 
- Pancreas, appendix and splenic cases; e.g. peri-pancreatic sepsis, 
appendicitis, overwhelming post-splenectomy sepsis. 
- Vascular cases, e.g. ischemic vascular diseases, stab injuries. 
- Other general surgery cases, e.g. hernias, intestinal obstruction, cutaneous 
abscesses.  
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 Type of surgical procedures 
The type of surgical procedures was also categorised based on the type of 
wound (Knight et al., 2001): 
- Clean surgery, 
- Clean-contaminated surgery, 
- Contaminated surgery, 
- Dirty surgery,  
 
 Clinical indication for antibiotic therapy 
- Empiric: a presumptive use of antibiotics before the result of culture. 
- Targeted: the use of antibiotics based on the results of culture. 
- Prophylactic: the use of antibiotics during surgical procedures to prevent SSIs. 
- Others: this involve the use of erythromycin to stimulate gastrointestinal motility 
in newly operated patients, or azithromycin as an anti-biofilm agent. 
 
3.3.5  Data analysis 
Data was analysed using Stata software version 14 (StataCorp, College Station, 
TX, USA). Descriptive analysis, as well as graphical representation and 
comparison tables were used to present the data. Continuous variables were 
presented as means and standard deviations where data was normally 
distributed, or median and interquartile ranges where data was not normally 
distributed. Differences in percentages were analysed using chi-square tests. 
An independent sample t-test was used to compare the cost, DDDs and 
DDD/1000 patient days, between two stages of the study where data was 
normally distributed, or a non-parametric test such as Wilcoxon signed rank sum 
test, and was used where data was not normally distributed. A binary logistic 
regression model was used to predict the factors responsible for 
appropriateness prescriptions. A p value of <0.05 was regarded as significant.  
 
3.4  ETHICAL CONSIDERATION 
3.4.1  Permission to conduct the study 
Permission to conduct the study was sought from the University of the 
Witwatersrand Human Research Ethics Committee and approved as per study 
ethics, approval number is M151142 (Appendices 8 and 9). Approval was also 
obtained from the chief executive officer (CEO) of the CMJAH (Appendix 10) 
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and Head of the Surgery Department, (Appendix 11). Permission to conduct the 
study was also granted by the heads of the two wards after approval was 
granted by the CEO and the head of department. The protocol was approved 
by the University of the Witwatersrand Protocol Assessment committee 
(Appendix 12).  
 
3.4.2 Informed consent 
A written informed consent was sought from all the patients that participated in 
the intervention stage of the study as required by the ethics committee and 
hospital letter of permission to conduct the study (Appendix 13). Patients were 
also given an information sheet about the investigator and reasons for 
conducting the study; only three patients declined consent for their records to 
be reviewed (Appendix 14). 
 
3.4.3  Anonymity and confidentiality 
Patients’ anonymity was adhered to throughout the study, any information that 
may reveal patient identity such as name and address were not recorded to 
ensure confidentiality. A unique study number was assigned to their records and 
the list of study numbers and patients record numbers are kept in a password 
protected data file and only accessible to my supervisors and me. No patient 
file was taken away from the facility during the study, and their identity will not 
be revealed when the study is reported or published. 
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CHAPTER FOUR: RESULTS 
 
The results of the two stages of the study are presented to compare the 
outcomes of the stages by demographic characteristics followed by antibiotic 
utilisation, laboratory investigations, appropriateness of antibiotic utilisation and 
cost. A total of 476 patient records were evaluated in this study, of which 264 
were in the baseline stage and 212 in the intervention stage. 
 
4.1 DEMOGRAPHIC CHARACTERISTICS OF PATIENTS 
4.1.1  Gender 
Overall, there were on average four-fold more patients in the General Surgery 
Ward than the Vascular Ward and in the intervention stage, the proportion of 
patients was less in the General Surgery Ward (Tables 4.1 and 4.2). In both 
stages of the study there were more males than females, with a preponderance 
of males of 56.82% overall in the baseline stage and 53.77% in the intervention 
stages (Tables 4.1 and 4.2). The results of the Pearson’s chi-square test 
showed that there is no statistically significant difference in gender between the 
baseline and intervention stages of the study (X2 = 0.44, p = 0.501). 
 
Table 4.1:  Gender distribution of patients in the baseline stage. 
 
 
 
Table 4.2:  Gender distribution of patients in the intervention stage.  
 
 
 
 
 
 
 
 
 Type of Ward 
Gender Vascular Ward n (%) 
General Surgery 
Ward n (%) 
Total of both 
Wards n (%) 
Male 29 (54.72) 121 (57.35) 150 (56.82) 
Female 24 (45.28) 90 (42.65) 114 (43.18) 
Total 53 (100.00) 211 (100.00) 264 (100.00) 
 Type of Ward 
Gender 
Vascular Ward 
n (%) 
General Surgical 
Ward n (%) 
Total of both Wards 
n (%) 
Male 40 (60.61) 74 (50.68) 114 (53.77) 
Female 26 (39.39) 72 (49.32) 98 (46.23) 
Total 66 (100.00) 146 (100.00) 212 (100.00) 
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4.1.2  Age distribution 
In both stages of the study, most patients fell within the age bracket of 36 to 75 
years (Figures 4.1 and 4.2). In the baseline stage the averages age of patients 
were 56 and 43 years in Vascular and General Wards, respectively, while in the 
intervention stage the average ages of patients were 56 and 49 years in 
Vascular and General Wards, respectively. This show that patients in the 
intervention stage were slightly older than those in the baseline stage. An 
independent sample t-test was conducted to examine the differences between 
ages of the participants in the baseline and intervention stages of the study. The 
results indicated ages of study participants in the baseline stage (mean = 45.77 
± 16.81 years), and intervention stage (mean = 51.50 ± 15.91 years) were 
statistically significantly different (p = 0.01 < 0.05).  
 
 
Figure 4.1: Patient age distribution in the baseline stage. 
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Figure 4.2:  Patient age distribution in the intervention stage. 
 
4.1.3  Hospital length of stay 
In the baseline stage, the overall average Length of Stay (LOS) was 8.27 ± 9.52 
days, while the average LOS in the Vascular and General Wards was 12.66 ± 
10.03 and 7.16 ± 9.08 days, respectively. However, during the intervention 
stage, the average overall LOS was 13.23 ± 11.81 days, with 16.94 ± 15.44 and 
11.55 ± 9.32 days as the average LOS in the Vascular and General Wards, 
respectively. An independent sample t-test was conducted to examine the 
differences between LOS of the participants in the baseline and intervention 
stages of the study. The results indicated that the LOS of the patients in the 
baseline stage (mean = 8.33 ± 9.58 days) and the intervention stage (mean = 
13.44 ± 11.83 days) were statistically significantly different (p = 0.01 < 0.05).  
 
4.1.4 Type of diagnoses 
Lower gastrointestinal cases (LGCs) were the most common cases in the 
General Ward in the baseline stage 31%, while gallbladder, biliary tract and liver 
(GBLCs) 25%, in the intervention stage (Figures 4.3 and 4.4). In the Vascular 
Ward most of the patients had vascular cases comprising 89% and 91% in the 
baseline and the intervention stages, respectively (Figures 4.3 and 4.4). There 
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were few patients with non-vascular cases in Vascular Ward, and they were 
mostly transferred from the General Ward due shortage of bed space. 
 
 
Figure 4.3:  Categories of diagnoses in the baseline stage. 
 
 
Figure 4.4: Categories of diagnoses in the intervention stage. 
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4.1.5 Classification of surgical procedures 
In the baseline stage, most of the surgical operations were clean (40%) and 
dirty (40%) in the Vascular Ward, while in the General Ward contaminated 
surgeries (35%) were the most frequent type of surgical operations. However, 
during the intervention stage, in the Vascular Ward the majority of the patients 
had dirty surgical procedures (48%) (this is probably due to an increase in 
patients who had amputations), followed by clean surgical cases (26%). In the 
General Ward most of the cases were clean operations (34%) followed by those 
with contaminated surgeries (26%). 
 
 
Figure 4.5: Surgery type based on type of surgical wound in the baseline 
stage.  
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Figure 4.6: Surgery type based on type of surgical wound in the intervention 
stage.  
 
4.1.6  Number of surgical procedures per stay 
During the baseline stage, more than 90% of all the patients who were operated 
on had only a single procedure during their inpatient stay, while the remaining 
patients on average had either two or three procedures. In the intervention stage 
about 75% of the patients had a single procedure, 16.37% had two procedures, 
while the remainder had between three and five procedures (Tables 4.3 and 
4.4). 
 
Table 4.3:  Number of surgical procedures per patient per stay in the baseline 
stage. 
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Number of  
Surgical Procedures 
Vascular  
Ward n (%) 
General Surgery  
Ward n (%) 
Total of both 
Wards    
n (%) 
One procedure 42 (85.71) 164 (92.66) 206 (91.15) 
Two procedures 6 (12.25) 10 (5.65) 16 (7.08) 
Three procedures 1 (2.04) 3 (1.69) 4 (1.77) 
Total 49 (100.00) 177 (100.00) 226 (100.00) 
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Table 4.4: Number of surgical procedures per patient per stay in the 
intervention stage. 
 
 
 
 
 
 
 
 
4.2  ANTIBIOTIC UTILISATION 
4.2.1  Number of antibiotics per patient per stay 
In both stages of the study most of the patients had only one antibiotic per stay 
followed by those with two and three antibiotics and few patients had more than 
five antibiotics (Figures 4.7 and 4.8). In the baseline stage, there was a single 
patient who had a total of eleven antibiotics per stay due to sepsis and ICU 
admission (Figure 4.7). This patient was managed as a case of peri-pancreatic 
abscess with sepsis, spent 80 days on admission and had three surgical 
operations. More patients had a single agent in the General Ward of the 
baseline stage compared to the intervention stage, while in the Vascular Ward 
there were more patients that had one antibiotic in the intervention stage 
compared to baseline stage. 
Figure 4.7:  Number of antibiotics per patient per stay in the baseline stage. 
Number of 
Surgical Procedures 
Vascular 
Ward n (%) 
General Surgery  
Ward n (%) 
Total of both 
Wards 
n (%) 
One procedure 40 (75.47) 89 (75.42) 129 (75.44) 
Two procedures 8 (15.09) 20 (16.95) 28 (16.37) 
Three procedures 2 (3.77) 7 (5.93) 9 (5.26) 
Four procedures 2 (3.77) 2 (1.69) 4 (2.34) 
Five procedures 1 (1.89) 0 (0.00) 1 (0.58) 
Total 54 (100.00) 118 (100.00) 171 (100.00) 
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Figure 4.8:  Number of antibiotics per patient per stay in the intervention stage. 
 
4.2.2  Duration of antibiotic therapy  
Overall, in the baseline stage 49.31% of patients received their antibiotic 
therapy for less than two days and 6.19% for more than seven days; while in 
the intervention stage 56.09% received their therapy between 2 to 7 days and 
only 2.07% had treatment for more than seven days. The overall average 
duration of therapy (DoTh), in the baseline stage was 2.62 ± 3.38 days, while in 
the Vascular and General Wards it was 2.83 ± 3.36 and 2.53 ± 2.66 days, 
respectively. During the intervention stage, the overall average duration was 
2.49 ± 2.38 days, while in Vascular and General Wards it was 2.53 ± 2.66 and 
2.47 ± 2.23 days, respectively (Tables 4.5 and 4.6). An independent sample t-
test was conducted to examine the differences between the patients who had a 
duration of antibiotics therapy for two days and more between the two stages of 
the study. The results indicated that the duration of antibiotic therapy for two 
days and more in the baseline stage (mean = 4.74 ± 4.58 days) was statistically 
significantly greater (p = 0.01 < 0.05) than the intervention stage (mean = 3.96 
± 2.04 days). The classification of 2 days or more was also made in such a way 
to exclude those that were used for prophylaxis. 
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Table 4.5: Patients duration of antibiotic therapy in days’ in the baseline 
stage. 
 
Table 4.6:  Patients duration of antibiotic therapy in days’ in the intervention 
stage. 
 
4.2.3 Clinical indications for the use of antibiotics 
There was an overall increase in culture targeted therapy in both wards in the 
intervention stage (n = 88) compared to the baseline stage (n = 67), however 
the shift was not statistically significant (p = 0.125). In the General Ward, there 
was a reduction in empiric therapy from 186 prescriptions in the baseline stage 
to 158 prescriptions during the intervention stage. The “Others” category 
represents the use of macrolides such as erythromycin to stimulate 
gastrointestinal motility in patients who underwent abdominal surgery and 
azithromycin as an anti-biofilm agent (Figures 4.9 and 4.10). 
 
 
Figure 4.9: Antibiotic treatment based on clinical indications in the baseline 
stage. 
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Duration of Therapy Vascular Ward n (%) 
General Surgical 
Ward n (%) 
Total of both 
Wards 
n (%) 
0 - 1 day 48 (47.52) 167 (49.85) 215 (49.31) 
2 - 7 days 44 (43.56) 150 (44.78) 194 (44.50) 
>7 days 9 (8.91) 18 (5.35) 27 (6.19) 
Mean duration of therapy  2.83 ± 3.36 2.56 ± 4.12 2.62 ± 3.96 
Duration of Therapy 
Vascular  
Ward n (%) 
General Surgical  
Ward n (%) 
Total of both 
Wards 
n (%) 
0 - 1 day 64 (44.76) 118 (40.41) 182 (41.84) 
2 - 7 days 74 (51.75) 170 (58.22) 244 (56.09) 
>7 days 5 (3.50) 4 (1.37) 9 (2.07) 
Mean duration of therapy 2.53 ± 2.66 2.47 ± 2.23 2.49 ± 2.38 
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Figure 4.10:  Antibiotic treatment based on clinical indications in the 
intervention stage. 
4.2.4  Allergy to prescribed antibiotics 
There were a few cases of allergy to prescribed drugs in both stages of the 
study, where penicillin allergy was the most common in both stages (Tables 4.7 
and 4.8). Patients who had an allergy to penicillin presented with itching and 
skin rashes, it was stopped immediately and replaced with clindamycin. A 
patient who was found allergic to be sulphur in the intervention stage also 
presented with skin rashes and the drug was immediately stopped with no life 
threating symptoms. There was no proper documentation of symptoms among 
patients who were allergic to vancomycin in the baseline stage but the drug was 
stopped immediately.  
 
Table 4.7:  Allergy to prescribed drugs in the baseline stage. 
 
 Table 4.8:  Allergy to prescribed drugs in the intervention stage. 
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Vascular Ward (n = 144) General Ward (n = 298) Total of both Wards (n = 442)
Allergy 
Vascular Ward  
n (%) 
General Surgical Ward 
n (%) 
Total of both Wards n (%) 
Penicillin 3 (2.91) 2 (0.59) 5 (1.13) 
Vancomycin 4 (3.88) 0 (0.00) 4 (0.90) 
No allergy 96 (93.00) 338 (99.41) 434 (97.97) 
Total 103 (100.00) 340 (100.00) 443 (100.00) 
Allergy 
Vascular ward 
n (%) 
General surgical 
ward n (%) 
Total of both Wards n (%) 
Penicillin 3 (2.08) 8 (2.68) 11 (2.49) 
Sulphur 0 (0.00) 1 (0.34) 1 (0.23) 
No allergy 141 (97.92) 289 (96.98) 430 (97.29) 
Total 144 (100.00) 298 (100.00) 442 (100.00) 
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4.2.5  Route of drug administration 
The intravenous route of administration was the most utilised route in both 
stages of the study where 89.39% and 84.16% of all drugs were administered 
intravenously at baseline and in the intervention stage, respectively (Tables 4.9 
and 4.10).   
 
 Table 4.9:  Route of drug delivery in the baseline stage. 
 
 Table 4.10: Route of drug delivery in the intervention stage. 
 
4.2.6 Antibiotic prescriptions 
The average number of antibiotics per patient was 1.7 and 2.1 in the baseline 
and intervention stages, respectively. This show that more patient received 
combination therapy in the intervention stage, however this was mostly 
appropriate and sequentially administered. In the baseline stage 
amoxicillin/clavulanic acid was the most frequently used antibiotic (52.59%) 
followed by piperacillin/tazobactam (16.25%). During the intervention stage, 
though still the most used agent the frequency of amoxicillin/clavulanic reduced 
to (33.71%), while piperacillin/tazobactam increased to (26.02%) (Tables 4.11 
and 4.12). Flucloxacillin is not accessible in South Africa, but was documented 
to have been used on one patient only in the baseline stage, where data was 
captured retrospectively. It could have been that flucloxacillin was written 
mistakenly instead of cloxacillin. However, the limitation here is that there is no 
opportunity to meet the patient and verify what was actually given as the data 
was captured retrospectively. 
 
Route of Administration 
Vascular Ward 
n (%) 
General Surgery Ward 
n (%) 
Total of both 
Wards 
n (%) 
Intravenous 88 (85.45) 308 (90.59) 396 (89.39) 
Oral 15 (14.56) 32 (9.41) 47 (10.61) 
Total 103 (100.00) 340 (100.00) 443 (100.00) 
Route of Administration 
Vascular Ward 
n (%) 
General Surgery 
Ward n (%) 
Total of both 
Wards n (%) 
Intravenous 125 (86.81) 247 (82.89) 372 (84.16) 
Oral 19 (13.19) 51 (17.11) 70 (15.84) 
Total 144 (100.00) 298 (100.00) 442 (100.00) 
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Table 4.11:  Number of antibiotic prescriptions in the baseline stage. 
Name of Antibiotics ATC Codes  
Number of 
Prescriptions  
(%) of Total 
Prescriptions 
Amoxicillin/Clavulanic acid J01CR02 233 52.59 
Piperacillin/Tazobactam J01CR05 72 16.25 
Cefazolin J01DB04 36 8.13 
Metronidazole J01XD01 20 4.52 
Fluconazole J02AC01 13 2.93 
Vancomycin J01XA01 10 2.26 
Cloxacillin J01CF02 7 1.58 
Imipenem J01DH51 7 1.58 
Ciprofloxacin J01MA02 6 1.35 
Sulfamethoxazole/Trimethoprim J01EE01 5 1.13 
Clarithromycin J01FA09 5 1.13 
Cefepime J01DE01 4 0.90 
Amoxicillin J01CA04 4 0.90 
Azithromycin J01FA10 3 0.67 
Clindamycin J01FF01 3 0.68 
Colistin J01XB01 3 0.67 
Amikacin J01GB06 2 0.45 
Ertapenem J01DH03 2 0.45 
Erythromycin J01FA01 2 0.45 
Gentamycin J01GB03 2 0.45 
Amphotericin B J02AA01 1 0.23 
Ceftazidime J01DD02 1 0.23 
Ceftriaxone J01DD04 1 0.23 
Flucloxacillin J01CF05 1 0.23 
Total  443 100.00 
 ATC Codes (Appendix 1) (WHO, 2016a). 
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Table 4.12:  Number of antibiotic prescriptions in the intervention stage. 
Name of Antibiotics ATC Codes 
Number of 
Prescriptions 
(%) of Total 
Prescriptions 
Amoxicillin/Clavulanic acid J01CR02 149 33.71 
Piperacillin/Tazobactam J01CR05 115 26.02 
Cefazolin J01DB04 31 7.01 
Fluconazole J02AC01 19 4.3 
Ertapenem J01DH03 18 4.07 
Metronidazole J01XD01 18 4.07 
Azithromycin J01FA10 15 3.39 
Ciprofloxacin J01MA02 13 2.94 
Clindamycin J01FF01 12 2.71 
Imipenem J01DH51 8 1.81 
Clarithromycin J01FA09 7 1.58 
Vancomycin J01XA01 6 1.36 
Amoxicillin J01CA04 5 1.13 
Cefepime J01DE01 3 0.68 
Cefotaxime J01DD02 3 0.68 
Cloxacillin J01CF02 3 0.68 
Nystatin A07AA02 3 0.68 
Sulfamethoxazole/Trimethoprim J01EE01 3 0.68 
Amikacin J01GB06 2 0.45 
Erythromycin J01FA01 2 0.45 
Meropenem J01DH02 2 0.45 
Ceftazidime J01DD02 1 0.23 
Ceftriaxone J01DD04 1 0.23 
Doxycycline J01AA02 1 0.23 
Gentamycin J01GB03 1 0.23 
Linezolid J01XX08 1 0.23 
Total  442 100.00 
 
4.2.7  Volume of antibiotic consumption 
In the baseline stage, a total of 1618.36 DDDs were prescribed compared to 
1584.17 DDDs during the intervention stage, whilst a total of 739.30 DDDs/1000 
patient days of antibiotics were consumed in the baseline stage compared to 
564.93 DDDs/1000 patient days in the intervention stage (Table 4.13). During 
the baseline stage a total of 497.10 DDDs and 227.09 DDDs/1000 patient days 
of amoxicillin/clavulanic acid and 373.18 DDDs and 170.48 DDDs/patient days 
of piperacillin/tazobactam were utilised. While in the intervention stage a total of 
375.16 DDDs and 133.80 DDDs/1000 patient days of amoxicillin/clavulanic acid 
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and piperacillin/tazobactam 330.43 DDDs and 117.84. DDDs/1000 patient days 
were consumed (Tables 4.13 and 4.14). An independent sample t-test indicated 
that there was no statistically significant difference between the baseline DDD 
and the intervention DDD p = 0.92. However, an independent sample t-test did 
show a statistically significant difference in the volume of antibiotic consumption 
measured in DDD per 1000 patient days between the baseline stage and 
intervention stage p = 0.038.  
 
Table 4.13:  Antibiotic consumption in the baseline stage. 
Name of 
Antibiotics 
ATC Codes 
WHO 
DDD 
(g) 
Total DDDs (95% CI) 
DDD per 1000 Patient 
Days (95% CI) 
Amoxicillin/ 
Clavulanic acid 
J01CR02 3 497.10 (432.38 - 561.82) 227.09 (197.52 - 256.65) 
Piperacillin/ 
Tazobactam 
J01CR05 14 373.18 (185.12 - 561.24) 170.48 (84.57 - 256.39) 
Cefazolin J01DB04 3 17.50 (14.79 - 20.21) 7.99 (6.75 - 9.23) 
Metronidazole J01XD01 1.5 51.40 (24.28 - 78.52) 23.48 (11.09 - 35.87) 
Fluconazole J02AC01 0.2 296.00 (88.09 - 503.91) 135.22 (40.24 - 230.20) 
Vancomycin J01XA01 2 22.83 (4.16 - 41.50) 10.43 (1.90 - 18.96) 
Cloxacillin J01CF02 2 33.50 (17.98 - 49.02) 15.30 (8.22 - 22.39) 
Imipenem J01DH51 2 58.75 (24.51 - 92.99) 26.84 (11.19 - 42.48) 
Ciprofloxacin J01MA02 1 28.00 (9.31 - 46.69) 12.79 (4.25 - 21.33) 
Sulfamethoxazole/ 
Trimethoprim 
J01EE01 . 15.60 (5.32 - 25.88) 7.13 (2.43 - 11.82) 
Clarithromycin J01FA09 0.5 24.75 (11.56 - 37.94) 11.31 (5.28 - 17.33) 
Cefepime J01DE01 2 41.50 (10.99 - 72.01) 18.96 (5.02 - 32.89) 
Amoxicillin J01CA04 1 11.50 (4.26 - 18.74) 5.25 (1.94 - 8.56) 
Azithromycin J01FA10 0.5 27.00 (14.73 - 39.27) 12.33 (6.73 - 17.94) 
Clindamycin J01FF01 1.8 1.56 (-0.050 - 3.16) 0.71 (-0.02 - 1.45) 
Colistin J01XB01 3 33.00 (15.31 - 50.69) 15.08 (6.99 - 23.16) 
Amikacin J01GB06 1 5.37 (-4.53 - 15.26) 2.45 (-2.07 - 6.97) 
Ertapenem J01DH03 1 25.00 (-12.34 - 62.34) 11.42 (-5.64 - 28.48) 
Erythromycin J01FA01 2 8.25 (-0.10 - 16.60) 3.77 (-0.05 - 7.58) 
Gentamycin J01GB03 0.24 22.00 (2.35 - 41.65) 10.05 (1.07 - 19.03) 
Amphotericin B J02AA01 35mg 18.57 8.48 
Ceftazidime J01DD02 4 3.00 1.37 
Ceftriaxone J01DD04 2 1.00 0.46 
Flucloxacillin J01CF05 2 2.00 0.91 
Total   1,618.36 739.30 
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Table 4.14:  Antibiotic consumption in the intervention stage.  
Name of 
Antibiotics 
ATC 
Codes 
WHO 
DDD 
(g) 
Total DDDs (95% CI) 
DDD per 1000 Patient 
Days (95% CI) 
Amoxicillin/ 
Clavulanic acid 
J01CR02 3 375.16 (310.04 - 438.68) 133.80 (110.57 - 156.45) 
Piperacillin/ 
Tazobactam 
J01CR05 14 330.43 (295.45 - 365.41) 117.84 (105.37 - 130.32) 
Cefazolin J01DB04 3 31 (17.52 - 44.48) 11.06 (6.25 - 15.86) 
Fluconazole J02AC01 0.2 323 (204.67 - 441.33) 115.19 (72.99 - 157.39) 
Ertapenem J01DH03 1 74 (53.79 - 94.20) 26.39 (19.19 - 33.59) 
Metronidazole J01XD01 2 42.07 (17.83 - 66.30) 15.00 (6.36 - 23.65) 
Azithromycin J01FA10 0.5 68.83 (44.06 - 93.61) 24.55 (15.71 - 33.38) 
Ciprofloxacin J01MA02 1 45 (31.47 - 58.53) 16.05 (11.22 - 20.88) 
Clindamycin J01FF01 1.8 49.67 (22.77 - 76.56) 17.71 (8.12 - 27.30) 
Imipenem J01DH51 2 20.63 (12.09 - 29.15) 7.36 (4.32 - 10.39) 
Clarithromycin J01FA09 1 42.50 (15.55 - 69.21) 15.16 (5.54 - 24.77) 
Vancomycin J01XA01 2 20.25 (1.19 - 39.31) 7.22 (0.42 - 14.02) 
Amoxicillin J01CA04 1 19.5 (7.83 - 31.17) 6.95 (2.79 - 11.11) 
Cefepime J01DE01 2 38.5 (10.93 - 66.07) 13.73 (3.89 - 23.56) 
Cefotaxime J01DD02 4 14.25 (12.78 - 15.72) 5.08 (4.56 - 5.61) 
Cloxacillin J01CF02 2 36.50 (3.79 - 69.21) 13.02 (1.35 - 24.68) 
Nystatin A07AA02 1.5 0.1 0.0 
Sulfamethoxazole/ 
Trimethoprim 
J01EE01 - 14.4 (11.13 - 17.67) 5.14 (3.97 - 6.30) 
Amikacin J01GB06 1 2 (0.03 - 3.97) 0.71 (0.01 - 1.41) 
Erythromycin J01FA01 2 3.75 (2.28 - 5.22) 1.34 (0.81 - 1.86) 
Meropenem J01DH02 2 6.25 (-5.05 - 17.55) 2.23 (-1.80 - 6.26) 
Ceftazidime J01DD02 4 3.25 1.16 
Ceftriaxone  J01DD04 2 1.75 0.62 
Doxycycline J01AA02 0.1 12 4.28 
Gentamycin J01GB03 0.24 4.38 1.56 
Linezolid J01XX08 1.2 5 1.78 
Total   1,584.17 564.93 
 
4.2.8  Most frequently utilised antibiotics 
The volumes of piperacillin/tazobactam consumed for empiric and culture 
directed therapy during the baseline stage were 147.57 and 22.91 DDDs/1000 
patient days and 323.04 and 50.14 DDDs, respectively; compared to a lower 
utilisation of empiric (90.16 DDDs/1000 patient days and 252.80 DDDs) and 
increased culture-directed therapies (27.65 DDDs/1000 patient days and 77.62 
DDDs) in the intervention stage (Tables 4.15 and 4.16). The consumption of 
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ertapenem increased during the intervention stage where 5.35 and 21.04 
DDDs/1000 patient days and 15.00 and 59.00 DDDs were utilised for empiric 
and targeted purposes. In the baseline stage, 7.99 DDDs/1000 patient days and 
17.5 DDDs of cefazolin were used for prophylactic purpose; while an increase 
was seen in the intervention stage to 11.06 DDDs/1000 patient days and 31.00 
DDDs (Tables 4.15 and 4.16). 
 
Table 4.15:  DDDs and DDD/1000 patient days of the most frequently used   
antibiotics in the baseline stage. 
Most Used 
Antibiotics 
Indication 
Prophylaxis 
(95% CI) 
Empiric 
(95% CI) 
Targeted 
(95% CI) 
Total DDD by Antibiotics 
Amoxicillin/ 
Clavulanic acid 
61.60 (47.41 - 75.79) 373.63 (322.07 - 425.19) 61.86 (42.06 - 81.67) 
Cefazolin 17.5 (14.78 - 20.22) - - 
Fluconazole 114.00 182.00 (107.56 - 256.44) - 
Metronidazole 0.33 42.60 (16.08 - 69.12) 8.47 (3.79 - 13.14) 
Piperacillin/ 
Tazobactam 
- 323.04 (135.42 - 510.66) 50.14 (32.99 - 67.30) 
Total DDD per 1000 patient Days by Antibiotics 
Amoxicillin/ 
Clavulanic acid 
28.14 (21.66 - 34.63) 170.69 (147.14 - 194.24) 28.26 (19.21 - 37.31) 
Cefazolin 7.99 (6.75 - 9.24) - - 
Fluconazole 52.08 83.14 (49.14 - 117.15) - 
Metronidazole 0.15 19.46 (7.35 - 31.57) 3.87 (1.73 - 6.00) 
Piperacillin/ 
Tazobactam 
- 147.57 (61.86 - 233.29) 22.91 (15.07 - 30.74) 
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Table 4.16:  DDDs and DDD/1000 patient days of the most frequently used 
antibiotics in the intervention stage. 
Most use 
Antibiotics 
Indication 
Prophylaxis 
(95% CI) 
Empiric 
(95% CI) 
Targeted 
(95% CI) 
Total DDD by Antibiotics 
Amoxicillin/ 
Clavulanic acid 
34.80 (23.68 - 45.92) 300.16 (251.68 - 348.63) 39.40 (19.96 - 58.84) 
Cefazolin 31.00 (17.51 - 44.49) - - 
Ertapenem - 15.00 (10.05 - 19.95) 59.00 (39.17 - 78.83) 
Fluconazole 34.00 (26.13 - 41.87) 223.00 (133.25 - 312.75) 66.00 (7.00 - 125.00) 
Metronidazole 0.27 34.20 (11.02 - 57.38) 7.60 (-0.06 - 15.26) 
Piperacillin/ 
Tazobactam 
- 252.80 (222.59 - 283.02) 77.63 (60.40 - 94.85) 
Total DDD per 1000 Patient Days by Antibiotics 
Amoxicillin/ 
Clavulanic acid 
12.41 (8.45 - 16.38) 107.05 (89.76 - 124.33) 14.05 (7.12 - 20.98) 
Cefazolin 11.06 (6.25 - 15.87) - - 
Ertapenem - 5.35 (3.58-7.11) 21.04 (13.97 - 28.11) 
Fluconazole 12.13 (9.32 - 14.93) 79.53 (47.52 - 111.54) 23.54 (2.49 - 44.58) 
Metronidazole 0.10 12.20 (3.93 - 20.46) 2.71 (-0.02 - 5.44) 
Piperacillin/ 
Tazobactam 
- 90.16 (79.30 - 100.93) 27.68 (21.54 - 33.83) 
 
4.2.9 Comparison of average daily DDD to WHO DDD 
In the baseline stage the average daily doses of the most frequently used drugs, 
prescribed for their empiric and targeted purposes such as IV 
amoxicillin/clavulanic acid and piperacillin/tazobactam appeared to have been 
used within the recommended WHO DDDs (Tables 4.17 and 4.18). While some 
of the less commonly used agents such as colistin and ertapenem which were 
used to treat multidrug resistant A. baumannii, CREs and Pseudomonas were 
used at high doses and for a long duration of 10 – 14 days, hence a high ratio. 
Other drugs with high ratios such as cloxacillin and fluconazole were also used 
for a longer duration. The intravenous ciprofloxacin was given at a high dose 
which resulted in high ratio. However, in the intervention stage the average daily 
consumption of IV amoxicillin/clavulanic acid, piperacillin/tazobactam and IV 
metronidazole were still within the recommended WHO recommended DDD. 
The less frequently used antibiotics such as ertapenem and cefepime were 
used for longer durations of 10 – 14 days to treat Pseudomonas, which resulted 
in a high ratio. Meropenem was used at doses higher than the WHO 
recommended DDD, while fluconazole was prophylactically used for a longer 
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duration which resulted in high ratio. The amikacin ratio appeared to be low in 
both stages, this could indicate wrong dosing although it was adjusted in some 
patients to as low as 400 – 500mg daily due to renal insufficiency. Also, the ratio 
of amphotericin was low and that of oral amoxicillin/clavulanic acid was high. 
The WHO DDD of gentamycin of 0.24g appears to be low (Tables 4.17 and 
4.18). 
 
Table 4.17: Average DDD/WHO DDD ratio in the baseline stage. 
Name of Antibiotics 
*Average Daily 
Dose (g) 
WHO 
DDD (g) 
DDDs Ratio (Average 
Daily Dose/WHO DDD) 
Amikacin 0.6 1 0.6 
Amoxicillin 2.0 1 2.0 
IV Amoxicillin/Clavulanic acid 3.3 3 1.1 
Oral Amoxicillin/Clavulanic acid 1.8 1 1.8 
Amphotericin B 10mg 35mg 0.3 
IV Azithromycin 3.3 0.5 6.6 
Oral Azithromycin 0.8 0.3 2.7 
Cefepime 4.4 2 2.2 
Ceftazidime 6.0 4 1.5 
Ceftriaxone 2.0 2 1.0 
IV Ciprofloxacin 0.8 0.5 1.6 
Oral Ciprofloxacin 1.4 1 1.4 
Clarithromycin 1.6 0.5 3.2 
Clindamycin 0.9 1.8 0.5 
Cloxacillin 3.4 2 1.7 
Colistin 8.2mu 3mu 2.7 
Ertapenem 1.8 1 1.8 
Erythromycin 0.5 1 0.5 
Flucloxacillin 4.0 0.2 3.0 
Fluconazole 0.6 0.2 3.0 
Gentamycin 0.9 0.24 3.8 
Imipenem 3.5 2 1.8 
IV Metronidazole 1.2 1.5 0.8 
Oral Metronidazole 1.0 2 0.5 
Piperacillin/Tazobactam 13.9 14 0.9 
Sulfamethoxazole/Trimethoprim - - - 
Vancomycin 1.9 2 0.9 
*Drugs used for empiric/targeted therapy, mu = million unit. 
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Table 4.18: Average DDD/WHO DDD ratio in the intervention stage. 
Name of Antibiotics   
*Average 
DDD (g) 
WHO 
DDD (g) 
DDDs Ratio (Average 
Daily DDD/WHO DDD) 
Amikacin 0.5 1 0.5 
Amoxicillin 1.8 1 1.8 
IV Amoxicillin/Clavulanic acid 3.2 3 1.1 
Oral Amoxicillin/Clavulanic acid 2.5 1 2.5 
IV Azithromycin 0.9 0.5 1.8 
Oral Azithromycin  0.3 0.3 1.0 
Cefepime 4.0 2 2.0 
Cefotaxime 2.5 4 0.6 
Ceftazidime 3.3 4 0.8 
Ceftriaxone 2.5 2 1.3 
IV Ciprofloxacin 1.1 0.5 2.2 
Oral Ciprofloxacin 0.8 1 0.8 
IV Clarithromycin 0.8 1 0.8 
Oral Clarithromycin 1.1 0.5 2.2 
Clindamycin 1.7 1.8 0.9 
Cloxacillin 5.2 2 2.6 
Doxycycline 0.2 0.1 2.0 
Ertapenem 1.8 1 1.8 
Erythromycin 1.3 1 1.3 
Fluconazole 0.7 0.2 3.2 
Gentamycin 0.2 0.24 0.8 
Imipenem 2.2 2 1.1 
Linezolid 1.3 1.2 1.1 
Meropenem 6.3 2 3.3 
IV Metronidazole 1.5 1.5 1.0 
Oral Metronidazole 1.2 2 0.6 
Nystatin 0.0 1.5 0.0 
Piperacillin/Tazobactam 14.1 14 1.0 
Sulfamethoxazole/Trimethoprim - - - 
Vancomycin 0.8 2 0.4 
*Drugs used for empiric and targeted therapy 
 
4.3  UTILISATION OF LABORATORY INVESTIGATIONS 
4.3.1  Prevalence of pathogens 
In the baseline stage the most commonly cultured pathogens were E. coli 
(13.13%), P. aeruginosa (11.23%), K. pneumoniae (10.63%), and A. baumannii 
(9.38%) (Table 4.19). These were mostly isolated from specimens from the 
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General Ward. There were few fungal pathogens cultured and most of them 
were from General Ward. In contrast P. aeruginosa (13.94%), K. pneumoniae 
(11.06%), E. coli (10.58%), A. baumannii (7.21%) and Enterococcus faecium 
7.21% were the most commonly isolated bacteria in the intervention stage and 
were mostly isolated from the General Ward (Tables 4.20). The prevalence of 
C. difficile infection among patients was 3.13% and 3.85% in baseline and 
intervention stages, respectively.  
 
Table 4.19:  Prevalence of pathogens in the baseline stage. 
Cultured Pathogens 
Type of Ward Total of both 
Wards 
n (%) 
Vascular   
Ward n (%) 
General Surgical 
Ward n (%) 
Escherichia coli 4 (16.00) 17 (12.59) 21 (13.13) 
Pseudomonas aeruginosa 2 (8.00) 16 (11.85) 18 (11.23) 
Klebsiella pneumoniae - 17 (12.59) 17 (10.63) 
Acinetobacter baumannii 4 (16.00) 11 (8.15) 15 (9.38) 
methicillin-sensitive Staphylococcus 
aureus 
1 (4.00) 11 (8.15) 12 (7.50) 
Proteus mirabilis 2 (8.00) 9 (6.67) 11 (6.88) 
Enterococcus faecalis 1 (4.00) 8 (5.92) 9 (5.63) 
Enterococcus faecium - 7 (5.18) 7 (4.38) 
Clostridium difficile 1 (4.00) 4 (2.96) 5 (3.13) 
coagulase-negative Staphylococcus - 5 (3.70) 5 (3.13) 
methicillin-resistant Staphylococcus 
aureus 
4 (16.00) - 4 (2.50) 
Streptococcus agalactae 1 (4.00) 3 (2.22) 4 (2.50) 
Staphylococcus epidermidis - 4 (2.96) 4 (2.50) 
Morganella morganii - 3 (2.22) 3 (1.88) 
Candida albicans - 3 (2.22) 3 (1.88) 
Enterobacter aerugenes - 3 (2.22) 3 (1.88) 
Candida glabrata 1 (4.00) 1 (0.74) 2 (1.25) 
Bacillus specie 1 (4.00) 1 (0.74) 2 (1.25) 
Candida parapsilosis - 2 (1.5) 2 (1.25) 
Streptococcus constellatus - 2 (1.48) 2 (1.25) 
Providentia rettgeri - 2 (1.48) 2 (1.25) 
Streptococcus anginosus - 1 (0.74) 1 (0.63) 
Streptococcus haemolyticus - 1 (0.74) 1 (0.63) 
Corynebacterium species - 1 (0.74) 1 (0.63) 
Prevotella bivia - 1 (0.74) 1 (0.63) 
Peptostreptococcus anaerobius - 1 (0.74) 1 (0.63) 
Clostridium perfringes 1 (4.00) - 1 (0.63) 
Klebsiella oxytoca 1 (4.00) - 1 (0.63) 
Micrococcus specie - 1 (0.74) 1 (0.63) 
Enterococcus cloacae - 1 (0.74) 1 (0.63) 
Trichosporon asashi 1 (4.00) - 1 (0.63) 
Total 25 (100.0) 135 (100.0) 160 (100.00) 
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Table 4.20:  Prevalence of pathogens in the intervention stage. 
Cultured Pathogens 
Type of Ward Total of both 
Wards 
n (%) 
Vascular   Ward 
n (%) 
General Surgical 
Ward n (%) 
Pseudomonas aeruginosa 11 (22.45) 18 (11.32) 29 (13.94) 
Klebsiella pneumoniae 7 (14.29) 16 (10.06) 23 (11.06) 
Escherichia coli - 22 (13.84) 22 (10.58) 
Enterococcus faecium 1 (2.04) 14 (8.81) 15 (7.21) 
Acinetobacter baumannii 3 (6.12) 12 (7.55) 15 (7.21) 
Coagulase-negative 
Staphylococcus 
2 (4.08) 11 (6.92) 13 (6.25) 
Enterococcus cloacae 2 (4.08) 9 (5.66) 11 (5.29) 
Enterococcus faecalis - 9 (5.66) 9 (4.33) 
methicillin-sensitive 
Staphylococcus aureus 
7 (14.29) 1 (0.63) 8 (3.85) 
Candida albicans 1 (2.04) 7 (4.40) 8 (3.85) 
Clostridium difficile 1 (2.04) 7 (4.40) 8 (3.85) 
methicillin-resistant 
Staphylococcus aureus 
3 (6.12) 2 (1.26) 5 (2.40) 
Proteus mirabilis 1 (2.04) 4 (2.52) 5 (2.40) 
Burkholderia cephacia 2 (4.08) 1 (0.63) 3 (1.44) 
Citrobacter koseri 2 (4.08) 1 (0.63) 3 (1.44) 
Streptococcus agalactae - 2 (1.26) 2 (0.96) 
Enterobacter aerugenes - 2 (1.26) 2 (0.96) 
Acinetobacter iwoffii - 2 (1.26) 2 (0.96) 
Bacteroides eggerthi - 2 (1.26) 2 (0.96) 
Serratia marcescens - 2 (1.26) 2 (0.96) 
Streptococcus gallolyticus - 2 (1.26) 2 (0.96) 
Trischosporon mucoides - 2 (1.26) 2 (0.96) 
Staphylococcus epidermidis 1 (2.04) - 1 (0.48) 
Candida glabrata - 1 (0.63) 1 (0.48) 
Streptococcus anginosus - 1 (0.63) 1 (0.48) 
Corynebacterium specie - 1 (0.63) 1 (0.48) 
Klebsiella oxytoca - 1 (0.63) 1 (0.48) 
Micrococcus species - 1 (0.63) 1 (0.48) 
Bacteroides thetaiotaomicron - 1 (0.63) 1 (0.48) 
Citrobacter braakii 1 (2.04) - 1 (0.48) 
Citrobacter freudii 1 (2.04) - 1 (0.48) 
Streptococcus mitis 1 (2.04) - 1 (0.48) 
Pseudomonas fluorescen - 1 (0.63) 1 (0.48) 
Haemophilus influenzae 1 (2.04) - 1 (0.48) 
Prevotella oralis - 1 (0.63) 1 (0.48) 
Achromobacter xylosoxidans - 1 (0.63) 1 (0.48) 
Stenotrophomonas maltophilia - 1 (0.63) 1 (0.48) 
Fusobacterium necrophorum - 1 (0.63) 1 (0.48) 
Gemella morbillorum - 1 (0.63) 1 (0.48) 
Total 49 (100.00) 159 (100.00) 208 (100.00) 
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4.3.2  Multi-drug resistant pathogens  
Overall, 40 cases of multi-drug resistant pathogens were cultured in the 
baseline stage compared to 62 in the intervention stage. In both stages of the 
study Gram-negative bacteria were the most common bacteria that showed 
resistance to most classes of antibiotics. Some of these were MRSA requiring 
the use of vancomycin, and of the enterococci some were VREs. Most of the 
Enterobacteriaceae were ESBLs, while almost all the Klebsiella pneumoniae 
were carbapenemase producers. Most of these pathogens were cultured from 
specimens of the General Ward (Tables 4.21 and 4.22). In the baseline stage 
Acinetobacter baumannii (20.00%), Klebsiella pneumoniae (17.50%) and 
Enterococcus faecium (12.50%) were the most common resistant bacteria while 
in the intervention stage, Klebsiella pneumoniae (22.58%), Enterococcus 
faecium (20.97%), and Acinetobacter baumannii (19.35%) were the most 
common bacterial pathogen causing resistance. In the baseline stage, most of 
the resistant organisms were isolated from urine samples (25%) and were 
mostly from the General Ward, followed by blood (20%) and superficial swabs 
17.5% (Appendix 15). During the intervention stage, resistant organisms were 
mainly isolated from fluid/tissue (50%) and superficial swabs (21%) (Appendix 
16).  
 
Table 4.21:  Pattern of multi-drug resistant bacteria in the baseline stage. 
Resistant Pathogens 
Type of Ward Total of both 
Wards 
n (%) 
Vascular 
Ward n (%) 
General Surgical 
Ward n (%) 
Acinetobacter baumannii 2 (25.00) 6 (18.75) 8 (20.00) 
Klebsiella pneumoniae - 7 (21.88) 7 (17.50) 
Enterococcus faecium - 5 (15.63) 5 (12.50) 
Escherichia coli 1 (12.50) 3 (9.38) 4 (10.00) 
methicillin-resistant Staphylococcus aureus 4 (50.00) - 4 (10.00) 
Enterococcus faecalis 1 (12.50) 2 (6.25) 3 (7.50) 
Staphylococcus epidermidis - 3 (9.38) 3 (7.50) 
Pseudomonas aeruginosa - 2 (6.25) 2 (5.00) 
Enterobacter aerugenes - 2 (6.25) 2 (5.00) 
Streptococcus haemolyticus - 1 (3.1) 1 (2.50) 
Morganella morganii - 1 (3.13) 1 (2.50) 
Total 8 (100.00) 32 (100.00) 40 (100.00) 
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Table 4.22:  Pattern of multi-drug resistant bacteria in the intervention stage. 
Resistant Pathogens 
Type of Ward 
Total of both 
Wards 
n (%) 
Vascular 
Ward n (%) 
General 
Surgical 
Ward n (%) 
Klebsiella pneumoniae 4 (33.33) 10 (20) 14 (22.58) 
Enterococcus faecium 1 (8.33) 12 (24) 13 (20.97) 
Acinetobacter baumannii 2(16.67) 10 (20.00) 12 (19.35) 
Escherichia coli - 6 (12.00) 6 (9.68) 
methicillin-resistant Staphylococcus aureus 4 (33.34) 2 (4.00) 6 (9.68) 
Pseudomonas aeruginosa - 4 (8) 4 (6.45) 
Burkholderia cephacia 1 (8.33) 1 (2) 2 (3.23) 
Enterococcus faecalis - 1 (2) 1 (1.61) 
Enterococcus cloaclae - 1 (2) 1 (1.61) 
Acinetobacter iwoffii - 1 (2) 1 (1.61) 
Serratia marcescens - 1 (2) 1 (1.61) 
Achromobacter xylosoxidans - 1 (2) 1 (1.61) 
Total 12 (100.00) 50 (100.00) 62 (100.00) 
 
4.3.3  Classification of cultured pathogens 
In the Vascular Ward of the baseline stage, 23% of the cultured pathogens were 
either mixed isolates or normal flora, this high yield of polymicrobial organisms 
suggested a high collection of superficial swabs (Figures 4.11 and 4.12). Gram-
negative bacteria were the most common isolates in the Vascular (42%) and 
General (55%) Wards. Similarly, in the intervention stage, Gram-negative 
bacteria were the most prevalent bacteria with a prevalence of 56% and 54% in 
the Vascular and General Wards, respectively. There was a reduction of normal 
flora/mixed isolate bacteria especially in the Vascular Ward from 23% in the 
baseline stage to 11% in the intervention stage, and this is probably due to 
increases in the collection of tissue specimens in the intervention stage   
(Figures 4.11 and 4.12).  
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Figure 4.11:  Nature of cultured pathogens in the baseline stage. 
 
 
 
Figure 4.12:  Nature of cultured pathogens in the intervention stage. 
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4.3.4  Timing of culture request 
Overall, in the baseline stage of the study, only 22.16% of the cultures were 
requested before the commencement of antibiotics, while in the intervention 
stage only 24.20% of the cultures were requested before the commencement 
of antibiotics (Tables 4.23 and 4.24). 
 
Table 4.23:  Time of request culture in the baseline stage.  
Time when Culture was Requested 
Vascular 
Ward n (%) 
General 
Surgery Ward 
n (%) 
Total of both 
Wards n (%) 
Culture requested to monitor disease 
progression 
24 (36.92) 131 (39.46) 155 (39.04) 
Culture requested 2 – 3 days after 
commencement of antibiotic 
27 (41.54) 127 (38.25) 154 (38.79) 
Culture requested before commencement of 
antibiotic 
14 (21.54) 74 (22.29) 88 (22.16) 
Total 65 (100.00) 332 (100.00) 397 (100.00) 
 
Table 4.24:  Time of request culture in the intervention stage. 
Time when Culture was Requested 
Vascular 
Ward n (%) 
General 
Surgery Ward 
n (%) 
Total of both 
Wards n (%) 
Culture requested to monitor disease 
progression 
65 (58.56) 158 (43.89) 223 (47.35) 
Culture requested 2 – 3 days after 
commencement of antibiotic 
27 (24.32) 107 (29.72) 134 (28.45) 
Culture requested before commencement of 
antibiotic 
19 (17.11) 95 (26.39) 114 (24.20) 
Total 
111 
(100.00) 
360 (100.00) 471 (100.00) 
 
4.3.5  Nature of specimens collected for culture 
In the baseline stage, the most commonly requested specimens for culture were 
blood (23.87%), urine (22.36%) and fluid/tissue (15.32%); while in the 
intervention stage fluid/tissue (28.81%), blood (27.75%) and urine (16.53%) 
were requested (Tables 4.25 and 4.26). The request of superficial swabs for 
culture in the Vascular Ward reduced from (22.73%) in the baseline stage to 
(11.16%) in the intervention stage.  
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Table 4.25:  Specimens collected in the baseline stage. 
Specimens 
Type of Ward Total of both 
Wards 
n (%) 
Vascular 
Ward n (%) 
General Surgical 
Ward n (%) 
Blood 11 (16.67) 84 (25.30) 95 (23.87) 
Urine 16 (24.24) 73 (21.99) 89 (22.36) 
Fluid/Tissue 13 (19.72) 48 (14.45) 61 (15.32) 
Superficial swab 15 (22.73) 39 (11.74) 54 (13.57) 
Abscess 5 (7.58) 23 (6.93) 28 (7.04) 
Stool 1 (1.52) 27 (8.13) 28 (7.04) 
Sputum 4 (6.06) 20 (6.02) 24 (6.03) 
Drain fluid (sterile cavity) - 8 (2.41) 8 (2.01) 
Drain fluid 1 (1.52) 5 (1.51) 6 (1.51) 
Tracheal aspirate - 4 (1.20) 4 (1.01) 
Cerebrospinal fluid - 1 (0.30) 1 (0.25) 
Total 66 (100.00) 332 (100.00) 398 (100.00) 
 
 Table 4.26: Specimens collected in the intervention stage.  
Specimens 
Type of Ward Total of both 
Wards 
n (%) 
Vascular 
Ward n (%) 
General Surgical 
Ward n (%) 
Fluid/Tissue 30 (26.79) 106 (29.44) 136 (28.81) 
Blood 32 (28.57) 99 (27.50) 131 (27.75) 
Urine 27 (24.11) 51 (14.17) 78 (16.53) 
Superficial swab 13 (11.61) 36 (10.0) 49 (10.38) 
Stool 4 (3.57) 34 (9.44) 38 (8.05) 
Sputum 6 (5.36) 18 (5.0) 24 (5.08) 
Drain fluid (sterile cavity) - 15 (4.17) 15 (3.18) 
Cerebrospinal fluid - 1 (0.28) 1 (0.21) 
Total 112 (100.00) 360 (100.00) 472 (100.00) 
 
4.4 APPROPRIATENESS OF ANTIBIOTIC UTILISATION AND SURGICAL                
PROPHYLAXIS  
In this study the appropriateness of prescription was determined according to 
the Gyssen’s guidelines (Appendix 4) and it was analysed by the categories of 
prophylaxis, empiric or targeted and overall. The appropriateness of surgical 
prophylaxis was based on the recommendations of the SAASP (Wasserman et 
al., 2014) and Standard Treatment Guidelines and Essential Medicines Lists for 
South Africa (NDoH, 2015).  
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4.4.1  Appropriateness of all antibiotic prescriptions 
In the baseline stage of the study 33% and 35% of all antibiotic prescriptions 
were inappropriate in the Vascular and General Wards, and overall 35% of 
antibiotic utilisation in this stage was inappropriate (Figure 4.13). However, in 
the intervention stage, 28% and 25% of prescriptions in the Vascular and 
General Wards were measured as inappropriate, while overall 26% of all 
antibiotics prescription were inappropriate (Figure 4.14). There is a statistically 
significant difference in appropriateness of all antibiotic prescriptions between 
the two stages of the study (p = 0.006). 
 
 
 
Figure 4.13:  Appropriateness of antibiotic utilisation in the baseline stage. 
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Figure 4.14:  Appropriateness of antibiotic utilisation in the intervention stage.  
 
4.4.2  Categories of inappropriate prescriptions 
In the baseline stage, the main reasons for inappropriate prescriptions were due 
to use of less effective agents (27%), unjustified prescription (22%) and use of 
more broad-spectrum/more expensive agents (21%) where less broad-
spectrum and less expensive agents were available (Figure 4.15). In the 
intervention stage, the use of less effective agents (40%), use of more 
expensive agents (17%) and unjustified prescription (14%) were the major 
causes of inappropriate utilisation (Figure 4.16).  
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Figure 4.15: Categories of inappropriate antibiotic utilisation in the baseline 
stage. 
  
 
Figure 4.16: Categories of inappropriate antibiotic utilisation in the intervention 
stage.  
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4.4.3  Appropriateness of all prophylactic therapy 
In the baseline stage of the study, 64% of all prophylactic therapy including 
surgical prophylaxis and cases where fluconazole was used prophylactically 
(Figure 4.17). The latter was used in patients with suspected intra-abdominal 
sepsis, while in the intervention stage 59% of prophylactic therapy was 
inappropriate (Figure 4.18). 
 
 
 Figure 4.17: Appropriateness of prescriptions used for all prophylactic 
therapy in the baseline stage. 
 
 
Figure 4.18: Appropriateness of prescriptions used for all prophylactic therapy      
           in the intervention stage. 
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4.4.4  Appropriateness of surgical prophylaxis 
Amoxicillin/clavulanic acid was the most commonly used agent for surgical 
prophylaxis 68.03% in the baseline stage followed by cefazolin at 29.51% 
(Table 4.27). According to the classification system used and based on the  
South African guidelines, nearly 65% of all surgical prophylaxis was 
inappropriate based on the agent choice, while (n = 9/122) 7.34% was 
inappropriate based on the duration of prophylaxis. Similarly, in the intervention 
stage amoxicillin/clavulanic acid and cefazolin were the two most frequently 
used agents for surgical prophylaxis, and 61.54% of all surgical prophylaxis in 
this stage was inappropriate based on the choice of agent (Table 4.28), while 
6.59% (n = 6/91) was inappropriate based on the duration of prophylaxis. 
 
Table 4.27:  Surgical prophylaxis in the baseline stage. 
Agents Used for Surgical 
Prophylaxis 
Vascular 
Ward 
n (%) 
General 
Ward 
n (%) 
Total of both 
Wards n (%) 
Amoxicillin/Clavulanic acid 18 (60.00) 65 (70.65) 83 (68.03) 
Cefazolin 11(36.67) 25 (27.17) 36 (29.51) 
Clindamycin 1 (3.33) 1 (1.09) 2 (1.64) 
Metronidazole 0 (0.00) 1 (1.09) 1 (0.82) 
Total 30 (100.00) 92 (100.00) 122 (100.00) 
Appropriateness of Surgical Prophylaxis 
Inappropriate 17 (56.67) 62 (67.39) 79 (64.75) 
Appropriate 13 (43.34) 30 (32.61)0 43 (35.25) 
Total 30 (100.00) 92 (100.00) 122 (100.00) 
 
Table 4.28:  Surgical prophylaxis in the intervention stage. 
Agents Used for Surgical Prophylaxis 
Vascular 
Ward n (%) 
General 
Ward n (%) 
Total of both 
Wards n (%) 
Amoxicillin/Clavulanic acid 18 (50.00) 38 (69.09) 56 (61.54) 
Cefazolin 17 (47.22) 14 (25.45) 31 (34.07) 
Clindamycin 0 (0.00) 3 (5.45) 3 (3.30) 
Metronidazole 1 (2.78) 0 (0.00) 1 (1.10) 
Total 36 (100.00) 55 (100.00) 91 (100.00) 
Appropriateness of Surgical Prophylaxis 
Inappropriate 19 (52.78) 37 (67.27) 56 (61.54) 
Appropriate 17 (4.22) 18 (32.73) 35 (38.46) 
Total 36 (100.00) 55 (100.00) 91 (100.00) 
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4.4.5 Appropriateness of empiric/targeted therapy  
Up to 21% of all antibiotic prescriptions used for empiric and targeted indications 
in the baseline were measured as inappropriate based on the Gyssen’s 
classification (Figure 4.19) (Appendix 4); while in the intervention stage 18% of 
antibiotics utilised for empiric and targeted treatment were inappropriate (Figure 
4.20).  
 
 
 Figure 4.19:  Appropriateness of prescriptions for empiric and targeted therapy 
in the baseline stage. 
 
 
 Figure 4.20: Appropriateness of prescriptions for empiric and targeted therapy 
in the intervention stage. 
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4.4.6  Predictors of appropriateness of antibiotic prescription  
The association between the dependent and independent variables for 
appropriateness of antibiotics prescription are shown in Table 4.29 using 
univariate and multivariate logistic regression models. In the unadjusted model, 
the age of patients was significantly associated with the appropriateness of 
antibiotics prescription. Patients aged 36 to 75 years were 47% more likely to 
have an appropriate antibiotics prescription compared to those aged 18 to 35 
years and this was statistically significant, (OR: 1.47, 95%CI: 1.01 - 2.14). For 
patients aged 75 years and above, they were 2.32 times more likely to have an 
appropriate prescription of antibiotics compared to those aged 18 to 35 years; 
however, this was not statistically significant (OR: 2.32, 95% CI: 0.96 - 5.63). 
After adjusting for DoTh, type of surgery, whether microscopy or culture was 
requested, type of diagnoses and type of ward, there was an increasing odds of 
appropriateness with increasing age of patients such that patients aged 36 to 75 
years were 44% more likely to have appropriate prescription of antibiotics 
compared those aged 18 to 35 years old (OR: 1.44, 95%CI: 0.95 - 2.19). Patients 
aged >75 years were 3.09 times more likely to have appropriate antibiotics 
prescription compared to those aged 18 to 35 years and this was statistically 
significant (OR: 3.09, 95% CI: 1.11 - 8.14). 
 
The DoTh by patients is associated with appropriateness in the crude model 
such that patients who had antibiotics for 2 to 7 days were 3.21 times more likely 
to have an appropriate prescription of antibiotics compared to those who had 
treatment for >7 days and this was statistically significant (OR: 3.21, 95%CI: 1.63 
- 5.23). After adjusting for patient’s age, type of surgery, whether microscopy or 
culture tests was requested, type of diagnoses, and type of ward, patients who 
were treated for 2 to 7 days were 64% more likely to have an appropriate 
prescription of antibiotics compared to those who received them for >7 days, 
and this was statistically significant (OR: 1.64, 95%CI: 1.06 - 3.41). 
 
There was a statistically significant association between the type of surgery and 
appropriateness of antibiotics prescription (p = 0.001). In the crude model, there 
were increased odds of 35% and 80% of appropriate prescription of antibiotics 
for patients who had clean and contaminated surgery, respectively, compared 
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to those who had clean-contaminated surgery - but this was not statistically 
significant (OR: 1.35, 95%CI: 0.74 - 2.46; OR: 1.80, 95%CI: 0.98 - 3.29). 
 
Table 4.29:  Crude and adjusted odds ratio (OR) of the appropriateness of antibiotics 
prescription, where the correct classification rate of the model is 71.23% 
(ⱡ: Statistically Significant). 
 
Characteristics 
Crude Adjusted* 
OR (95% CI) P-Value OR (95% CI) P-Value 
Age Group (in Years) 
18 - 35 1.00  1.00  
36 - 75 1.47 (1.01 - 2.14) 0.044ⱡ 1.44 (0.95 - 2.19) 0.084 
>75 2.32 (0.96 - 5.63) 0.063 3.09 (1.11 - 8.14) 0.030ⱡ 
DoTh (in days)     
>7 1.00  1.00  
2 – 7 3.21 (1.63 - 5.23) <0.001 ⱡ 1.64 (1.06 - 3.41) 0.028 ⱡ 
Type of Surgery 
Clean-contaminated 
surgery 
1.00  1.00  
Clean surgery 1.35 (0.74 - 2.46) 0.331 1.52 (0.77 - 3.01) 0.223 
Contaminated surgery 1.80 (0.98 - 3.29) 0.058 3.11 (1.49 - 6.48) 0.002ⱡ 
Dirty surgery 3.31 (1.82 - 5.99) <0.001 ⱡ 2.34 (1.15 - 4.76) 0.019 ⱡ 
No surgical procedure 
done 
3.16 (1.57 - 6.52) 0.002 ⱡ 3.93 (1.77 -8.73) 0.001ⱡ 
Whether Culture/Microscopy was Requested 
Culture/microscopy 
requested 
1.00  1.00  
No culture/microscopy 
requested 
0.51 (0.35 - 0.74) <0.001 ⱡ 0.69 (0.44 - 1.10) 0.210 
Type of Diagnoses 
Gallbladder, biliary tract 
and Liver cases 
1.00  1.00  
Lower GI cases 1.03 (0.44 - 2.41) 0.943 0.52 (0.19 - 1.40) 0.197 
Other general surgery 
cases 
1.15 (0.48 - 2.72) 0.758 0.52 (0.18 - 1.40) 0.217 
Pancreas, spleen and 
appendix cases 
3.90 (1.59 - 9.55) 0.003 ⱡ 2.01 (0.71 - 5.67) 0.186 
Upper GI cases 0.82 (0.33 - 2.01) 0.659 0.56 (0.20 - 1.62) 0.286 
Vascular cases 1.70 (0.71 - 4.05) 0.234 0.95 (0.23 - 3.88) 0.940 
Type of Ward 
Vascular Ward 1.00  1.00  
General Surgery ward 0.88 (1.58 - 3.51) <0.001 ⱡ 1.33 (0.49 - 3.58) 0.578 
Gram-Positive/-Negative Bacteria and Fungi 
Fungi 1.00    
Gram-negative bacteria 1.13 (0.20 - 6.53) 0.889   
Gram-positive bacteria 0.95 (0.16 - 5.63) 0.959   
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Patients who had dirty surgery and those who had no surgical procedure are 
3.31 and 3.26 times more likely to have an appropriate prescription of 
antibiotics, respectively; compared to those who had clean-contaminated 
surgery (OR: 3.31, 95%CI: 1.82 - 5.99; OR: 3.16, 95%CI: 1.57 - 6.52). After 
adjusting for other variables, there was an increased odds of 52% for patients 
who had clean surgery to have an appropriate antibiotic prescription compared 
to patients who had clean-contaminated surgery (OR: 1.52, 95%CI: 0.77-3.01). 
Patients who had contaminated surgery, dirty surgery, and no surgical 
procedure had statistically significant odds of 3.11, 2.34 and 3.93, respectively; 
compared to those who had clean-contaminated surgery (OR: 3.11, 95%CI: 
1.49 - 6.48, OR: 2.34; 95%CI: 1.15 - 4.76, OR: 3.93, 95%CI: 1.77 - 8.73). 
 
There were 51% reduced odds of appropriate prescription of antibiotics for 
patients who had no culture/microscopy requested compared to those with 
culture/microscopy requested. This was statistically significant (OR: 0.51, 
95%CI: 0.35 - 0.74). There were increased odds of 3%, 15%, and 70% of 
receiving an appropriate prescription in lower GI cases, other general surgical 
cases, and vascular cases, respectively; compared to those with gallbladder, 
biliary tract and liver cases. This were also not statistically significant (OR: 1.03, 
95%CI: 0.44 - 2.41; OR: 1.15, 95%CI: 0.48 - 2.72; OR: 1.70, 95%CI: 0.71 - 
4.05). Patients who were diagnosed with pancreas, spleen and appendix cases 
were 3.9 times more likely to have an appropriate prescription of antibiotics 
compared to those diagnosed of the gallbladder, biliary tract and liver cases. 
This was statistically significant (OR: 3.90, 95%CI: 1.59 - 9.55). There was an 
82% reduction in the odds of appropriate prescription of antibiotics for patients 
diagnosed with upper GI cases compared to those diagnosed with gallbladder, 
biliary tract and liver cases. This was not statistically significant. (OR: 0.82, 
95%CI: 0.33 - 2.01). After adjusting for other variables there was a reduction in 
the odds of appropriate prescriptions for patients diagnosed with lower GI 
cases, other general surgical cases, upper GI cases and vascular case 
compared to those with diagnoses of gallbladder, biliary tract and liver cases. 
This was not statistically significant (OR: 0.52, 95%CI: 0.19 - 1.40; OR: 0.52. 
95%CI: 0.18 - 1.40; OR: 0.56, 95%CI: 0.20 - 1.62, OR: 0.95, 95%CI: 0.23 - 
3.88). 
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In the unadjusted model, the type of ward was significantly associated with the 
appropriateness of antibiotics prescription (OR: 0.88, 95%CI: 1.58 - 3.51), such 
that patients admitted in the General Surgery Ward were 88% less likely to have 
an appropriate prescription of antibiotics compared to those admitted to the 
Vascular Ward. Although there was a 33% increased odds of appropriate 
antibiotics prescriptions for patients admitted to the General Ward compared to 
those in the Vascular Ward, after adjusting for other variables i.e. Age, DoTh, 
type of surgery, whether microscopy or culture was requested, type of 
diagnoses and type of ward in the model, the statistical significance observed 
in the crude model disappeared (OR: 1.33, 95% CI: 0.49 - 3.58). While there 
were increased odds of 13% and 95% of appropriate prescription of antibiotics 
for Gram-negative and Gram-positive bacteria, respectively; compared with 
fungi, this is not statistically significant. (OR: 1.13, 95% CI: 0.20 - 6.53, OR: 
1.33, 95%CI: 0.19 - 9.27).  
 
4.5  COMPLIANCE RATE TO AMS RECOMMENDATIONS  
About 71.18% of the recommendations made during the AMS round were 
implemented, however there were some recommendations that were not found 
in patient records after discharge (Table 4.30). 
 
Table 4.30:  Rate of recommendations compliance. 
Recommendations 
Number of 
Recommendations 
Compliance 
Rate 
Intravenous to oral route 68 53 
Oral to intravenous route 13 9 
Discontinuation of an antibiotic therapy  54 36 
Removal of intravenous cannulae 16 16 
 Removal of urethral catheters 4 4 
Tissue cultures 67 43 
CRP 144 103 
Procalcitonin 41 32 
Blood cultures 52 41 
Other specimen cultures 27 15 
Conversion from broad-spectrum to 
narrow-spectrum antibiotics 
38 21 
Total 524 373 
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4.6  COST 
4.6.1  Average cost of antibiotics and laboratory investigations 
The average cost of antibiotics per patient in the Vascular Ward was R 268.23 
± 389.32 in the baseline stage (Table 4.31); while in the intervention stage, it 
reduced to R 228.03 ± 326.88 (Table 4.32). However, in the General Ward, the 
average cost of antibiotic per patient was less at R 219.80 ± 400.75 in the 
baseline stage compared to R 284.06 ± 461.28 in the intervention stage. 
Overall, the average costs of antibiotics per patient in the baseline and 
intervention were R 231.06 ± 398.21 and R 265.81 ± 422.66, respectively; which 
showed an increase of R 34.75 per patient in the intervention stage. The 
average costs of CRP and FBC per patient in the baseline stage were R 304 ± 
447.51 and R 187.51 ± 273.00, respectively; while in the intervention stage 
these costs increased to R 452.82 ± 400.98 and R 285.22 ± 258.03, 
respectively. The mean cost of PCT per patient in the Vascular Wards during 
the baseline stage was R 641.42 ± 594.81 and this increased to R 839.95 ± 
666.90 in the intervention stage in the same ward. There was also an increase 
in the cost of MCS per patient in the intervention stage. However, this increase 
in the cost was not due to an increase in the cost of the test, rather due to an 
increase in the number of tests ordered (Tables 4.31 and 4.32). 
 
Table 4.31: Patient’s average cost of antibiotics and laboratory investigations in the 
                    baseline stage  
Characteristics 
Vascular Ward 
Mean (R) 
General Surgical 
Ward Mean (R) 
Total of both 
Wards 
Mean (R) 
Average cost of antibiotic per 
patient 
268.23 ± 389.32 219.80 ± 400.75 231.06 ± 398.21 
Average cost of PCT per patient 641.42 5 ± 94.81 
1259.93 ± 
3334.51 
1040.45 ± 
2705.48 
Average cost of CRP per patient  434.84 3 ± 67.29 274.44 ± 459.58 304.00 ± 447.51 
Average cost of FBC per patient  265.13 ± 199.59 169.14 ± 284.96 187.51± 273.00 
Average cost of MCS per 
patient  
96.33 ± 42.52 102.42 ± 54.42 101.41 ± 52.63 
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Table 4.32:  Patient’s average cost of antibiotics and laboratory investigations in the 
intervention stage. 
Characteristics 
Vascular   
Ward Mean (R) 
General Surgical 
Ward Mean (R) 
Total of both 
Wards 
Mean (R) 
Average cost of antibiotic per 
patient 
228.03 ± 326.88 284.06 ± 61.28 265.81± 422.66 
Average cost of PCT per patient 839.95 ± 666.90 1124.80 ± 1122.66 
1021.94 ± 
987.12 
Average cost of CRP per 
patient  
446.65 ± 414.82 455.32 ± 396.78 452.82 ± 400.98 
Average cost of FBC per patient  279.12 ± 280.62 287.89 ± 248.53 285.22 ± 258.03 
Average cost of MCS per 
patient  
104.35 ± 61.61 132.71 ± 84.12 117.81 ± 71.64 
 
4.6.2 Overall antibiotic cost 
Amoxicillin/clavulanic acid was the highest prescribed agent in both stages of 
the study followed by piperacillin/tazobactam, but in term of cost incurred 
piperacillin/tazobactam was the highest (Tables 4.33 and 4.34). The frequency 
of amoxicillin/clavulanic acid prescription in the baseline and intervention stages 
were 52.59% and 33.71%, respectively. An independent sample t-test showed 
that there was no statistically significant difference in the overall cost of 
antibiotics in the baseline and the intervention p = 0.21. 
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Table 4.33:  Cost of antibiotics utilisation in the baseline stage. 
Name of 
Antibiotics 
Number of 
Prescription
s 
(%) 
of Total 
prescriptions 
Total Cost per Antibiotic (R) 
(95% CI) 
Amoxicillin/ 
Clavulanic acid 
233   52.59 22,990.19 (19,797.05 - 26,183.33)  
Piperacillin/ 
Tazobactam 
72 16.26 47,726.98 (38,340.64 - 57,133.32) 
Cefazolin 36 8.13 434.18 (366.84 - 501.51) 
Metronidazole 20 4.52 697.87 (210.56 - 1,185.17) 
Fluconazole 13 2.93 2,677.43 (995.99 - 4,358.87) 
Vancomycin 10 2.26 1,721.93 (233.05 - 3,210.81) 
Cloxacillin 8 1.81 1,839.92 (982.61 - 2,678.27) 
Imipenem 7 1.58 10,112.00 (4799.70 - 15,424.30) 
Ciprofloxacin 6 1.35 751.10 (-150.79 - 1,652.99) 
Sulfamethoxazole/ 
Trimethoprim 
5 1.13 9.87 (3.37 - 16.38) 
Clarithromycin 5 1.13 1,256.74 (785.82 - 1,727.65) 
Cefepime 4 0.90 2,857.47 (757.05 - 4,957.90) 
Amoxicillin 4 0.90 10.52 (3.89 - 17.14) 
Azithromycin 3 0.67 1,768.70 (655.84 - 2,881.56) 
Clindamycin 3 0.68 66.36 (29.10 - 103.62) 
Colistin 3 0.67 2,031.48 (942.60 - 3,120.36) 
Amikacin 2 0.45 1,134.56 (-776.70 - 3,045.82) 
Ertapenem 2 0.45 1,504.99 (119.44 - 2,890.54) 
Erythromycin 2 0.45 1,504.99 (119.44 - 2,890.54) 
Gentamycin 2 0.45 144.87 (15.45 - 274.29) 
Amphotericin B 1 0.23 565.50 
Ceftazidime 1 0.23 395.39 
Ceftriaxone 1 0.23 11.68 
Total 443 100.00  
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Table 4.34:  Cost of antibiotics utilisation in the intervention stage. 
Name of Antibiotics 
Number of 
Prescriptions 
(%) 
of Total 
Prescription 
Total Cost per Antibiotic (R) 
(95% CI) 
Amoxicillin/ 
Clavulanic acid 
149 33.71 12,224.55 (9,950.03 -14,417.83) 
Piperacillin/ 
Tazobactam 
115 26.02 55,501.51 (49,626.34 - 61,376.68) 
Cefazolin 31 7.01 769.11 (434.77- 1,103.46) 
Fluconazole 19 4.30 2,000.41 (949.63 - 3,051.18) 
Ertapenem 18 4.07 27,256.42 (1,9815.83 - 3,4697.01) 
Metronidazole 18 4.07 415.64 (34.29 - 796.98) 
Azithromycin 15 3.39 3,188.39 (2,025.08 - 4,351.70) 
Ciprofloxacin 13 2.94 1,243.14 (423.86 - 2,062.42) 
Clindamycin 12 2.71 1,412.52 (647.63 - 2,177.41) 
Imipenem 8 1.81 3,258.75 (1,911.65 - 4,605.85) 
Clarithromycin 7 1.58 217.89 (89.39 - 346.40) 
Vancomycin 6 1.36 1,621.82 (95.24 - 3,148.40) 
Amoxicillin 5 1.13 8.92 (3.58 - 14.25) 
Cefepime 3 0.68 2,650.91 (752.75 - 4,549.07) 
Cefotaxime 3 0.68 306.26 (274.58 - 337.94) 
Cloxacillin 3 0.68 997.18 (103.54 - 1,890.82) 
Nystatin 3 0.68 6.82 (2.35 - 11.29) 
Sulfamethoxazole/ 
Trimethoprim 
3 0.68 4.56 (3.52 - 5.59) 
Amikacin 2 0.45 162.08 (2.81 - 321.35) 
Erythromycin 2 0.45 375.00 (227.60 - 522.40) 
Meropenem 2 0.45 438.90 (-177.24 - 1,055.04) 
Ceftazidime 1 0.23 428.34 
Ceftriaxone 1 0.23 40.87 
Doxycycline 1 0.23 4.10 
Gentamycin 1 0.23 32.93 
Linezolid 1 0.23 2,920.30 
Total 442 100.00  
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CHAPTER FIVE: DISCUSSIONS AND CONCLUSION 
 
5.1  INTRODUCTION 
Over-consumption and inappropriate utilisation of antibiotics are the main 
factors fuelling AMR with consequent additional hospital costs. AMS 
programmes are the gold standard in improving appropriate antibiotic utilisation, 
with a reduction of antibiotic consumption and cost in a hospital setting (Akhloufi 
et al., 2015; Klepser et al., 2016; Sartelli et al., 2016a). However, there are a 
limited number of intervention studies conducted in Africa, especially in a 
surgical setting, designed to encourage appropriate antibiotic utilisation. Hence 
the need to conduct this study. This study aimed at investigating the 
appropriateness of antibiotic consumption and the impact of introducing an AMS 
intervention. It involved a retrospective review of patient records in the baseline 
stage followed by an intervention which involved a weekly antibiotic ward round 
led by an infectious diseases specialist. A recent study of the impact of 
implementation of an AMS programme which involved a weekly antibiotic round 
in the medical department of a South African public tertiary hospital showed a 
considerable reduction of consumption and cost of antibiotics (Boyles et al., 
2017).  
 
SSIs constitute a significant proportion of hospital-acquired infections 
(Anderson et al., 2013) which increase the duration of hospital stay and cost 
(Anderson et al., 2013; Călina et al., 2017). Surgical infections are associated 
with high morbidity / mortality, poor clinical outcomes and treatment failures if 
appropriate antibiotic therapies are not instituted. A key component in the 
management of these infections is good source control and appropriate 
antibiotic management (Sartelli et al., 2016a). Antibiotics play a critical role in 
the management of surgical conditions, cancer therapy and organ transplant. 
However, irrational usage of antibiotics is associated with the selection and 
spread of resistant pathogens (Bell, 2014). Berrington (2010) reported that the 
measurement of antibiotic consumption is a principal component of any AMS 
programme to enable comparison and benchmarking between study stages and 
other studies.  
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5.2  PATIENT DEMOGRAPHIC CHARACTERISTICS 
The demographic characteristics of the participants in both stages of the study 
show that the patients were relatively evenly distributed between males and 
females with a slightly higher proportion of males in the study. More patients 
were admitted into the General Ward compared to the Vascular Ward which is 
likely because patients stayed longer in the Vascular Ward (Tables 4.1 and 4.2). 
Other studies of antibiotic utilisation in surgical settings in other parts of the 
world also show a higher preponderance of males (James and Venu, 2016; 
Zygourakis et al., 2017) where a study in an Australian hospital involving 
different departments including surgery showed a preponderance of males 
(58%) (Akhloufi et al., 2015) similar to the 66.6% of males noted in an Indian 
ICU (Anand et al., 2016). 
 
The overall mean age of the patients was 45.77 ± 16.81 and 51.50 ± 15.91 years 
in the baseline and intervention stages, respectively (Section 4.1.2). The 
statistically significant difference in age between the study stages, showed that 
older patients were admitted during the intervention stage.  This could have 
been that the patients in the intervention stage could have had more co-
morbidities and ICU admissions compared with their counterparts in the 
baseline stage due to their advanced age. Most of the patients in both stages 
of the study fell within the age category of 36 to 75 years. In a similar study 
conducted in an Indian ICU, most patients were within the 51 to 65-year-age 
bracket with a mean age of 52.9 ± 16.9 years (Anand et al., 2016).  Other studies 
in general wards have reported average ages of 54.8 ± 13.2 years (James and 
Venu, 2016) and 60 years (Ingram et al., 2012). 
 
The overall average LOS of patients in the baseline and intervention stages 
were 8.27 ± 9.52 and 13.23 ± 11.81 days, respectively (Section 4.1.3). There 
was also a statistically significant difference in the overall LOS between the two 
stages of the study. Although many AMS programmes have reported a 
reduction in LOS during the intervention stage (Nault et al., 2016; Sintchenko et 
al., 2005), in contrast, this study showed an increase in LOS. This may be due 
to the fact this study was conducted in a surgical setting and older patients were 
admitted during the intervention stage, compared to the baseline stage. 
Differences in LOS were observed between the wards; where patients in the 
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Vascular Ward stayed longer in both stages compared with those in the General 
Ward, probably due to their advanced age. The average LOS was 12.66 ± 10.03 
days in the Vascular Ward and 7.16 ± 9.08 days in the General Ward at baseline 
stage; compared to 16.94 ± 15.44 in the Vascular Ward and 11.55 ± 9.32 days 
in the General Ward during the intervention stage (Section 4.1.3). It was 
observed in this study that patients with peripheral vascular disease with 
ischemia and other vascular complications of diabetes stayed longer, not 
because of infections, but because they had a series of procedures such as 
angiograms, angioplasties and bypass surgeries in attempting limb salvage 
before resorting to amputation when all conservative measures failed. It has 
been observed that many patients stayed longer because they were on IV 
therapy although they do not need IV medications. So early IV to oral conversion 
alone is shown to reduce the LOS in many AMS studies (Barlam et al., 2016; 
Shrayteh et al., 2014), and one may expect a reduction in the LOS with 
reduction in the use of IV antibiotics.  
 
It was also noted that patients had a long waiting time before surgical operations 
especially in the Vascular Ward. Although, due to their advanced age in the 
intervention stage, patients stood a higher chance of having other associated 
co-morbidities which may have extended their hospital stay. James and Venu 
(2016) found the LOS to be 16.6 ± 8.1 days in a gastroenterology unit of a 
tertiary hospital in India; this being higher than the LOS of the patients in the 
General Ward of this study which comprised of a large proportion of 
gastroenterology cases. Patients who underwent vascular neurosurgical 
procedures in the USA had an average LOS of 11.2 to 13.9 days (Zygourakis 
et al., 2017). This was nearly the same as the LOS of the patients in the 
Vascular Ward in the baseline stage; but was slightly lower than the LOS of 
patient in the intervention stage. An AMS programme in a surgical setting at a 
Taiwanese hospital did not find any significant difference in the average LOS 
between the study stages; where the average LOS was 6.2 ± 7.0 and 6.3 ± 7.4 
days in the pre-implementation and implementation stages, respectively (Chang 
et al., 2006). Similarly, a three-year AMS programme at another Taiwanese 
teaching hospital did not find any significant difference in LOS (Lin et al., 2013). 
Recently, an AMS study in Cape Town conducted in a medical setting showed 
an initial reduction in mean LOS from 7.4 days in 2011 to 6.5 days in 2013; but 
105  
 
subsequently increased to 7.6 days in 2015, with no reason given for this 
increase (Boyles et al., 2017). 
 
Clean and dirty surgical operations were the most common surgical operations 
performed on patients in the Vascular Ward during baseline stage, whereas in 
the General Ward contaminated surgical operations were the most frequent, 
followed by clean procedures (Figure 4.5). During the intervention stage, the 
dirty and clean operations were still the most common operations in the 
Vascular Ward with a preponderance of dirty procedures and this was likely 
because of increased cases of patients who had amputations during this stage 
(Figure 4.6). While in the General Ward clean operations were the most 
common surgical operations followed by contaminated procedures (Figure 4.6). 
Patients who had dirty procedures were likely to stay longer and consume more 
antibiotics, while those with clean surgeries were likely to consume less. 
However, prompt and early source control may reduce LOS and volume of 
antibiotic consumption (Sartelli et al., 2016a). A 3.5-year study in a 
gastrointestinal unit at a Dutch tertiary health centre observed slightly different 
trends to our General Ward, in which 12% of surgeries were clean cases, 42% 
clean-contaminated, 25% contaminated and 20% dirty (Ramcharan et al., 
2014). Most patients in both stages of the study had only one procedure, 
however, the proportion of those who had two and more procedures were higher 
in the intervention stage (Tables 4.3 and 4.4). 
 
In this study, as there was a significant increase in the age and LOS during the 
intervention stage, ordinarily one should expect an increased consumption of 
antibiotics. However, with the intervention which encouraged source control, 
rational antibiotic utilisation and unnecessary antibiotic consumption in patients 
who were waiting for surgical procedures or even after surgical operations this 
led to a reduction in antibiotic consumption during intervention stage (Tables 
4.13 and 4.14).  
 
5.3  ANTIBIOTIC UTILISATION 
The five most commonly prescribed agents in the baseline stage were 
amoxicillin/clavulanic acid, piperacillin/tazobactam, cefazolin, metronidazole 
and fluconazole (Table 4.15). During the intervention, amoxicillin/clavulanic 
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acid, piperacillin/tazobactam, cefazolin, fluconazole, ertapenem and 
metronidazole were the most frequently used antibiotics (Table 4.16). There 
was an increase in the utilisation of piperacillin/tazobactam in the intervention 
stage which is likely due to an increase in the prevalence of P. aeruginosa 
compared to the baseline stage (Table 4.20). On the other hand, there was also 
an increase in the consumption of ertapenem in the intervention stage, although 
it was mostly used for culture directed therapy and this was mostly due to an 
increase in the prevalence of multidrug-resistant Klebsiella pneumoniae during 
the intervention stage (Table 4.22). Ertapenem has shown in vitro activity 
against ESBL- producing Enterobacteriaceae such as K. pneumoniae 
(Livermore et al., 2003).  A case of an ertapenem – resistant ESBL producing 
K. pneumoniae has since been reported in South Africa (Elliott et al., 2006). 
More recently Klebsiella pneumoniae carbapenemase which are plasmid-
encoded enzymes capable of hydrolysing all β- lactams including 
monobactams, extended-spectrum cephalosporins and carbapenems have 
been reported in South Africa (Vasaikar et al., 2017). South African studies have 
looked at the utilisation of antibiotics, but only a few have specified the type of 
antibiotic used for treating infections. A recent study, in Cape Town in a medical 
setting found ampicillin and benzylpenicillin as the most frequently prescribed 
agents followed by ceftriaxone, cloxacillin and carbapenems; while 
amoxicillin/clavulanic acid was among the least prescribed agents (Boyles et 
al., 2017). Though the types of bacterial infections treated were not mentioned 
in the Cape Town study to justify the choice of the antibiotics, the difference in 
the choice of antibiotics observed with the current study was probably because 
the two studies were conducted in different settings, with likely differences in 
prevalence of pathogens.  
 
In a study conducted at a Dutch tertiary centre, β-lactam - β-lactamase inhibitors 
combination – amoxicillin/clavulanic acid 34%, and piperacillin/tazobactam 26% 
were the most frequently used antibacterials followed by fluoroquinolones 37%. 
Where 17.3% of all prescriptions were ordered in surgery wards (Akhloufi et al., 
2015). Although, the types of bacterial infections treated and reasons for the 
choice of these antibiotics were not reported in the Dutch study, the choice of 
antibiotics were similar to the current study. Researchers in an Indian ICU found 
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ceftriaxone 22.77% as the most commonly utilised agent, followed by 
piperacillin/tazobactam 15.79%, metronidazole 12.03%, amoxicillin/clavulanic 
acid 6.44%, and azithromycin 4.34% (Anand et al., 2016). In Europe, an AMS 
programme showed cefuroxime as the most frequently prescribed agent in both 
control and post-intervention stages of the study in a Hungarian Surgical ICU, 
followed by vancomycin and ciprofloxacin in the control stage, while 
amoxicillin/clavulanic acid and meropenem in the post-intervention stage. 
Where MRSA, VRE, K. pneumoniae, P. aeruginosa and A. baumannii were the 
most prevalent bacteria in both stages of the study (Peto et al., 2008).  
 
Most of the patients in both stages of this study had one antibiotic, followed by 
those who had two and three agents, while few even had four and more during 
their inpatient stay (Figure 4.7 and 4.8). This is similar to the Akhloufi study 
where 68.3% of patients had only one antibiotic, 25.8% had two agents and 
5.9% received three and more agents (Akhloufi et al., 2015). In this study, most 
of the antibiotic therapies were empiric in nature, macrolides such as 
erythromycin were used in newly operated patients as a prokinetic agent, while 
azithromycin as an anti-biofilm agent (Figures 4.9 and 4.10). There was a shift 
from empiric to culture targeted therapy between baseline and intervention 
stages with 31.34% more scripts based on the laboratory results, although the 
shift was statistically insignificant (p = 0.125) (Figures 4.9 and 4.10). Results of 
a similar study at a secondary Spanish Health Centre from 2009 to 2011 showed 
a reduction of empiric antibiotics therapy from 46% in 2009 to 31% in 2011 due 
to the implementation of an AMS programme (Del Arco et al., 2015). The 
percentage of inappropriate antibiotic utilisation in another Spanish Hospital in 
the first quarter of their AMS programme was 56% of surgical prophylaxis, 
55.2% of empiric therapy and 46.6% of targeted therapy. However, this reduced 
to 15.8% of surgical prophylaxis, 33.3% empiric and 21.6% of targeted therapy 
in the fourth quarter of the program (Cisneros et al., 2014). These studies have 
indicated an improvement in the utilisation of antibiotics. 
 
More patients received combination therapy during the intervention stage 
(Section 4.2.6). This was mostly an appropriate combination used to treat 
infections caused by multi-drug resistant Klebsiella pneumoniae and 
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Acinetobacter baumannii. The reported prevalence of these pathogens 
increased in the intervention stage (Tables 4.21 and 4.22), probably due to 
increases in the request of cultures during AMS rounds. Also, de-escalation to 
narrow-spectrum antibiotics from broader agents initiated by the surgeons 
during AMS rounds based on the results of cultures could have also increased 
the number of antibiotics received by the patients in this stage. Of note, in the 
intervention stage most of the patients that received more than one antibiotic 
had them sequentially, except in situations where there was need to broaden 
the empiric cover. 
 
5.3.1  Antibiotic consumption 
There was a statistically significant reduction in the consumption of antibiotics 
between the two stages of the study, from 739.30 DDDs/1000 patient days, in 
the baseline to 564.93 DDDs/1000 patient days in the intervention stage (p = 
0.038) (Tables 4.13 and 4.14). This concurred with many AMS studies, such as 
the one conducted at two medical wards of Groote Schuur Academic Hospital 
in Cape Town where there was a reported 19.6% reduction in antibiotic 
consumption from 592.0 DDDs/1000 patient days in the pre-implementation 
stage to 475.8 DDDs/1000 patient days in the implementation stage after 
introduction of dedicated antibiotic chart and weekly antibiotic round (Boyles et 
al., 2013). Recently Boyles reported a sustained reduction in antibiotic utilisation 
from 1,046 DDDs/1000 patient bed days in 2011 to 864 DDDs/1000 patient 
beds in 2015 after extending the programme to two other medical wards (Boyles 
et al., 2017). Although our intervention resulted in a significant reduction of 
antibiotic consumption, it is still high compared to what was found in the 2013 
Cape Town study where the study took place in medical wards compared to the 
surgical setting in this study (Tables 4.13 and 4.14). Other AMS studies showed 
a reduction in the consumption of antibiotic during second stage, except in a 
study at surgical/medical ICU of an academic hospital in Toronto where an 
increased consumption was reported (Table 5.1). 
 
In both stages of the study the average daily doses of the most frequently used 
drugs such as IV amoxicillin/clavulanic acid and piperacillin/tazobactam used 
for treatment purposes, appeared to have been used within the recommended 
WHO DDD (Tables 4.17 and 4.18). While some of the less commonly used 
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agents such as colistin, meropenem, cefepime and ertapenem which were used 
to treat multidrug resistant Acinetobacter baumannii, CREs and Pseudomonas 
were used at high doses and for a longer duration of 10 – 14 days, hence a high 
average daily DDD/WHO DDD high ratio. However, even though DDD is the 
most widely used and reliable method of quantifying volume of drug 
consumption and also recommended by WHO it has its own limitations 
especially the WHO assigned DDD. The ATC/DDD methodology possesses 
advantages over other methods of quantifying drug consumption especially in 
developing countries, but it also requires some minor corrections regarding 
WHO assigned DDD. However, WHO Collaborating Centre for Drug Statistics 
Methodology Oslo, which is responsible for assigning ATC codes and DDD to 
drugs, periodically review DDD of drugs when it receives comments or 
suggestions for review (WHO, 2016a). For instance it has been documented in 
the literature that the IV form of amoxicillin/clavulanic acid which is given at 1.2g 
three times daily has a WHO DDD of 3g, while the oral form which is given at 
1g twice daily has a DDD of 1g (WHO, 2016a). This is probably the reason why 
the average daily DDD/WHO DDD ratio of oral amoxicillin/clavulanic acid 
appears to be on the high side (Tables 4.17 and 4.18). The WHO DDD for IV 
amoxicillin/clavulanic acid used to be 1g like the oral form, until 2005 when it 
was changed to 3g, because of proposals for review (Muller et al., 2006) The 
average daily dose represents the daily maintenance dose of drug received by 
a patient, while the average PDD represents the daily amount of a drug that is 
actually prescribed. The PDD does not reflect actual drug utilisation, because 
some of the prescribed medications are not always dispensed, and the patient 
does not always take all the medications that are dispensed (WHO, 2003). This 
is the reason why PDD was not used to quantify drug consumption in this study. 
 
5.3.2  Route of administration 
AMS programmes encourage an early switch from IV to oral formulation as soon 
as the patient can tolerate oral administration especially with agents that have 
high bioavailability such as fluoroquinolones (Sartelli et al., 2016a). Decreased 
use of IV antibiotics is associated with reduced LOS (Shrayteh et al., 2014). In 
this study, most antibiotics were administered intravenously in both stages with 
a slight reduction during the intervention stage (Tables 4.9 and 4.10). The high 
use of IV route in this study may be because the study was conducted in a 
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surgical setting. Patients in some surgical settings, on cancer therapy and those 
with gastrointestinal conditions especially those that interfere with absorption 
are associated with increased use of intravenous antibiotics (Shrayteh et al., 
2014). The perception that drugs delivered intravenously tend to work faster and 
effectively compared to those delivered orally, even when a patient can tolerate 
oral doses could have increased the use of IV antibiotics.  
 
This ignores the cost implications of using administration sets and possibly IV 
fluids, as well as the risk of developing local and even systemic infections 
associated with this route.  IV routes also require some expertise and extra time 
to set-up which amounts to an additional cost to both the hospital and patients, 
especially in the private hospital setting. Researchers in three Lebanese 
academic hospitals also found a higher use of IV antibiotics, where 79.4% of 
patients received their antibiotics intravenously, while 20.6% received theirs via 
oral and IV antibiotics simultaneously (Shrayteh et al., 2014). Other studies 
have also shown a high use of IV administrations where around 60% to 65% of 
antibiotics were delivered via this route (Ingram et al., 2012; James and Venu, 
2016). The use of oral antibiotics was found to be very low in a Hungarian ICU 
with about 6.9% and 4.4% in control and post-intervention stages, respectively 
(Peto et al., 2008). This would be acceptable since most of the cases in ICU 
were critical and cannot tolerate oral medications. 
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Table 5.1: AMS studies that showed improvement of antibiotic consumption. 
S/N Study Setting AMS 
Intervention 
Outcome 
1. Peto et al., 2008 Surgical ICU of the 
University of Szeged, 
Academic Hospital Hungry. 
Formulary 
restriction, Daily 
bed side 
consultation 24-
hour, 
Telemedicine 
consultation. 
Reduced 
antibiotic 
consumption 
from 162.9 to 
101.3 
DDDs/100 
patient days. 
2a. Taggart et al., 
2015 
Trauma/Neurosurgery ICU 
of an academic hospital in 
Toronto. 
AMS audit and 
feedback. 
Reduction in 
antibiotic 
consumption 
from 1,433 to 
1,037 
DDDs/1000 
patient days. 
2b. Taggart et al., 
2015 
Surgical/Medical ICU of an 
academic hospital in 
Toronto. 
AMS audit and 
feedback. 
Increase in 
antibiotic 
consumption 
from 1,705 to 
1,936 
DDDs/1000 
patient days. 
3. Hou et al., 2014 Chinese tertiary hospital 
ICU. 
Formulary 
restriction, 
Preauthorisation, 
Perioperative 
quinolone 
restriction. 
A 27.44% 
reduction in an 
antimicrobial 
consumption 
from 197.7 to 
143.4 
DDDs/100 
patient days. 
4. Cisneros et al., 
2014 
Spanish tertiary hospital 
ICU. 
Local guidelines 
and educational 
intervention. 
A reduction in 
antibiotic 
consumption 
from 1,150 
DDDs/1000 
patient days in 
the 1st quarter of 
the programme 
to 852 
DDDs/1000 
days 4th quarter. 
 
 
5.3.3  Duration of therapy  
There was an improvement in DoTh in this study (Tables 4.5 and 4.6). There 
was a statistically significant reduction (p = 0.01) in the DoTh among patients 
who had antibiotics for two days and more between the two stages of the study. 
The average DoTh for patients who received antibiotics for two days and more 
in the baseline and intervention stages was 4.74 ± 4.58 days and 3.96 ± 2.04 
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days, respectively, 6.19% of patients had DoTh for >7 days in the baseline stage 
compared to 2.07% in the intervention stage (Tables 4.5 and 4.6). In this study 
the duration of antibiotic therapy for Pseudomonas and Acinetobacter of up to 
10 – 14 days is considered appropriate. The reduction in DoTh was expected 
as during AMS rounds the researcher encouraged source control and early 
discontinuation of antibiotic treatment. It was also recommended that the 
consumption of antibiotics should be reduced in patients waiting for surgical 
operations, especially when there was no clear indication for antibiotic therapy. 
James and Venu (2016) reported a duration of therapy of up to 15 ± 7.9 days in 
some surgical cases in a Gastroenterology Unit of an Indian Hospital, this was 
longer than the DoTh in the General Ward in this current study, which consisted 
of a large proportion of a gastroenterology cases. 
 
There are controversies about the DoTh in patients with complicated intra-
abdominal infections, where the Surgical Infection Society and IDSA 
recommends 4 to 7 days of therapy, except in cases where there is difficulty in 
achieving source control (Solomkin et al., 2010). Similarly, the French 
guidelines propose 5 to 7 days of therapy (Montravers et al., 2015). The World 
Society of Emergency Surgery has advocated short DoTh in patients with 
resolved fever and leucocytosis (Sartelli et al., 2013). It has also been a 
recommendation to decrease the DoTh with antibiotics except in situations that 
require prolonged treatment, as in cases of immunocompromised individuals or 
those with ongoing sepsis. If features of sepsis persist after 5 to 7 days of 
therapy, a septic workup should be considered to determine the focus of 
infection or antibiotic treatment failure (Sartelli et al., 2016a).  
 
5.3.4 Appropriateness of antimicrobial prescription 
In this study the appropriateness of antibiotic therapy was determined using 
Gyssen’s algorithm. Gyssen’s algorithm assesses appropriateness of antibiotic 
therapy beyond the use of microbiology results. It considers other parameters 
such as choice of agent, duration of therapy as well as the cost effectiveness of 
the therapy i.e. the use of less expensive agents instead of more expensive 
agents etc. (Figures 4.15 and 4.16). For instance, a culture result may show 
both a narrow- and broad-spectrum and could be used for target therapy. 
Cisneros et al., 2014, show that targeted therapy could be inappropriate if 
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agents are not appropriately selected, or if  an agent was not given over an 
appropriate duration, which is one of the parameters Gyssen’s guideline 
assesses. In the Cisneros’ study the percentage inappropriate targeted therapy 
improves between stages of the study (Cisneros et al., 2014). This shows that 
the use of Gyssen’s algorithm and microbiology results in this study is superior 
to the use of microbiology result alone, to determine the appropriateness of 
antibiotic prescription. Overall, there was a statistically significant reduction in 
the inappropriate antibiotic utilisation in this study from 35% in the baseline 
stage to 26% during the intervention stage (p = 0.006) using a guideline 
developed by Gyssens and colleagues (Plenat et al., 1992) (Figures 4.13 and 
4.14, Appendix 4). Among the patients who received antibiotics for treatment 
purposes (empiric/targeted), there was a reduction in inappropriate utilisation 
during the intervention stages (Figures 4.19 and 4.20). There are limited studies 
conducted to determine the appropriateness of antibiotic therapy in surgical 
settings especially in developing countries (Lim et al., 2015). A literature search 
does not find any AMS intervention study conducted in a surgical setting in 
South Africa, which was why this study was conducted. However, a personal 
communication with Prof Mendelson found that there is one currently going on 
at Groote Schuur Academic Hospital Cape Town (Personal communication). A 
study conducted in two surgical wards of a Malaysian tertiary hospital, in which 
appropriateness of antibiotic therapy was determined using a different guideline 
found that 42.0% of antibiotic used for treatment purposes was inappropriate 
(Lim et al., 2015). The proportion of inappropriate utilisation for treatment 
purposes in a Malaysian study was higher than what was found in this study.  
 
A study in five public hospitals in Lesotho, in which appropriateness of antibiotic 
prescription was assessed also using a different guideline found that 32.2% and 
78.4% of the empirically prescribed antibiotics were appropriate among 
inpatient and outpatient cohort, respectively (Adorka et al., 2014). It has been 
reported previously that both public and private ICUs across South Africa, had 
a high percentage of inappropriate usage of antibiotics, where 43.5% and 60.8% 
of prescriptions were inappropriate in public and private ICUs, respectively 
(Paruk et al., 2012). This is higher than observed in the current study, possibly 
due to the study being conducted in the ICU setting where higher antibiotic 
consumption is likely.  
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Other studies using the guideline by Gyssens and colleagues (Plenat et al., 
1992) also reported higher a percentage of inappropriate prescription, and 
researchers in an Australian tertiary centre found that 47% of all prescriptions 
were inappropriate and were mostly due to unjustified prescriptions 35%. 
Though that was not an intervention study, the percentage of inappropriate 
prescription was 12% higher than the baseline stage of this study. It further 
showed that 56% of prescriptions in Vascular, 43% in General and 56% in 
Gastroenterology/Hepatology units were inappropriate with the underlying 
reasons being similar to those in this study (Ingram et al., 2012). In a 
Gastroenterology Unit of an Indian Tertiary Hospital the Gyssen’s guideline was 
implemented and it was reported that 39.9% of all antibiotics were 
inappropriately used; where the percentage of inappropriate prescriptions was 
slightly higher 35% than the percentage of inappropriate prescriptions in 
baseline stage of the current study (James and Venu, 2016). A point prevalence 
study at a tertiary hospital in Netherlands found that 29.3% of all antibiotic 
prescriptions usage were inappropriate and mostly was due to unjustified 
prescriptions (Akhloufi et al., 2015).  
 
A high proportion of inappropriate antibiotic utilisation was seen in patients who 
received antibiotics for surgical prophylaxis in both stages of the study. Where 
64.75% and 61.54% of the prophylaxis were inappropriate in the baseline and 
intervention stages, respectively, based on wrong choice of agents (Tables 4.27 
and 4.28). While 7.34% and 6.59% were inappropriate in the baseline and 
intervention stages, respectively, based on the duration of more than 24 hours 
(Section 4.4.4). A high percentage of inappropriate surgical prophylaxis was 
because of the wrong choice and prolonged duration of prophylaxis where 
amoxicillin/clavulanic acid was the most frequently used prophylactic agent in 
both stages. Amoxicillin/clavulanic acid is not recommended for surgical 
prophylaxis by SAASP and the Standard Treatment Guidelines and Essential 
Medicines Lists for South Africa, in all the type of procedures conducted in both 
stages of the study (NDoH 2015; Wasserman et al., 2014). Surgical prophylaxis 
aims to reduce SSIs which are mostly Gram-positive. The high Gram-negatives 
prevalence in South Africa is from invasive infections not SSIs. 
Amoxicillin/clavulanic has an excellent Gram-negative cover which is 
considered unnecessary for surgical prophylaxis.  On the other hand, cefazolin, 
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aside from its cost-effectiveness, is considered the gold standard surgical 
prophylactic agent in many surgical prophylactic guidelines, due to its 
favourable pharmacokinetic profile and the broad cover it has against both 
Gram-positive and -negative bacteria, except for Enterococcus (Bratzler et al., 
2013; Kusaba, 2009). The results from this study and many other studies across 
South Africa have shown that Gram-negative bacteria were the most prevalent 
pathogens (Brink et al., 2007; Greatorex and Oosthuizen, 2015). 
 
In a Malaysian study 66.3% of prophylaxis were determined to be inappropriate, 
and 34.5% of inappropriate prophylaxis was due to inappropriate duration and 
16.4% was due to wrong choice (Lim et al., 2015). This is similar to the findings 
of this study (Tables 4.27 and 4.28). Even high inappropriate prophylactic usage 
was found in other surgical settings, a study in a Jordanian cardiac surgery 
centre, found that up to 98.3% of surgical prophylaxis was inappropriate based 
on wrong antibiotic choice, while 58.9% was inappropriate because of duration 
of more than 48 hours as recommended by the guideline (Al-Momany et al., 
2009). A study in a private surgical setting in India found that 32% of surgical 
prophylaxis was inappropriate because the agents were inappropriately chosen 
while 37% was inappropriate due to prolonged duration of prophylaxis 
(Parulekar et al., 2009). China, another BRICS country, adopted an AMS 
programme in 2012 to encourage appropriate antibiotic utilisation (Xiao and Li, 
2013). A study conducted across Chinese provinces showed a reduction in 
inappropriate surgical prophylaxis (mostly due to incorrect choice of antibiotic) 
for clean surgeries from 44.38% in 2011 to 33.25% in 2012 (Zhou et al., 2016).  
Based on the CMAJH drug price list and the South African National Price 
Catalogue, amoxicillin/clavulanic acid is 2.5 times more expensive than 
cefazolin where, 1g of cefazolin costs R 8.27 (US$ 0.56) while 1.2g of 
amoxicillin/clavulanic acid cost R 20.31 (US$ 1.37) (Appendix 5). Two grams of 
cefazolin is the recommended prophylactic dosage in most of the surgical cases 
seen in the Vascular and General Wards, so the use of cefazolin apart from 
being recommended in the guidelines, is also cheaper for the patients and 
hospital. This intervention brought about little reduction in inappropriate surgical 
prophylaxis, because the drugs were mostly started in the theatre before they 
were admitted to the ward where the intervention took place. Prophylactic 
antibiotics were reviewed during a weekly round where recommendations were 
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made to change the patient’s antibiotic or to stop therapy if the patient has been 
receiving them for more than 24 hours. In the baseline stage, the main factors 
associated with inappropriate antibiotic utilisation were the use of less effective 
agents instead of more effective drugs, unjustified prescriptions, use of more 
expensive agents and use of more broad-spectrum antibiotics (Figure 4.15). In 
the intervention stage the use of less effective agents instead of more effective, 
use of more expensive agents, unjustified prescription and use of more broad 
agents instead of less broad-spectrum agent were attributed with inappropriate 
prescriptions (Figure 4.16). 
 
Inappropriate use of antibiotics was high amongst patients who received it for 
prophylaxis compared to those who received it for treatment purposes, where 
64% and 59% of the prophylactic antibiotic usage in baseline and intervention 
stages was classified as inappropriate (Figures 4.17 and 4.18). For the 
antibiotics used for treatment (targeted/empiric), 21% and 18% were 
inappropriate in the baseline and intervention stages, respectively (Figures 4.19 
and 4.20). This study concurs with an Australian study where the percentage of 
inappropriate antibiotic utilisation was high among the patients who had it for 
prophylaxis 63% compared to those that received it for treatment purposes 
(empiric and targeted) 52%. The high inappropriate antibiotic usage was largely 
due to wrong agent choice and unjustified use (Ingram et al., 2012). 
Researchers at the New York Hospital for Joint Diseases found no difference in 
likelihood of developing SSIs among patients who had antibiotic prophylaxis for 
24 hours and those who had prophylaxis for the entire period they had a surgical 
drain after spinal procedures (Takemoto et al., 2015). The findings of this New 
York study showed that prolonging the duration of surgical prophylaxis does not 
offer additional benefits to the patient and consequently results in the selection 
of resistant pathogens and additional cost.  
 
5.4  PREDICTORS OF APPROPRIATENESS OF ANTIBIOTIC THERAPY 
In this current study, a binary logistic regression model was used to predict the 
factors associated with the appropriateness of antibiotic prescription. In the 
crude model increasing age, decreased DoTh, dirty surgical procedures 
compared to clean-contaminated procedures, use of microscopy/culture, having 
diagnoses of pancreas, spleen and appendix cases compared to gallbladder, 
117  
 
biliary tract and liver cases and Gram-positive/-negative and fungi were 
associated with the odds of having an appropriate antibiotic. All these variables 
except Gram-positive/-negative and fungi were statistically associated with the 
appropriateness of antibiotic prescription in the crude model (Table 4.29). 
However, in the adjusted model, it was only age, DoTh, and type of surgery that 
were statistically associated with predicting appropriateness of prescription. A 
multivariate logistic regression showed that culture directed therapy was linked 
with high odds of getting appropriate antimicrobial therapy. While, carbapenems 
and macrolides usage, antibiotic treatment in patients with creatinine levels of 
more than 120 μmol/L and the presence of joint/bone disease were statistically 
associated with an increased odd of receiving inappropriate therapy (Ingram et 
al., 2012).  
 
It was also determined using logistic regression that previous antimicrobial 
treatment and age are variables related to inappropriate empiric antimicrobial 
treatment in patients with a UTI (Velasco et al., 2010). In China, a binary logistic 
regression was used to predict factors associated with the odds of adhering to 
the recommendations of the National AMS programmes on surgical prophylaxis 
in patients with clean operations (Zhou et al., 2016). Geographic region (i.e. 
province) and hospital bed capacity were significant predictors in both univariate 
and multivariate models, where hospitals in the western provinces had better 
outcomes compared to those in the central provinces. On the other hand, 
hospitals with a bed capacity of less than or equal to 500 had better outcomes 
compared to those with bed capacity of more than1500 (Zhou et al., 2016).   
 
5.5  PREVALENCE OF PATHOGENS                                                                                                                                                                                                                             
Laboratory medicine plays a critical role in the success of any AMS programme; 
it also helps in determining the appropriateness of antibiotic therapy. MCS 
guides the selection of the right antimicrobial agent, and provides an avenue to 
either streamline the empiric treatment to a narrow agent if the initial drug was 
too broad or to escalate to a broad-spectrum if the agent used was too narrow 
(Sartelli et al., 2016a). Gram-negative bacteria were the most common 
pathogens in both stages of the study, followed by Gram-positive bacteria. 
There was a reduction in the culture yield of mixed isolate/normal flora in the 
Vascular Ward during the intervention stage. This represented a shift from 
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collecting a superficial specimen to tissue/fluid during the intervention stage. 
Although this is a more invasive procedural change for the patient, the 
advantage is that the causative agent is identified and can be more 
appropriately treated. 
 
In both stages of the study E. coli, P. aeruginosa, K. pneumoniae and A. 
baumannii were the most prevalent pathogens (Tables 4.19 and 4.20) and were 
mostly cultured from specimens of the General Ward. The prevalence of P. 
aeruginosa and K. pneumoniae in the intervention stage increased mostly in the 
General Ward. It was observed in this study that MSSA was the most frequently 
cultured bacteria from superficial abscesses, but patients were usually started 
on empiric amoxicillin/clavulanic acid. A. baumannii, K. pneumoniae, and 
Enterococcus faecium were the most common resistant pathogens requiring the 
use of last resort antibiotics such as carbapenems or colistin in both stages of 
the study (Tables 4.21 and 4.22).  Greatorex and Oosthuizen (2015) in Kwazulu-
Natal, South Africa, found a high preponderance of Gram-negative bacteria in 
an ICU where 27% of cultured pathogens were K. pneumoniae, 22% E. coli, 
and 17% Acinetobacter baumannii. The resistance rate of K. pneumoniae to 
first- and second-line antibiotics was higher - ampicillin 97%, 
amoxicillin/clavulanic acid 35%, ciprofloxacin 43%, piperacillin/tazobactam 12% 
but resistance to ertapenem and colistin was 0%. E. coli was 79% resistant to 
ampicillin, 4% to amoxicillin/clavulanic acid and meropenem with 0% resistant 
rate to piperacillin/tazobactam, ertapenem and colistin (Greatorex and 
Oosthuizen., 2015). Similarly, Gram-negative bacteria such as K. pneumoniae, 
and E. coli were the most frequently isolated bacteria in a study in the South 
African private health setting. E. coli was 84% resistant to ampicillin and 20% to 
fluoroquinolones, while K. pneumoniae showed a regional variation in 
resistance to ceftriaxone/cefotaxime of 39% to 87% (Brink et al., 2007). A study 
conducted in a tertiary hospital in southern Netherland involving gastrointestinal 
surgical cases show a similar prevalence of pathogens with this study, where 
E. coli 25% and P. aeruginosa 10% were the most prevalent pathogens 
(Ramcharan et al., 2014).  
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A sentinel survey across the United States and Canadian hospitals shows that 
S. aureus and E. coli were the most common pathogens causing blood stream 
infections followed by coagulase-negative Staphylococci and Enterococcus 
species (Pfaller et al., 1998). Similarly, S. aureus was the most prevalent 
bacteria causing infections in a Hungarian ICU and most of the cases were 
MRSA (Peto et al., 2008). In 2005, a surveillance study across hospitals in 
England also found S. aureus as the major cause of SSIs among patients who 
underwent total hip replacement, in which it was implicated in 50% of the cases, 
and 59% of these cases were due to MRSA (Ridgeway et al., 2005). Whilst in 
other countries MRSA is a leading pathogen, its prevalence in this study was 
low. The results from this study showed an increased request of fluid/tissue and 
blood culture in the intervention stage (Table 4.26); where the most common 
specimens requested in the baseline stage were blood, urine followed by 
fluid/tissue. On the other hand, in the intervention stage, fluid/tissue was the 
most commonly requested specimen followed by blood and urine. This showed 
an increase in the request of biological specimens, which contributed towards 
improvement in appropriateness of antibiotic utilisation in the intervention stage.  
 
Despite high inappropriate antibiotic usage in developing African countries, the 
prevalence of C. difficile infection is low compared to developed countries. The 
prevalence of C. difficile infection in this study was low with 3.13% and 3.85% 
in the baseline and intervention stages, respectively (Tables 4.19 and 4.20). 
The findings were similar to results from other studies across Africa - for 
instance in the Vhembe region of the Limpopo province a prevalence of C. 
difficile of 7.1% was reported (Samie et al., 2008). Similarly, at Bugando and 
Sekou Toure hospitals in Tanzania the prevalence of C. difficile was 6.4% where 
all patients had a preceding history of antibacterial therapy before the onset of 
diarrhoea (Seugendo et al., 2015). In neighbouring Zimbabwe, the prevalence 
of C. difficile among the stool samples collected from patients attending 
hospitals in Harare aged two years and above was 8.6% (Simango and Uladi, 
2014). However, a higher prevalence than what was seen in African countries 
was found in a Peruvian academic hospital, where 35.2% of hospital-acquired 
diarrhoea in both medical and surgical units was caused by C. difficile - this was 
even higher than what is seen in developed countries (Garcia et al., 2007).  
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At a geriatric unit of the University of Hamburg academic hospital Germany, 
16.4% of asymptomatic patients tested positive for toxigenic C. difficile on 
geneXpert (Nissle et al., 2016). A study in the United Kingdom showed that, 
reduced consumption of cephalosporins and fluoroquinolones in two hospitals 
led to a significant reduction in the prevalence of C. difficile infection from 280 
cases/year in 2007/2008 to 72 cases/year in 2011/2012 (Sarma et al., 2015). 
Dancer et al. (2013) reported a 77% reduction in the prevalence of C. difficile 
infection at a district hospital in Glasgow, over a two-year period after 
implementation of an antibiotic restriction programme. The programme led to a 
95% decrease in the consumption of ceftriaxone from 46.21 to 2.13 DDDs/1000 
patient days and 72.5% decrease in ciprofloxacin consumption from 109.80 to 
30.21 DDDs/1000 patient days. 
 
These results also showed that the request of culture before commencement of 
antibiotics was low in both stages of the study. The low requests of culture 
before the commencement of antibiotics could be explained by the fact that 
CMJAH receives many patients already on antibiotics from other centres. Often, 
these patients are apyrexial and are therefore changed empirically without 
cultures. Usually, cultures are only taken with spiking temperatures. Cultures 
can and must be taken before antibiotics are commenced in moribund patients.  
 
5.6      COMPLIANCE TO AMS RECOMMENDATIONS  
This study showed high compliance to recommendations made during AMS 
rounds, with 71.18% of recommendations implemented by the surgeons. 
Though this study has shown a good compliance rate, this was lower when 
compared to what was seen in other studies. For instance, at the Médecins 
Sans Frontières medical centre Jordan, there was an increase in compliance to 
AMS team recommendations from 78% in the first quarter to 97% in the fourth 
quarter of 2014 (Bhalla et al., 2016). In Spain, compliance had increased from 
89% at the inception of the program in 2009 to 93% in 2011. The compliance 
rate was higher possibly because the intervention was carried out for a longer 
period than the current study (Del Arco et al., 2015). An AMS programme 
designed to guide utilisation of antifungal agents at a French academic hospital 
reported an 88% adherence rate (Mondain et al., 2013). There was no 
resistance from the surgeons or other professionals in the wards during this 
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study. However, it was observed that some of the recommendations made at 
the beginning of the programme such as collection of appropriate samples for 
culture were not complied with, probably because some doctors were not aware 
of the programme. This was discussed with the consultants in charge of the 
units and thereafter compliance rate improved.  It is also believed that active 
participation of senior consultants in AMS rounds, training and practical 
teaching could have increased the compliance rate. In Cape Town, all efforts of 
the AMS team to persuade consultants to participate in weekly round failed. 
Consequently, it was suggested that the residents who participated in rounds 
are better trained in rational antibiotic usage than their consultants (Boyles et 
al., 2017). After the implementation of an AMS programmes in China, one of the 
countries with the highest percent of inappropriate antibiotic utilisation in the 
world, prescribers in public hospitals faced serious penalties for their failure to 
adhere to antibiotic prescription guidelines (Bao et al., 2015). 
 
5.7  COST 
5.7.1  Cost of antibiotic utilisation  
The results showed that the average costs of antibiotics per patient in the 
Vascular Ward had reduced in the intervention stage from the baseline stage, 
while in the General Ward it increased in the intervention stage. The cost 
increment in the General Ward during intervention stage was likely due to costs 
incurred by the increase in the consumption of more expensive antibiotics such 
as piperacillin/tazobactam and ertapenem. There was greater detection of 
resistant organisms in the intervention stage because more cultures were 
requested hence more targeted therapy (Section 4.3.2). 
 
The total cost of piperacillin/tazobactam and ertapenem increased during the 
intervention stage compared to the baseline stage in both wards. There was no 
statistically significant difference in the overall cost of antibiotics between the 
two stages of this study (p = 0.21). Although ertapenem was not among the five 
most commonly used agents in the baseline stage, its utilisation increased 
during the intervention stage for culture directed treatment. A single dose of 4.5 
g piperacillin/ tazobactam which is usually given 6 hourly, cost R 53.99 (US$ 
3.65) and a dose of ertapenem which is usually given as a daily dose, cost R 
368.33 (US$ 24.90), while a dose of amoxicillin/clavulanic acid cost R 20.31 
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(US$ 1.37) and R 1.81 (US$ 0.12) for IV and oral formulations, respectively 
(Appendix 5). Based on the latter costing, amoxicillin/clavulanic acid was the 
most commonly used agent in both stages of the study. In the Cape Town study, 
there was a 35% reduction in total cost of antibiotics from R 1,068, 328 (US$ 
72,233) in the baseline stage to R 373,620 (US$ 25,262) during the intervention 
stage (Boyles et al., 2013). Recent results of an extension to a 5-year AMS 
study conducted in Cape Town, showed a substantial reduction in the cost of 
antibiotics from R 2,191,594 (US$ 148,181) in the pre-implementation stage to 
R 1,187,942 (US$ 80,321) in the implementation stage, i.e. a R 1,003,652 (US$ 
67,860) saving for the hospital and patients (Boyles et al., 2017). 
 
 An AMS programme which also looked at costs was introduced at the Médecins 
Sans Frontières, Medical Centre Amman in Jordan, which receives surgical war 
victims from Iraq, Syria and Yemen. The programme was driven by a non-
specialist medical doctor and a pharmacist with the support of an infectious 
diseases specialist and involved a weekly antibiotic round. This led to a 
reduction of antibiotic cost from US$ 252,077 (mean cost US$ 21,006 per 
month) in the baseline stage to less than US$ 159,948 (mean cost US$ 13,329 
per month) in the intervention stage (Bhalla et al., 2016). Implementation of an 
AMS programme in a hospital in the United States resulted in a substantial 
reduction in the cost of antibiotic from US$ 4,028,068 in 2010 to US$ 2,135,173 
in 2013 (Timbrook et al., 2016). A remarkable reduction in the cost of antibiotics 
was noted after implementation of an AMS programme in a Saudi Arabian 
hospital, involving many departments including surgery. A sum of US$ 326,020 
was saved monthly because of decreased antibiotic consumption from 
restricted lists (Alawi and Darwesh, 2016). The two stages of this study were 
conducted between Febuary and September 2016 at a time when the exchange 
rate of South African Rand (R) to the United State Dollar was at an average of 
R 14.79 to US$ 1 (Oanda, 2017). Thus the cost benefit of such a programme 
has generally been shown to lead to improvements and can assist hospitals with 
restricted funding to manage more patients with increased efficacy and 
improved outcomes.  
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5.7.2  Cost of laboratory investigation 
The results showed an increase in the cost of laboratory investigations per 
patient in the intervention stage. However, this was not due to increase in the 
cost of the test but rather due to an increase in the request of cultures and 
biomarkers during AMS rounds (Tables 4.31 and 4.32). Biomarkers such as 
CRP and PCT were requested during AMS ward rounds especially in cases 
where surgeons requested superficial cultures which mostly yielded 
polymicrobial organisms on culture, making it difficult to reach any decision. The 
increase in the cost of laboratory investigations during the intervention stage 
concurred with the findings of a previous study. In the Cape Town study, there 
was an increase in the total cost of laboratory investigations from R 463,580 
(US$ 31,344) at the baseline stage to R 608,232 (US$ 41,125) during the 
implementation stage; which was also due to an increase in the utilisation of 
biomarkers in the intervention stage (Boyles et al., 2013). The cost of laboratory 
investigations in the 2017 Cape Town study also increased from R 504,333 
(US$ 34,099) in 2011 to R 575,144 (US$ 38,887) in 2015 (Boyles et al., 2017).  
 
5.8  STUDY LIMITATIONS 
 There were number of limitations to this study which included the following; 
5.8.1  Lack of electronic patient records - in this study, data from patient records were 
manually captured on data collection sheets, transferred to excel spreadsheets, 
cleaned and analysed. Unlike in the private healthcare sector in South Africa or 
other countries with established databases where patients’ information can be 
exported directly and transferred to a spreadsheet for analyses - this was a 
laborious and tedious exercise, which considerably prolonged the duration of 
data collection. Additionally, the absence of computerised electronic 
prescription platforms in the study wards made it difficult to monitor 
recommendations compliance rates. Currently electronic data capturing is being 
piloted in the public healthcare sector in South Africa as part of a nation-wide 
roll-out programme from the NDoH which will improve data collection 
substantially for studies such as this (Personal communication – cluster of 
Sector Wide Procurement NDoH).  
 
5.8.2  Reproducibility – although the study has led to an improvement in the 
appropriateness of antibiotic utilisation and a, reduction in the volume of 
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antibiotic consumption and cost in certain wards, it may be difficult to replicate 
in many South African public sector hospitals and other hospitals across Africa, 
outside of the academic setting. This is because of the limited number of 
infectious diseases physicians in the continent, hence the need to train other 
professionals. Also, the availability of laboratory and other diagnostic facilities 
at CMJAH, aided monitoring of biomarkers and drug toxicity levels which led to 
the success of this study, whereas such facilities are absent in many hospitals 
across the continent (Boyles et al., 2013). 
 
5.8.3  Generalisability – it is difficult at this point to draw any conclusion based on the 
findings of this study about antibiotic utilisation in South Africa in general, 
because the study was conducted in only two wards of a surgery department in 
a tertiary health centre. Additional studies are required specifically in the surgery 
setting as well as in other wards and in other hospitals across South Africa.  
 
5.8.4  Even though the study has led to the reduction in antibiotic consumption, which 
is an important driver that encourages the development of AMR, it is not 
possible to say this study has led to the reduction of AMR.  It was not assessed 
during the study period which was deemed too short to generate a meaningful 
conclusion regarding changing resistance patterns. Additionally, in a referral 
hospital such as the CMJAH which receives patients harbouring multi-drug 
resistant pathogens from other South African hospitals and across Africa, 
unless there is proper screening at the point of entry, it is difficult to attribute any 
reduction in resistance rate to the success of AMS programme (Boyles et al., 
2013).  
 
5.8.5  A weekly round is insufficient to adequately monitor antibiotic therapy. Patients 
who had antibiotics and were discharged after spending a few days in the ward 
may not have been seen by the AMS team. In addition, patients receiving 
prophylactic antibiotics mostly received treatment prior to being admitted to the 
ward, e.g. if patients had a surgical intervention directly from the Emergency 
Department.  
 
5.8.6 Lack of manpower and poor funding – despite the available data showing the 
usefulness of AMS programmes in improving patients’ clinical outcomes and a 
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reduction in hospital expenditure, AMS programmes are still challenged with 
poor funding because of competition with other hospital programmes (Coulter 
et al., 2015). Hospitals need additional funds to support the personnel who 
dedicate extra hours to the project (Drew, 2009). Perhaps a further economic 
evaluation of AMS programmes beyond antibiotic cost savings is required to 
convince the decision-makers, to support the programme (Dik et al., 2015). A 
study conducted at a urology unit of a teaching hospital in Holland in which a 
total of 114 patients receiving antibiotics were reviewed by AMS team on their 
second day of antibiotic therapy has resulted in a total saving of € 60,306. Whilst 
the operational cost of implementing the programme including personnel cost 
was € 17,732 (Dik et al., 2015).  
 
 From a survey conducted in France it was determined that the number of 
professionals required to implement AMS programme was approximately 3.6 
infectious diseases specialists' full-time equivalents (FTEs) positions/1000 
acute care beds and 2.5 pharmacists FTEs/1000 beds and 0.6 microbiologists 
FTEs/1000 beds. This totalled 1,960 FTE positions required at the cost of € 200 
million per year to implement AMS programmes in French public and private 
hospitals (Le Coz et al., 2016). In another survey carried out in the United States 
involving infectious diseases specialists, most of the participants reported that 
insufficient funding and shortage of personnel were the main challenges 
affecting successful implementation of AMS (Johannsson et al., 2011). About 
half of them complained of poor incentives for participating in such programmes 
(Johannsson et al., 2011). Infectious diseases specialists who often drive AMS 
programmes were shown to be the least remunerated among 25 major medical 
professionals in the United States (O'Neill, 2016).  An AMS programme 
implemented at an orthopaedic surgery unit of a German hospital employed the 
services of an infectious diseases specialist who devoted 10% of his time to the 
programme at the cost of € 850/ month (Borde et al., 2016).  
 
5.8.7 Inadequate training – high levels of inappropriate antibiotic treatment in surgery 
are largely due to inadequate training on infectious conditions, and this seems 
to be true especially of surgeons, probably because rational antimicrobial 
utilisation in the treatment of surgical infections is not efficiently taught in their 
training (Çakmakçi, 2015). So, their active participation in AMS projects may 
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increase the success rate of such programmes (Çakmakçi, 2015). Depriving 
surgeons of their right to prescribe restricted antibiotics affects their working 
relationship with the AMS team, hence the need to involve them especially 
those with a good understanding of surgical infections to audit prescriptions and 
give feedback to their colleagues (Sartelli et al., 2016b). 
 
5.8.8 Increase of laboratory cost – following the introduction of an AMS programme in 
Cape Town, an increase in laboratory costs was seen, this was attributed to 
increased utilisation of biomarkers such as CRP and PCT (Boyles et al., 2013; 
Boyles et al., 2017). The routine use of CRP and PCT as a way of distinguishing 
bacterial from acute viral respiratory tract infections in a resource challenged 
country like South Africa with a high prevalence of tuberculosis is of less benefit 
as both markers are increased in tuberculosis (Mendelson, 2015a).  
 
5.9  RECOMMENDATIONS 
5.9.1  Training – due to a high proportion of inappropriate surgical prophylaxis and 
high use of IV antibiotics in this study, training such as short courses on surgical 
prophylaxis and rational antibiotic usage for surgeons and theatre staff is 
recommended. Additionally, incorporation of AMS courses in the curricula of 
South African medical, veterinary and other health science students, as some 
South African schools of pharmacy have started, will prepare the next 
generation of health professionals to embrace the culture of rational antibiotic 
prescribing early in their professional career. It is also recommended to include 
AMS training into curricula of surgery residency programmes as this may 
increase registrar’s understanding of surgical infections.  
 
5.9.2  Multidisciplinary team – it is recommended to form a multidisciplinary team in 
the hospital comprising of infectious diseases specialists, clinical 
microbiologists, pharmacists, infection control nurses, and hospital 
administrative staff. Increased frequency of ward rounds to about 2 to 3 times a 
week will provide an opportunity to more closely monitor patients on antibiotic 
therapy. Regional hospitals are also encouraged to implement AMS 
programmes and liaise with the infectious diseases physicians in academic 
hospitals to give expert and technical advice.  
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5.9.3  The hospital is encouraged to continue with the weekly antibiotic round to 
maintain the successes achieved during the study. Now that the programme is 
completed, the absence of ongoing AMS ward rounds could allow the process 
to reverse to where it started. They are also encouraged to develop a 
computerised decision support system which provides physicians with 
appropriate treatment options and guides when prescribing drugs which, will 
improve rational antimicrobial utilisation.    
 
5.10 CONCLUSION 
Even though antibiotic resistance is a natural phenomenon and an inevitable 
event, rational antibiotic prescribing, AMS programmes, infection and 
prevention control measures will go a long way in slowing or even reversing the 
fast approaching post-antibiotic era. This study has attempted to provide the 
clinicians with an overview of antibiotic utilisation and an AMS intervention in a 
surgical setting of a public South African tertiary health institution. The findings 
show an improvement in an appropriateness of antibiotic utilisation, reduction 
in antibiotic consumption and DoTh. In addition, there was reduction in cost of 
antibiotics in one of the study wards, after implementation of the AMS 
programme. Also, there was an improvement in culture directed treatment, 
requests for biological specimens for culture, with a consequent increase in the 
cost of laboratory investigations per patient due to increased culture requests 
during the intervention stage. The high rate of AMR especially in developing 
countries necessitates proactive measures to address the problem; as such a 
multidisciplinary approach through AMS is an option to address inappropriate 
antimicrobial use with cost savings in hospitals.  
 
5.11  FUTURE RESEARCH 
Further research is required to understand why clinicians and surgeons are not 
adhering to the local surgical prophylaxis guidelines. Further research is also 
required to evaluate the importance of AMS interventions in clinical outcomes 
and long term changes in pattern of resistance. There is a need to conduct 
studies on SSIs in other clinical setting such as cardiothoracic surgery and 
orthopaedics. Also, there is a need to conduct a study to assess the impact of 
increasing frequency of AMS ward round on clinical outcomes. There is also 
need to repeat this study in the same wards in years’ time to see if the successes 
128  
 
recorded now are maintained. Qualitative research would also add value in 
better understanding what behavioural factors and challenges would need to be 
addressed to further improve adherence to AMS programmes. 
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APPENDIX 1  
 ANTIBIOTICS ATC CODES 
 Table A.1: Antibiotics ATC codes 
Name of Antibiotics ATC Code 
Amoxicillin/Clavulanic acid J01CR02 
Piperacillin/tazobactam J01CR05 
Cefazolin J01DB04 
Metronidazole J01XD01 
Fluconazole J02AC01 
Vancomycin J01XA01 
Cloxacillin J01CF02 
Imipenem J01DH51 
Ciprofloxacin J01MA02 
Sulfamethoxazole/Trimethoprim J01EE01 
Clarithromycin J01FA09 
Cefepime J01DE01 
Cefotaxime J01DD02 
Linezolid J01XX08 
Amoxicillin J01CA04 
Azithromycin J01FA10 
Clindamycin J01FF01 
Colistin J01XB01 
Amikacin J01GB06 
Ertapenem J01DH03 
Erythromycin J01FA01 
Gentamycin J01GB03 
Amphotericin B J02AA01 
Ceftazidime J01DD02 
Ceftriaxone J01DD04 
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APPENDIX 2 
 DATA COLLECTION TABLE ON DEMOGRAPHIC CHARACTERISTICS AND 
NATURE OF SURGERY 
 Table A.2:  Collection sheet to collate demographic characteristics and nature 
of surgery of patients. 
Study 
number 
Age Sex Ward DOA DOD LOS Diagnoses 
Type of 
surgery 
Number of 
procedures 
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APPENDIX 3 
 DATA COLLECTION TABLE ON DRUG UTILISATION 
 Table A.3:  Collection sheet to collate drug utilisation 
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DDD: Defined Daily Doses 
Date 1: the day antibiotic started.  
Date 2: the day antibiotic stopped  
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APPENDIX 4 
 GYSSEN’S CRITERIA FOR ASSESSING APPROPRIATENESS OF 
ANTIMICROBIAL DRUG THERAPY (ADT) 
 
i.  Appropriate ADT. 
 
ii.  Inappropriate ADT, due to: 
a. Improper dosage 
b. Improper dosage interval 
d. Improper route 
 
iii. Inappropriate ADT prescription due 
a. Excessive length 
b. Duration of therapy too short 
 
iv.  Inappropriate ADT, due to incorrect choice: 
a. More effective agent is available  
b. Less toxic alternative agent is available 
c. Less expensive alternative agent is available 
d. Less broad-spectrum alternative agent is available 
 
v. Inappropriate ADT, due to unjustified prescription (use of any antimicrobial is 
not indicated). 
 
vi. Insufficient information. 
 
ADT = Antimicrobial Drug Therapy 
(Plenat et al., 1992). 
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APPENDIX 5 
 ANTIBIOTIC PRICE LIST 
 Table A.4:  Table for antibiotic price list 
 
Name of antibiotics Price/Package (R) 
Price/Dose 
(R) 
Amikacin 500mg - 4.24 
Amoxicillin - 0.46 
IV Amoxicillin-clavulanic acid 1.2g - 20.31 
Oral Amoxicillin-clavulanic acid 500mg 18.1 1.81 
Amphotericin B 50mg - 43.50 
IV Azithromycin 500mg - 46.55 
Oral Azithromycin 500mg 14.64 4.88 
Cefazolin 1g - 8.27 
Cefepime 1g - 34.43 
Ceftazidime 1g - 65.89 
Ceftriaxone 1g - 5.84 
Cefotaxime 1g - 32.95 
IV Ciprofloxacin 500mg - 40.52 
Oral Ciprofloxacin 400mg    7.25 0.75 
Clarithromycin 500mg 69.33 4.95 
IV Clindamycin 600mg - 9.12 
Oral Clindamycin 600mg 65.19 3.26 
Cloxacillin 500mg - 13.66 
Colistin 2mu - 41.04 
Ertapenem 1g - 368.33 
IV Erythromycin 1000mg - 200.00 
Fluconazole 400mg - 16.63 
Gentamycin 240 - 6.59 
Imipenem 1g - 47.88 
Meropenem 1g - 62.70 
IV Metronidazole 500mg - 5.61 
Oral Metronidazole 400mg 12.13 0.43 
Piperacillin/tazobactam 4.5g - 53.99 
Sulfamethoxazole/trimethoprim 950mg 15.19 0.15 
Vancomycin 1g - 40.04 
Linezolid 600mg -` 292.03 
Nystatin drop 15.16 - 
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APPENDIX 6 
 DATA COLLECTION TABLE ON MICROSCOPY CULTURE AND SENSITIVITY 
AND BIOMARKERS 
 Table A.5:  Collection sheet to collate results of microscopy culture and 
sensitivity and biomarkers 
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TSL: Time from Specimen Collection to Result Release 
Date 1: the day specimen collected 
Date 2: the day result was released by the laboratory 
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APPENDIX 7 
 LABORATORY INVESTIGATIONS PRICE LIST 
 Table A.6:  Laboratory investigation price list 
 
S/NO TYPE OF INVESTIGATION PRICE(R) 
1. Blood culture  44.02 
2. CSF culture no growth 47.38 
3. CSF culture growth 47.38 
4. Culture anaerobic  33.97 
5. Urine culture 47.38 
6. Lowenstein-Jensen culture 14.33 
7. ZN Mycobacterium isolate on culture 23.11 
8. Fungal blood culture  44.02 
9. Fungal cultures 33.97 
10. Fungal identification 94.07 
11. Culture anaerobic 33.97 
12. Culture aerobic 47.38 
13. Culture for S. aureus 17.00 
14. Culture for Streptococcus pyogenes 47.38 
15. Faeces/urine culture S. typhi 47.38 
16. MIC 91.64 
17. Assay antifungal 106.65 
18. Candida serology 41.37 
19. Microscopy 36.89 
20. Clostridium difficile toxin 225.26 
21.  PCR for M. tuberculosis 530.96 
22. GeneXpert PCR tuberculosis 165.99 
23. FBC 50.16 
24. WBC only 15.60 
25. C-reactive protein 84.71 
26. Procalcitonin 335.98 
 
Source: NHLS State Price List 2015 
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APPENDIX 8 
 ETHICAL CLEARANCE CERTIFICATE TO CONDUCT A PROSPECTIVE STUDY 
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APPENDIX 9 
 ETHICAL CLEARANCE CERTIFICATE TO CONDUCT A RETROSPECTIVE 
STUDY 
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APPENDIX 10 
 LETTER OF HOSPITAL PERMISSION TO CONDUCT STUDY 
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APPENDIX 11 
 LETTER OF PERMISSION TO CONDUCT STUDY IN SURGERY DEPARTMENT    
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APPENDIX 12 
 LETTER OF PROTOCOL TITLE APPROVAL 
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APPENDIX 13 
 LETTER OF CONSENT 
 
Letter of consent seeking patient’s permission to review their records. 
 
Effects of Antimicrobial Stewardship policy in improving antibiotic utilisation 
and reducing drug costs in a public hospital in Gauteng province, South Africa 
 
 
Good day, Sir/Madam. 
 
My name is Dr. Bashar Muhammad Augie, and I am registered for a Pharmacology 
Masters (MSc Med) by dissertation at the Faculty of Health Sciences, University of the 
Witwatersrand. I am conducting this project as part of my master’s dissertation and it 
involves assessing the effect of Antimicrobial Stewardship (AMS) policy in improving 
antibiotic utilisation and reducing drug costs in a public hospital in Gauteng Province, 
South Africa, under the supervision of Dr. Jacqui Miot, Prof Robyn van Zyl and Dr. 
Evan Shoul.  I am seeking your permission to review your patient records; this will 
enable me to determine the impact of an AMS policy in improving antibiotic utilisation 
and reduction in drug costs. This is a combined prevalence cross-sectional analysis 
with a prospective observational study. 
 
Your anonymity will be ensured, any information that may reveal your identity such as 
name and address will not be recorded. A unique study number will be assigned to 
your records, the list of study numbers and patients record numbers will be kept in a 
password protected data file and only accessible to me and my supervisors. No patient 
file will be taken away from the facility nor will any copies of files or patient information 
be made, so your identity will not be revealed when the study is reported or published.  
 
If you have any questions about the study or participating in the study please feel free 
to ask me (Bashar Muhammad Augie), you can call me at 060 380 7904 or email me 
on 1332258@students.wits.ac.za. 
 
Your participation in this study is totally voluntary, you are under no obligation to 
participate, and you have the right to withdraw at any time if you care to without 
repercussion or penalty. 
. 
The ethics for the study has been approved by the University of the Witwatersrand 
Human Research Ethics Committee.  
 
I have discussed the above points with participants; it is my opinion that the participant 
understands the risks, benefit and obligations involved in participating in this project. 
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________________________ 
        
 Researcher’s signature  Date 
 
 
I understand that my participation is voluntary and that I may refuse to give permission 
or can withdraw my consent and stop taking part at any time without penalty. 
 
I hereby freely agree to a review of my patient records. 
 
 
                                    
 
            
 
 
 
 
Signature of participant Signature of witness Date 
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APPENDIX 14 
 INFORMATION SHEET 
 
Effects of Antimicrobial Stewardship policy in improving antibiotic utilisation 
and reducing drug costs in a public hospital in Gauteng province, South Africa 
 
Dear potential participant,  
 
I am Dr. Bashar Muhammad Augie, and I am a master’s student in the division of 
Pharmacology, Department of Pharmacy and Pharmacology, University of the 
Witwatersrand Johannesburg. I am doing research on the impact of an antimicrobial 
stewardship policy in improving antibiotic use and reducing drug costs in a public 
hospital in Gauteng Province, South Africa. This study will take place in the Department 
of Pharmacy and Pharmacology and the Surgery Department of Charlotte Maxeke 
Johannesburg Academic Hospital. Antimicrobial stewardship programmes (AMS), 
have been shown to improve appropriate use of antibiotics in some places with an 
overall reduction in drug cost and duration of hospital stay.  AMS also reduces toxicity 
from drugs by selecting the most appropriate drug at its correct dosage and route of 
delivery. 
 
 The aim of this study is to describe how antibiotics are currently prescribed and to 
measure the impact of introducing an antimicrobial stewardship intervention on cost 
and utilisation in your surgical ward of the Charlotte Maxeke Johannesburg Academic 
Hospital. I am seeking your permission to review your hospital records where I will 
capture information on your clinical condition, type of surgery, related blood tests and 
which antibiotics have been prescribed for you. 
 
Patient records for this study will be selected using a convenience sampling and 
inclusion criteria will be; patients who give consent for their records to be reviewed, 
any patient 18 years or older, currently taking an antibiotic for infection or having taken 
an antibiotic prescribed within the previous 48 hours of the time of capturing 
information. The exclusion criteria will include pregnant women and patients who have 
not taken an antibiotic within the previous 48 hours, before capturing of data. Patients 
are required to give consent before their records will be reviewed. There is no potential 
risk in participating in this study and potential benefits include an improvement in 
antibiotic utilisation in the Surgery Department. 
 
Your participation in this study is totally voluntary, you are under no obligation to 
participate, and you have the right to withdraw your consent at any time if you care to 
without repercussion or penalty.  Your anonymity will be ensured, any information that 
will reveal your identity such as name and address will not be recorded. A unique study 
number will be assigned to your records, the list of study numbers and patients record 
numbers will be kept in a password protected data file and only accessible to the me 
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and my supervisors. No patient file will be taken away from the facility nor will any 
copies of files or patient information be made, so your identity will not be revealed when 
the study is reported or published.  
 
If you have any questions about the study please feel free to ask me (Bashar 
Muhammad Augie), you can also call me at 060 380 7904 or email me on 
1332258@students.wits.ac.za. 
 
For any complaints or problem feel free to contact Administrative Officer: Human 
Research Ethics Committee (Medical), Ms Zanele Ndolovu on email 
zanele.ndlovu@wits.ac.za or call on 011 717-1234. 
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APPENDIX 15 
 SPECIMENS WHICH GREW MULTIDRUG RESISTANT BACTERIA IN THE 
BASELINE STAGE 
 Table A.7:  Specimens which grew multidrug resistant bacteria in the baseline stage 
 
Specimens that Yielded 
Resistant Pathogens 
Type of Ward 
Total of both 
Wards 
n (%) 
Vascular   
Ward 
 n (%) 
General surgical 
Ward n (%) 
Urine 1(12.5) 9(28.1) 10(25.0) 
Blood 2(25.0) 6(18.8) 8(20.0) 
Superficial swab 4(50.0) 3(9.4) 7(17.5) 
Fluid/tissue 1(2.5) 5(15.6) 6(15.0) 
Drain fluid - 4(12.5) 4(10.0) 
Drain fluid (sterile cavity) - 2(6.3) 2(5.0) 
Abscess - 2(6.3) 2(5.0) 
Tissue - 1(3.1) 1(2.5) 
Total 8(100.0) 32(100.0) 40(100.0) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
174  
 
APPENDIX 16 
 SPECIMENS WHICH GREW MULTIDRUG RESISTANT BACTERIA IN THE 
INTERVENTION STAGE 
 Table A.8:  Specimens which grew multidrug resistant bacteria in the intervention 
stage. 
 
Specimens that Yielded 
Resistant Pathogens 
Type of Ward Total of both 
Wards 
n (%) 
Vascular   
Ward n (%) 
General Surgical 
Ward n (%) 
Urine 2 (16.67) 1 (2.00) 3(4.84) 
Blood 1 (8.33) 2 (4.00) 3(4.84) 
Superficial swab 3 (25.00) 10 (20.00) 13 (20.97) 
Fluid/tissue 3 (25.00) 28 (56.00) 31 (50.00) 
Drain fluid (sterile cavity) - 5(10.00) 5 (8.06) 
Sputum - 1 (2.00) 1 (1.61) 
Tissue 3 (25.00) 3 (6.00) 6(9.68) 
Total 12 (100.00) 50 (100.00) 62 (100.00) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
